drugbank id	name	groups	pubchem id	description	indication	target(s)	score	rank
DB12010	Fostamatinib	investigational; approved	11671467	-	"Fostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy [FDA Label]."	Q9Y2H1; P57078; P21802; Q9Y2H9; Q9UQB9; Q9Y4K4; Q9UGI9; Q13237; Q13523; Q13882; O14730; Q9H3Y6; Q86YV6; O14936; O15075; Q9UKI8; Q56UN5; O75460; Q15303; Q8TDR2; Q86UE8; P42680; P42681; P48736; P42685; P14616; Q05655; P22607; P16234; P35916; Q86V86; O95382; Q05397; Q96RR4; Q2M2I8; P08581; P10721; Q14012; Q13163; Q96BR1; P51956; P54756; Q13164; P51955; P22309; Q9Y463; Q00536; P07711; Q9Y2K2; Q00532; P51813; P51812; Q9UK32; O43283; P35590; O43353; Q9C098; Q96Q40; O14920; O15530; P07498; P30291; P52564; O75116; P53671; Q06187; P48729; Q9UF33; Q6P3R8; P0C264; P36896; Q13131; Q8N4C8; Q9NRP7; Q9NYY3; O15146; P08922; Q8IVH8; P11362; P17948; Q92772; Q16832; Q59H18; Q7L7X3; Q9Y6R4; Q13177; P41240; O00519; P9WI81; Q16539; P35968; Q8IU85; Q9UEW8; O43293; Q9H4B4; O75747; Q13470; Q6ZN16; O75716; P19525; P04049; Q8IW41; Q7KZI7; O15264; Q9P286; O14757; Q8NFD2; Q8N568; P29376; Q13627; Q16816; Q9UM73; Q9P289; Q9UBF8; Q00537; Q9BXA7; O95819; Q9NWZ3; P29597; P42684; O96017; P29317; Q14289; O96013; Q9Y2U5; P53667; Q8NG66; P78356; P51617; P54762; P0DMS8; Q02763; P46734; Q96NX5; Q9H0K1; Q13557; P51957; O95747; Q9UQM7; Q9NQU5; Q15375; P07332; Q15208; Q9H2K8; Q9Y6E0; Q16620; Q9H093; Q99808; Q12851; P42345; Q12852; Q99640; Q9UKE5; Q7Z460; O14976; Q9NSY1; Q13153; O75385; Q8TBX8; P08631; P23458; P31152; O94768; Q02779; P07947; O60285; P36897; P62344; P05129; Q8NI60; P17612; Q08881; P07948; P07949; Q13555; P00533; P11309; A0A0B4J2F2; Q9UL54; Q04912; P07333; Q9HBH9; P41743; P51451; Q9BYT3; P43405; P49761; Q9BUB5; P52333; Q6PHR2; P06213; P37173; P43403; Q07912; Q13873; O95835; Q12866; Q8WU08; O14965; P25774; Q5S007; Q16584; Q9BVS4; Q8N5S9; Q9H1R3; Q8NEV4; P09917; P36888; O00329; Q04759; P16591; O14578; Q9BQI3; O60674; P19784; Q92918; P80192; O00750; Q9H2X6; P53355; Q9NRH2; Q9BRS2; Q9UIK4; P29322; P27448; P29320; Q06418; Q9H422; P42679; P21709; P57059; P36507; O00238; P30530; Q9HAZ1; P49759; Q96PY6; P04626; P53350; O00444; P45984; P06493; P54760; Q8IYT8; Q15418; P11802; P54764; P53779; P04629; Q16288; P00519; Q8TD08; Q13233; O15197; Q14680; Q9P0L2; Q13546; P29323; P06239; Q9P2K8; P68400; Q15746; P49840; P33981; O94804; Q52WX2; P09769; Q9UEE5; Q9UHD2; P09619; O76074; P12931; Q9Y616; Q04771; Q13554; Q96GD4; Q08345; P49760; Q8IY84; Q15139; Q8TD19; Q14164; O75914; Q99759; P22694; Q13188; Q15569; Q16512; Q16513; Q9H2G2; P49841; Q6DT37; Q96D53; Q32MK0; P15056; P06241; Q02156; Q96L34	1.0	1
DB00995	Auranofin	investigational; approved	70788951	-	"Used in the treatment of active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis."	P04150; P09917; P18089; P30044; P08913; P35462; Q16881; O75762; P06241; O14920	0.970114114401	2
DB09130	Copper	investigational; approved	23978	-	"For use in the supplementation of total parenteral nutrition and in contraception with intrauterine devices [FDA Label] [L801]."	P51884; P30101; P27797; P15814; P10412; P68871; P07900; P31943; P31942; P35527; P01042; P31946; P14618; P08185; P31948; Q0VD83; P06396; P01009; P10997; P56537; P00390; Q15428; P29622; P02775; P30041; P02787; P23415; P19823; P63244; P04003; P51858; P48723; P04004; P45973; P61987; P35908; Q6MZM0; P05067; P00387; Q96PD5; P02765; P02766; P23560; P07358; P12814; P0C0L5; P04156; P42858; P23246; P00558; P29401; Q969S2; P05156; P05155; P14625; P14866; P48637; P62807; P13645; Q99497; P00734; P08865; P17174; P69905; P68104; P05090; P01857; Q07021; P01019; P26447; Q06323; P10809; Q03154; P09525; P07237; P22626; P18669; P36955; P05121; P51693; P0DPH7; P04406; P0DPH8; Q96FI4; P32119; Q08288; P00338; Q15185; P02750; P01008; P14550; P61769; P11142; Q9UHF0; Q06830; F7VJQ1; P43652; P30086; P29034; P27169; P06744; P23526; P23528; P10909; P09871; O75880; P50213; P05109; P05543; P05546; P02743; P05787; P02747; P01031; P02749; O00299; P60842; P04217; P02649; P08758; Q07955; P02647; P00739; P58876; P06733; P01861; O60701; P15531; P08697; P62937; P25311; P37840; P01024; P02748; P00747; P08603; P04264; P0C0L4; P02652; P02655; P35858; P02656; P15880; P06727; P43487; P05452; P07437; P63261	0.912863267292	3
DB01593	Zinc	investigational; approved	23994	-	"Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].      "	P08779; P05160; P04279; P04278; P03952; P30101; P68871; P03372; P22792; Q86YZ3; O75340; P35527; P01042; P04075; Q0VD83; P06396; P02795; P20851; P01308; P23415; P06702; P02787; P19827; P35908; P19823; P04003; P04004; P00450; O15304; P69905; P05067; O75636; Q96PD5; P02765; P02766; P07357; O14556; P07358; P02649; P29372; P0C0L5; O14618; P16455; P02671; P78330; P02746; P25713; Q06033; P56524; P05156; P20742; P46736; P15924; P46939; P00734; P13645; P00736; P13647; P68104; P00739; P80748; P01019; P08185; P01011; P19652; P04637; P31151; P07237; P04731; P51693; P60174; P14780; P08700; P01009; P02751; P81605; Q06830; Q14624; P14923; P08603; P29034; P27169; P01876; P01871; P09874; P10909; P09871; P06733; P45381; P05546; P02743; P02747; Q8N907; P00751; P49908; P01031; P00441; P04217; O14791; P29622; P46663; P05109; P15169; P15531; P01591; Q00987; P01599; P01024; P01023; Q13547; P02538; O15350; P02533; P00748; P04264; P0C0L4; P02647; P02652; P35858; Q9BY41; P06727; Q06481; P49411; P07360	0.655265432887	4
DB02709	Resveratrol	investigational	445154	-	"Being investigated for the treatment of Herpes labialis infections (cold sores)."	P54577; P05067; P31749; P16152; P49286; P35354; O75469; P48039; Q08499; P05106; P37840; P03372; P08648; P16050; P35869; Q92945; P68400; Q8TCG2; Q96EB6; P23219; P09917; P16083; Q14994; Q07869; P23786; Q86T13; P37231; Q07343; P11166	0.505137957743	5
DB00157	NADH	approved; nutraceutical	439153	-	"Some evidence suggests that NADH might be useful in treating Parkinson's disease, chronic fatigue syndrome, Alzheimer's disease and cardiovascular disease."	P09601; P40939; P07864; Q16878; P00374; O14561; P13995; P03891; P51553; P56937; Q9UDR5; P00390; P00326; P20839; P40925; P40926; O43920; P30043; Q9UBM7; Q02338; Q08426; P48728; P00367; O14556; Q13630; P31937; Q6ZMR3; P30519; P03897; P00387; O00483; P53004; P29803; P52895; Q9Y6M9; P47895; P15121; Q16795; O96000; P08559; Q16798; P16219; P30838; P03886; P26439; P43353; P49189; P30837; Q16718; Q02252; P03905; Q96C36; P03901; P19404; O75438; P51970; P42330; Q99714; O95139; Q04828; P28845; P05093; P05091; O95479; O43181; P21695; O43837; P56556; P03915; P12268; O43175; O75380; Q9NRX3; Q16836; O75306; Q15738; P04035; P17568; P48448; O00217; P49448; O95182; P04406; P10515; P17516; P00338; O43674; O43677; P11177; O43678; P09417; O75251; Q86Y39; O43676; P28331; Q00796; Q15800; P50213; P49821; P48163; P32322; P03923; P15428; P80365; O95298; O95299; Q9P0J0; O15239; P07195; P56181; Q9BYZ2; Q13423; P51648; P51649; O60701; P14679; P30038; O75489; P09622; P00352; O94788; O95168; O95169; P23368; O95167; Q02928; P11586; P51659; Q02218; Q92506; O95178; P16083; Q9UI09; P14061; P14060; P49419; P37059; P37058	0.489425946298	6
DB00188	Bortezomib	investigational; approved	387447	-	"For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies."	O00487; P51665; O00232; P28066; P28065; P28062; O14818; P60896; P20618; O43242; P08246; O00231; Q16186; P35998; P25786; P25787; P25788; Q99460; Q15008; P49721; A5LHX3; P17980; P40306; Q99436; P28074; P55036; P28070; P28072; Q13200; Q8TAA3; P48556; P00734; P49720; P62191; P62333; P62195; Q9UNM6; P60900; P25789; P43686	0.481561894591	7
DB08889	Carfilzomib	investigational; approved	11556711	-	"Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. "	O00487; O00231; O00232; P28066; P28065; P28062; O14818; P20618; O43242; P51665; Q16186; Q8TAA3; P25786; P25787; P25788; Q99460; A5LHX3; P17980; P40306; Q15008; P25789; P28074; P55036; P28070; P28072; Q13200; P60896; P48556; Q99436; P49720; P62191; P62333; P62195; Q9UNM6; P60900; P35998; P49721; P43686	0.481561894591	8
DB06448	Lonafarnib	investigational	148195	-	"Investigated for use/treatment in solid tumors, leukemia (unspecified), and lung cancer."	P49354; P49356; P17936; P01112; P01111; P01116	0.415256346734	9
DB09151	Flutemetamol (18F)	investigational; approved	15950376	-	"Flutemetamol F18 is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate ? amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. "	P05067	0.392514453013	10-16
DB09149	Florbetapir (18F)	investigational; approved	24822371	-	"Florbetapir 18F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate ?-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline."	P05067	0.392514453013	10-16
DB04892	Phenserine	investigational	192706	-	"For the treatment of Alzheimer's disease (AD)."	P05067; P22303; P06276	0.392514453013	10-16
DB06782	Dimercaprol	approved	3080	-	"For the treatment of arsenic, gold and mercury poisoning. Indicated in acute lead poisoning when used concomitantly with edetate calcium disodium (DB00974)."	P05067	0.392514453013	10-16
DB00746	Deferoxamine	investigational; approved	2973	-	"Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions."	P05067	0.392514453013	10-16
DB05088	Tetrathiomolybdate	investigational	25199766	-	"Investigated for use/treatment in liver disease and pulmonary fibrosis."	P05067	0.392514453013	10-16
DB09148	Florbetaben (18F)	approved	11501341	-	"Florbetaben is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate ?-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer?s Disease (AD) and other causes of cognitive decline."	P05067	0.392514453013	10-16
DB01179	Podofilox	approved	10607	-	"For treatment of external genital warts (<i>Condyloma acuminatum</i>)."	P04150; Q9BVA1; P68366; P68363; P07437; Q9BQE3; Q6PEY2; Q3ZCM7; Q9H4B7; P08684; Q13509; Q71U36; P68371; Q13885; P11388; Q9BUF5; P04350	0.366740840698	17
DB00257	Clotrimazole	vet_approved; approved	2812	-	"**Topical preparations**    Clotrimazole topical cream is indicated for the topical treatment of the following dermal infections [F3088], [F3121]:    Tinea pedis, tinea cruris, and tinea corporis due to _Trichophyton rubrum_, _Trichophyton mentagrophytes_, _Epidermophyton floccosum_    Candidiasis due to _Candida albicans_    Tinea versicolor due to _Malassezia furfur_    Diaper rash infected by _Candida albicans_      In some preparations, clotrimazole may be combined with betamethasone dipropionate, a corticosteroid [F3121].     **Oral preparations**    The oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis [FDA label].  It is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation [FDA label]. Troche preparations are not indicated for the treatment of any systemic mycoses [FDA label]."	P10613; P08173; O94759; P35354; P04626; P08913; P35462; P35372; Q8TD43; P04150; P00533; Q7Z2W7; P11229; Q12809; Q01959; Q9Y271; P21728; P08588; P05093; P14416; P29274; P30542; P08172; P41145; P22303; P28223; P51679; P41143; P28335; P18089; Q96RI1; P08684; P41595; O15554; P35367; P31645; P13945; P00918; P06241; P23975; P22001; P25021; P25103; Q14994; Q8TDS4; P20309; P08908; O75469; P11511; P25100; P30518	0.359503419993	18
DB00860	Prednisolone	approved; vet_approved	5755	-	"Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders, collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases, allergic and edematous states, and other conditions like tuberculous meningitis.[L9542]"	P04150; P04083; P08235; Q8TDV5; P08185; P05231; P10275	0.344784572469	19-20
DB01234	Dexamethasone	investigational; approved; vet_approved	5743	-	"Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]"	P04150; P06401; P51843; P08235; Q8TDV5; P04083; P35372; P10275; P35354; O75469; P05113; P35228	0.344784572469	19-20
DB01254	Dasatinib	investigational; approved	3062316	-	"For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy."	P21802; Q02750; P41240; P52333; P36507; P08631; P35968; P07949; P07947; P29597; P04626; Q9H3Y6; P09769; Q92570; P22607; Q07912; P54760; P07948; Q15303; P29317; P00533; P51692; P00519; P42684; P42685; P51451; P16234; P17948; P57059; P43405; P06239; P10721; P11362; P54756; P42336; P09619; Q9Y2K2; P12931; P07333; P36888; O00329; Q9H0K1; Q06203; P11274; Q06187; O60674; Q16539; P04049; Q9H2G2; P11142; P15056; P06241; A0A0B4J2F2; P42345	0.342426029625	21
DB00591	Fluocinolone acetonide	investigational; vet_approved; approved	6215	-	"Fluocinolone acetonide has been used extensively in different medical areas.    -In dermatology, it is extensively used for the relief of inflammatory dermatosis, dermatitis, psoriasis, hypertrophic tissues, keloid tissues and atopic dermatitis.[F1955]    -It has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalp.[L4682]    -In ear drops, it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and older.[L4683]    -As an intravitreal implant, it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure.[L4684]    -Fluocinolone acetonide was announced on October 15, 2018 to be FDA approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.[L4685]    -Some reports have indicated the use of fluocinolone acetonide as a vasoprotective agent and for its use in the treatment of first-degree hemorrhoids.[A39532]"	P04150; P04083; Q13255; P08758; P08185; P09525; P47712; P07355; P12429	0.338838896444	22
DB00367	Levonorgestrel	investigational; approved	13109	-	"**Emergency contraception**    Levonorgestrel, in the single-agent emergency contraceptive form, is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse. It is distributed by prescription for patients under 17, and over the counter for those above this age.[L7760] This levonorgestrel-only form of contraception is not indicated for regular contraception and must be taken as soon as possible within 72 hours after intercourse.[A181976,L7760] It has shown a lower efficacy when it is used off label within 96 hours.[T659]    **Long-term contraception or nonemergency contraception**    In addition to the above indication in emergency contraception, levonorgestrel is combined with other contraceptives in contraceptive formulations designed for regular use, for example with ethinyl estradiol.[L7766] It is used in various hormone-releasing intrauterine devices for long-term contraception ranging for a duration of 3-5 years.[L7778,L7781,L7787] Product labeling for Mirena specifically mentions that it is recommended in women who have had at least 1 child.[L7778] A subdermal implant is also available for the prevention of pregnancy for up to 5 years.[L7823]    **Hormone therapy and off-label uses**    Levonorgestrel is prescribed in combination with estradiol as hormone therapy during menopause to manage vasomotor symptoms and to prevent osteoporosis.[L7805]Off-label, levonorgestrel may be used to treat menorrhagia, endometrial hyperplasia, and endometriosis.[T659]"	P04150; P06401; P04278; P18405; P03372; P10275; P31645	0.325083457039	23-39
DB00717	Norethisterone	approved	6230	-	"Norethisterone is indicated as an oral contraceptive when given as monotherapy[L9527] or in combination with an estrogen component, such as [ethinylestradiol] or [estradiol].[L10313,L10307] In combination with an estrogen component, oral norethisterone is also indicated as a hormone replacement therapy in the treatment of postmenopausal osteoporosis and moderate-to-severe vasomotor symptoms arising from menopause.[L10304] When applied via transdermal patch, the combination of norethisterone and estradiol is indicated for the treatment of hypoestrogenism, vulvovaginal atrophy, and moderate-severe vasomotor symptoms.[L10301]    Norethisterone, taken in combination with intramuscular [leuprolide], is also indicated for the symptomatic treatment of endometriosis-related pain.[L10310]"	P04150; P06401; P03372; P10275; P31645; Q14833	0.325083457039	23-39
DB00977	Ethinylestradiol	approved	5991	-	"Ethinylestradiol is combined with other drugs for use as a contraceptive, premenstrual dysphoric disorder, moderate acne, moderate to severe vasomotor symptoms of menopause, prevention of postmenopausal osteoporosis.[L11944,L11965,L11947,L11950,L11845,L9806,L11953,L10304,L11956,L11959,L11962]"	P04150; P41145; P10275; Q92731; Q01959; P03372; P33261; P35372; P23975; O75469; P31645; P29274	0.325083457039	23-39
DB11619	Gestrinone	approved	27812	-	"Endometriosis with or without accompanying sterility. Treatment is limited to a single course of 6 months duration per lifetime [L1699, L1700]."	P04150; P06401; P04278; P03372; P10275; P30968	0.325083457039	23-39
DB00421	Spironolactone	approved	5833	-	"Spironolactone is indicated for the treatment of New York Heart Association Class III-IV heart failure, management of edema in cirrhotic adults not responsive to fluid and sodium restrictions, primary hyperaldosteronism short-term preoperatively, primary hyperaldosteronism long-term in patients with aldosterone producing adrenal adenomas that are not candidates for surgery or patients with bilarteral micro/macronodular adrenal hyperplasia, as an add-on therapy in hypertension, and in nephrotic syndrome when treatment of the disease as well as fluid and sodium restriction with other diuretics is inadequate.[Label]    Spironolactone has antiandrogenic activity which leads to many of its off label uses. Spironolactone is used off label in the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135]    Spironolactone is also frequently used for its antiandrogenic effects in transgender female patients due to its low cost and reducing male-pattern hair growth.[A178138]"	P04150; P06401; P08235; Q92731; P05093; Q9H8P0; Q9P0X4; P10275; O75469; P21860; P19099; P04278; P30874	0.325083457039	23-39
DB01395	Drospirenone	approved	68873	-	"Drospirenone, in combination with ethinyl estradiol, is indicated as an oral contraceptive for the prevention of pregnancy.  In addition to its use for contraceptive effects, this combination is used to treat moderate acne vulgaris and the symptoms of premenstrual dysphoric disorder.[L7973,L7976]  The drug has approved indications for combination with estrogens for the treatment of menopause-associated symptoms, such as vasomotor symptoms and vulvovaginal atrophy. Drospirenone combined with estrogen may also may aid in the prevention of osteoporosis in women who have been post-menopausal for at least a year and are not candidates for other therapies.[L7997,L8075]   It can sometimes be found in preparations containing estrogen and folic acid for folic acid replenishment during oral contraception.[L8078]    When used for the treatment of acne vulgaris, drospirenone-containing contraceptives should only be used in women ?14 years of age who have experienced menarche, desire oral contraception, and do not have any contraindications to oral contraceptives.[L7976] Off-label uses for this drug include the treatment of menstrual irregularities, dysmenorrhea, hirsutism, and endometriosis.[A2439,A182576]"	P04150; P33261; P08235; P06401; P10275	0.325083457039	23-39
DB00783	Estradiol	investigational; vet_approved; approved	5757	-	"Estradiol is indicated in various preparations for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of postmenopausal osteoporosis. It is also used for the treatment of breast cancer (only for palliation therapy) in certain men or women with metastatic disease, and for the treatment of androgen-dependent prostate cancer (only for palliation therapy).[L11485,L11494,L11497] It is also used in combination with other hormones as a component of oral contraceptive pills for preventing pregnancy (most commonly as [DB00977], a synthetic form of estradiol).    **A note on duration of treatment**    Recommendations for treatment of menopausal symptoms changed drastically following the release of results and early termination of the Women's Health Initiative (WHI) studies in 2002 as concerns were raised regarding estrogen use.[A31626] Specifically, the combined estrogen?progestin group was discontinued after about 5 years of follow up due to a statistically significant increase in invasive breast cancer and in cardiovascular events.[A31627]     Following extensive critique of the WHI results, Hormone Replacement Therapy (HRT) is now recommended to be used only for a short period (for 3-5 years postmenopause) in low doses, and in women without a history of breast cancer or increased risk of cardiovascular or thromboembolic disease.[A31628] Estrogen for postmenopausal symptoms should always be given with a progestin component due to estrogen's stimulatory effects on the endometrium, in women with an intact uterus, unopposed estrogen has been shown to promote the growth of the endometrium which can lead to endometrial hyperplasia and possibly cancer over the long-term.     "	P04150; Q99527; Q14457; Q92731; Q01959; P03372; P10275; P00846; P31645; O75469; P43681; Q12791	0.325083457039	23-39
DB08867	Ulipristal	approved	13559281	-	"As the product Ella (available in Canada and the US), ulipristal is indicated for use as emergency contraception after unprotected intercourse or possible contraceptive failure when administered within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. As the product Fibristal (available in Canada), ulipristal is indicated for treatment of the signs and symptoms of uterine fibroids in adult women."	P04150; P10275; P06401	0.325083457039	23-39
DB00834	Mifepristone	investigational; approved	55245	-	"For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery."	P04150; P41145; P08235; P06401; P07288; Q99720; P18089; P03372; P10275; P35372; O75469; Q92731; P08684; P06241	0.325083457039	23-39
DB01406	Danazol	approved	28417	-	"For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females."	P04150; P41145; P28223; P20309; P06401; P18825; P13500; Q01959; P18089; P03372; P10275; P35372; P08913; P13945; P30968; P35462; P31645; P21728; P23975; Q96P88	0.325083457039	23-39
DB00624	Testosterone	investigational; approved	6013	-	"Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]"	P04150; P08235; Q99720; P03372; P10275; P11511	0.325083457039	23-39
DB04839	Cyproterone acetate	investigational; approved	9880	-	"For the palliative treatment of patients with advanced prostatic carcinoma."	P04150; P07288; P35372; P10275; P06401	0.325083457039	23-39
DB00396	Progesterone	approved; vet_approved	5994	-	"**Gelatinized capsules**    The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea [FDA label].     **Vaginal gel**    Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (?ART?) treatment for infertile women with progesterone deficiency.  The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel [F3898].    **Vaginal insert**    This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women [F3901].    **Injection (intramuscular)**    This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer [F3907].     **Tablets, contraceptive**    The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy [F3904]. "	P04150; P41145; Q8NEC5; P08235; P06401; Q92731; P02763; Q7RTX7; P03372; Q9UL62; P10275; P04278; P05093; Q96P56; Q86XQ3; Q99720	0.325083457039	23-39
DB06710	Methyltestosterone	approved	6010	-	"Methyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency. It is also used in women to treat breast cancer, breast pain, swelling due to pregnancy, and with the addition of estrogen it can treat symptoms of menopause."	P04150; P10275; P03372	0.325083457039	23-39
DB00255	Diethylstilbestrol	investigational; approved	3054	-	"Used in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery."	P11474; Q15596; P18825; Q92731; P28223; P10275; P35372; P62508; O75469; P35462; P04150; O95718; P11229; Q01959; P03372; Q9Y271; P21728; P08913; P14416; P04278; P29274; P30542; P41145; P22303; P41143; P28335; P18089; P08588; P41595; P23219; P37288; P23975; P25100; P20309; P31645; P06241	0.325083457039	23-39
DB00603	Medroxyprogesterone acetate	investigational; approved	6279	-	"Medroxyprogesterone acetate (MPA) oral tablets are indicated to treat secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology.[L8657] Oral tablets containing MPA and conjugated estrogens are indicated to prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms, vulvar atrophy, and vaginal atrophy.[L8660] Subcutaneous MPA is indicated to prevent pregnancy and manage pain associated with endometriosis.[L8663] Intramuscular MPA is indicated to prevent pregnancy,[L8666] and at higher concentrations for palliative treatment of endometrial or renal carcinoma.[L8669]"	P04150; Q9UN88; P08235; P06401; Q92731; P25021; P03372; P10275; P48449	0.325083457039	23-39
DB01185	Fluoxymesterone	illicit; approved	6446	-	"In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal."	P04150; P10275; P16471; P80365; P03372	0.325083457039	23-39
DB14543	Hydrocortisone probutate	approved; vet_approved	636398	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease."	P04150; P04083; P14060; P80365	0.321444993463	40-59
DB00223	Diflorasone	approved	71415	-	"For relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses."	P04150; P04083; P04054	0.321444993463	40-59
DB00443	Betamethasone	approved; vet_approved	9782	-	"As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses.[L11991,L10782,L11997] Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis.[L12000] The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.[L11994]  "	P04150; P04083	0.321444993463	40-59
DB00288	Amcinonide	approved	443958	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."	P04150; P29371; P04083	0.321444993463	40-59
DB00764	Mometasone	vet_approved; approved	441335	-	"The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis."	P04150; P04083; P06401	0.321444993463	40-59
DB00547	Desoximetasone	approved	5311067	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."	P04150; P04054; P04083	0.321444993463	40-59
DB01013	Clobetasol propionate	approved	32798	-	"Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis[L11818,L118121,L11824] as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.[L11815,L11827]"	P04150; P04083; P08235	0.321444993463	40-59
DB14539	Hydrocortisone acetate	vet_approved; approved	5744	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease."	P04150; P04083; P80365; P14060; Q8TDV5	0.321444993463	40-59
DB00896	Rimexolone	approved	5311412	-	"For the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis."	P04150; P04083; P08185	0.321444993463	40-59
DB14544	Hydrocortisone valerate	approved; vet_approved	5282494	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease."	P04150; P04083; P14060; P80365	0.321444993463	40-59
DB01130	Prednicarbate	investigational; approved	6714002	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."	P04150; P04083; P04054	0.321444993463	40-59
DB00635	Prednisone	vet_approved; approved	5865	-	"Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.[L10502]"	P04150; P04083	0.321444993463	40-59
DB00620	Triamcinolone	approved; vet_approved	31307	-	"Triamcinolone hexacetonide injections are indicated for intralesional administration in alopecia areata, discoid lupus erythematosus, keloids, and necrobiosis lipoidica diabeticorum.[L8246] This formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques.[L8246]    Triamcinolone acetonide spray and cream are indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.[L8249,L8258] A triamcinolone acetonide 10mg/mL or 40mg/mL injection is indicated intra-articularly for acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L8252,L8255] The same 10mg/mL injection is indicated by the intralesional route for the treatment of alopecia areata, discoid lupus erythematosus, keloids, necrobiosis lipoidica diabeticorum, and tumors of an aponeurosis or tendon.[L8252] This formulation can also be used for localized hypertrophic infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus, and psoriatic plaques.[L8252] The 40mg/mL injection is indicated intramuscularly for controlling severe allergic conditions such as asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity, perennial or seasonal allergic rhinitis, serum sickness, and transfusion reactions, treatment of bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, Stevens-Johnson syndrome, congenital adrenal hyperplasia, hypercalcemia in  cancer, nonsuppurative thyroiditis, autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, secondary thrombocytopenia, trichinosis, tuberculous meningitis, acute exacerbations of multiple sclerosis or cerebral edema, sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammation, berylliosis, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis, dermatomyositis, polymyositis, and systemic lupus erythematosus, adjunct treatment of adrenocortical insufficiency, regional enteritis, ulcerative colitis, fulminating or disseminated pulmonary tuberculosis, acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, palliative management of leukemia and lymphoma, induction of diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus erythematosus.[L8255] A triamcinolone intravitreal injection is indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions.[L8261] The intravitreal injection is also used for visualization during vitrectomy.[L8261] An extended release suspension is indicated intra-articularly for management of pain in osteoarthritis of the knee.[L8264]"	P04150; P06401; P08185; P04083	0.321444993463	40-59
DB00240	Alclometasone	approved	5311000	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."	P04150; P04083; P08185	0.321444993463	40-59
DB01260	Desonide	investigational; approved	5311066	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose."	P04150; P04054; P04083	0.321444993463	40-59
DB00959	Methylprednisolone	approved; vet_approved	6741	-	"Oral and intramuscular methylprednisolone are indicated for a number of endocrine,  rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders.[L10785,L10788] Intra-articular and soft tissue injections are indicated for short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L10788] Intralesional injections are indicated for alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare.[L10788]"	P04150; P04083	0.321444993463	40-59
DB14596	Loteprednol etabonate	approved	9865442	-	"A number of prescription loteprednol etabonate ophthalmic products are specifically indicated for the treatment of post-operative inflammation and pain following ocular surgery [FDA Label]. "	P04150; P04083	0.321444993463	40-59
DB01222	Budesonide	approved	5281004	-	"Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn?s disease.[L10601,L10604] Various inhaled budesonide products are indicated for prophylactic therapy in asthma[L10607,L10613,L10619] and reducing exacerbations of COPD.[L10619] A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies.[L10616] Extended release capsules are indicated to induce remission of mild to moderate ulcerative colitis[L10622] and a rectal foam is used for mild to moderate distal ulcerative colitis.[L10625]"	P04150; P04083; P08235; P06401; P01579; P05113	0.321444993463	40-59
DB00769	Hydrocortamate	approved	84088	-	"Used topically as an antiinflammatory in the treatment of steroid-responsive dermatoses"	P04150; P04054; P04083	0.321444993463	40-59
DB00741	Hydrocortisone	vet_approved; approved	5754	-	"Otic solutions are indicated for infections of the external auditory canal caused by susceptible organisms and with inflammation.[L10529,L10532] Hydrocortisone tablets are indicated for certain endocrine, rheumatic, collagen, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, and other conditions.[L10535] A hydrocortisone enema is indicated for ulcerative colitis,[L10538] a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infections,[L7772] and a topical cream with [acyclovir] is indicated to treat cold sores.[L7321]"	P04150; P04083; P08235; P25103; P35228	0.321444993463	40-59
DB01384	Paramethasone	experimental	5875	-	"For the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone."	P04150; P08185; Q96F46	0.300216149548	60-88
DB09095	Difluocortolone	investigational; approved; withdrawn	11954369	-	"Difluocortolone is used as a topical treatment of the symptoms of inflammatory skin disorders like eczema, seborrheic eczema, lichen planus and psoriasis. All these disorders present as a common characteristic the occurrence of symptoms as itching, swelling, redness and scaling.[L1083]"	P04150; P12429	0.300216149548	60-88
DB00663	Flumethasone	vet_approved; approved	16490	-	"For the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions"	P04150	0.300216149548	60-88
DB00351	Megestrol acetate	investigational; vet_approved; approved	11683	-	"For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries."	P04150; P06401; O95977; P21453; P03372	0.300216149548	60-88
DB00700	Eplerenone	approved	443872	-	"For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction."	P04150; P08235	0.300216149548	60-88
DB01410	Ciclesonide	investigational; approved	6918155	-	"For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older."	P04150; P08185	0.300216149548	60-88
DB00394	Beclomethasone dipropionate	investigational; approved	21700	-	"Indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. The aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasm.[L6871]    Indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal.[L6880]    Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.[L10782] Corticosteroid-responsive dermatoses include psoriasis, contact dermatitis (dermatitis venenata), atopic dermatitis (infantile eczema, allergic dermatitis), neurodermatitis (lichen simplex chronicus, lichen planus, eczema, eczematous dermatitis), intertrigo, dyshidroses (pompholyx), seborrheic dermatitis, exfoliative dermatitis, solar dermatitis, stasis dermatitis, and anogenital and senile pruritus.[L6886]"	P04150; P05113; Q86Y34	0.300216149548	60-88
DB08906	Fluticasone furoate	approved	9854489	-	"Fluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label][F4364]. The fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitis[FDA Label][A177130]."	P04150; P06401; P08235	0.300216149548	60-88
DB04573	Estriol	investigational; approved; vet_approved	5756	-	"Used as a test to determine the general health of an unborn fetus."	P04150; P04278; P31645; P03372; Q92731	0.300216149548	60-88
DB13953	Estradiol benzoate	investigational; approved; vet_approved	222757	-	"Estradiol benzoate is not currently available in any FDA or Health Canada approved products."	P04150; Q15596; P18825; P43681; Q99527; Q92731; P41595; P03372; Q14457; P62508; P00846; P31645; O75469; P06241; P23975; P37059	0.300216149548	60-88
DB13158	Clobetasone	approved	71387	-	"In dermatology, topical clobestasone butyrate helps to reduce the itchiness and erythema associated with eczema and dermatitis.  In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sj?gren's Syndrome."	P04150	0.300216149548	60-88
DB06789	Hydroxyprogesterone caproate	investigational; approved	169870	-	"Hydroxyprogesterone caproate is indicated for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth. (1) "	P04150; P06401; Q01959; P51679	0.300216149548	60-88
DB15566	Prednisolone acetate	approved; vet_approved	5834	-	"Prednisolone acetate is indicated as an anti-inflammatory or immunosuppressive agent for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, or infectious conditions.[L9449] Prednisolone acetate is also indicated in organ transplant patients, as well as endocrine or neoplastic conditions.[L9449]"	P04150; P25090; P21462	0.300216149548	60-88
DB00588	Fluticasone propionate	approved	444036	-	"Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[F4355]. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis[L8309,F4358]."	P04150; P06401; P08235; P47712	0.300216149548	60-88
DB09091	Tixocortol	approved; withdrawn	162955	-	"Tixocortol is indicated for the treatment of rhinitis as a nasal suspension or aerosol. It is also used in the form of lozenges for the treatment of pharyngitis and in the form of enemas or rectal solution for the treatment of ulcerative colitis. Tixocortol can be used orally in a suspension or powder for the treatment of inflammatory conditions.[L1077] It is also the substance used for the screening of contact allergies to class A steroids.[A31435]"	P04150; Q92769	0.300216149548	60-88
DB06781	Difluprednate	approved	443936	-	"For the treatment of inflammation and pain associated with ocular surgery."	P04150	0.300216149548	60-88
DB00687	Fludrocortisone	investigational; approved	31378	-	"Fludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease. It is also indicated for the treatment of salt-losing androgenital syndrome.[L8971]"	P04150; P08235; O75874	0.300216149548	60-88
DB01047	Fluocinonide	investigational; approved	9642	-	"A topical anti-inflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."	P04150; P08185; P47712; Q99835	0.300216149548	60-88
DB00596	Ulobetasol	approved	5311167	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."	P04150	0.300216149548	60-88
DB00838	Clocortolone	approved	5311052	-	"For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp."	P04150	0.300216149548	60-88
DB11921	Deflazacort	investigational; approved	189821	-	"Deflazacort is indicated for the treatment of Duchenne Muscular Dystrophy (DMD) in patients 2 years of age and older.[FDA label]"	P04150	0.300216149548	60-88
DB01380	Cortisone acetate	investigational; approved	5745	-	"For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders."	P04150; Q8TDV5; Q09470	0.300216149548	60-88
DB06786	Halcinonide	investigational; withdrawn; approved	443943	-	"Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. "	P04150; Q99835	0.300216149548	60-88
DB00253	Medrysone	approved	247839	-	"For the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity."	P04150; P41231; P47712	0.300216149548	60-88
DB00846	Flurandrenolide	approved	15209	-	"For relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions"	P04150; P08185; P47712	0.300216149548	60-88
DB05423	ORG-34517	investigational	9867361	-	"Investigated for use/treatment in depression."	P04150	0.300216149548	60-88
DB00180	Flunisolide	investigational; approved	82153	-	"For the maintenance treatment of asthma as a prophylactic therapy."	P04150; P47712	0.300216149548	60-88
DB00633	Dexmedetomidine	approved; vet_approved	5311068	-	"For sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief, anxiety reduction and analgesia"	P04150; P18825; P25100; P08913; P18089; P35368; P35348	0.300216149548	60-88
DB00324	Fluorometholone	investigational; approved	9878	-	"For the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe."	P04150; P47712	0.300216149548	60-88
DB01229	Paclitaxel	vet_approved; approved	36314	-	"Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane? is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer."	P68366; P68363; Q6PEY2; P10636; Q3ZCM7; P32238; P10415; Q13885; Q13509; P04350; P11137; P0DPH7; P0DPH8; P41143; O75469; P11388; Q9BUF5; P68371; Q71U36; P27816; Q9BVA1; Q9H4B7; Q9BQE3; P07437; P04626; P06241	0.295194433273	89
DB00945	Acetylsalicylic acid	vet_approved; approved	2244	-	"**Pain, fever, and inflammation**    Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures [FDA label].     The _extra strength_ formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)[FDA label].    **Other indications**    ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:     Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) [FDA label].     Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction [FDA label].    For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) [FDA label].    For the prevention of thromboembolism after hip replacement surgery [FDA label].     For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) [FDA label].    Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site [FDA Label].     **Important note regarding use of the extended-release formulation [F4405]**    In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action [Label, F4405]. The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA [F4405].       "	P23786; Q04828; P04637; Q13164; P98066; P24385; P25963; P01106; Q9UGI9; P23219; P25090; P51812; P35354; P41595; P04035; P29466; P12004; P25101; P42574; Q9UHC3; O14920	0.292194905034	90
DB00313	Valproic acid	investigational; approved	3121	-	"**Indicated** for:[Label]     1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures.     2) Adjunctive therapy in the management of multiple seizure types that include absence seizures.     3) Prophylaxis of migraine headaches.    4) Acute management of mania associated with bipolar disorder.      **Off-label** uses include:     1) Maintenance therapy for bipolar disorder.[A177919]    2) Treatment for acute bipolar depression.[A177928,A177931,A177934]    3) Emergency treatment of status epilepticus.[A177955]"	P45954; P04035; P42858; Q9UKV0; Q13547; P54098; Q92769; P51649; P80404; P37231; Q03181; Q07869; Q8IWT1; Q02218	0.290337422596	91
DB00543	Amoxapine	approved	2170	-	"For the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. May also be used to treat depression accompanied by anxiety or agitation."	P18825; P10635; P28222; P28223; P35462; P46098; P11229; P42858; Q9H3N8; P34969; Q01959; P08912; P08913; P14416; P23975; P08172; P08173; P18507; P18440; P28335; P18089; P21918; P14867; P41595; P35367; P35348; P21917; Q9UN88; P25100; P50406; P47870; P20309; P08908; P31645; P21728	0.289120279807	92
DB00675	Tamoxifen	approved	2733526	-	"Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.[L7802]"	P08173; Q92731; P28223; Q15125; P10275; P35354; P62508; O75469; P08913; P35462; P35372; P45983; P00533; Q05513; P11229; Q99527; Q99720; Q12809; P06401; P03372; P21728; P08588; P06239; P04278; P23975; P12259; P30542; P08172; P41145; P32245; P14416; P41143; Q5S007; P28335; P18089; P41595; P23219; P13945; P00734; P08912; P29274; P04626; P25021; P25103; P25100; Q01959; P30411; P20309; P08908; P31645; P06241	0.271616786928	93
DB06700	Desvenlafaxine	investigational; approved	125017	-	"Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label]."	P31645; P42858; P23975; Q01959; P18440	0.267937815764	94-95
DB00579	Mazindol	investigational; approved	4020	-	"Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m<sup>2</sup>) or in patients with a body mass index of 27 kg/m<sup>2</sup> in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia."	P18440; Q99720; P42858; Q01959; Q05940; P35367; P31645; P23975	0.267937815764	94-95
DB05294	Vandetanib	approved	3081361	-	"Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure. "	P21802; Q02750; P36507; P08631; P35968; P07947; Q13882; P04626; P21860; P54762; P54760; P22607; Q13131; P54764; Q15303; P29317; P00533; P00519; P07333; P29376; O15197; Q9UM73; P21709; P16234; P17948; P35916; P07948; P06239; P08581; P07949; P11362; P54753; P54756; P09619; P12931; O75116; P22455; Q02763; P36888; P10721; P06241; Q06187; Q9UF33; Q15375; Q5JZY3; P15692; P29322; P29323; P29320	0.266415217158	96
DB06595	Midostaurin	investigational; approved	9829523	-	"Investigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). "	P21802; P24723; P52333; P05129; P08631; P23458; P07947; P29597; Q96GD4; P05771; P04629; Q07912; P07948; Q15303; P00533; P22607; Q16288; P00519; P07333; P29376; Q13131; Q05655; Q9UM73; P43405; P16234; P17948; P35916; P06239; P08581; P07949; P11362; O94806; Q14289; P42336; P17252; P08922; P09619; P35968; P12931; Q05513; Q13464; Q02763; P36888; Q15139; P06748; Q04759; P16591; O75116; O60674; Q02156; P10721; P49841; P49840; Q16620; P41743; P06241	0.262955192037	97-98
DB08865	Crizotinib	approved	11626560	-	"Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test. "	P08069; P52333; P07947; P29597; P22607; Q13131; P07948; P07949; P29317; P00533; P04629; Q16288; P00519; P07333; P29376; Q07912; Q9UM73; P17948; P43405; Q05397; P06213; P08581; P10721; Q14289; P06239; P23458; P12931; Q13464; Q02763; P36888; P06748; P16591; O75116; Q06187; O60674; P07332; Q16620; P08922; P06241; Q08881	0.262955192037	97-98
DB00171	ATP	investigational; nutraceutical	5957	-	"For nutritional supplementation, also for treating dietary shortage or imbalance"	P31749; Q9UM73; P51582; Q92736; O95342; O43681; P36896; P41231; O60706; P45844; Q15413; P00966; Q8TD43; P08243; Q13131; O95477; P00519; P42684; Q08828; Q07912; Q13564; P08183; P47900; Q9NUB1; P37023; P13569; Q16671; P53041; P68400; P51575; Q96QT4; Q9NR19; P21817; P42336; P12235; Q99572; Q04771; O14727; P35626; P33527; O95255; Q96Q40; O15439; P67870; P25098; Q09428; P10398; Q9Y4W6; Q13304; Q9BPV8; P49902; P33121; Q96G91; Q92887	0.260107293466	99
DB06589	Pazopanib	approved	10113978	-	"Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) "	P21802; P52333; P08631; P35968; P07947; P29597; P01889; P22607; Q08881; P07948; P07949; P00519; P07333; P29376; Q9UM73; P35916; P16234; P17948; P43405; P06239; P08581; P11362; P22309; P08922; P09619; P12931; P22455; Q02763; P36888; P10721; P16591; P05230; P07332; P04049; Q9UQQ2; P15056; P06241; O60674	0.257634482557	100
DB06616	Bosutinib	approved	5328940	-	"Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. "	Q02750; P57059; P36507; Q9Y4K4; P08631; O94804; Q8IU85; P07949; P07947; P29597; Q9Y2U5; P04626; P04629; Q13131; P07948; Q15303; P29317; P00533; P42681; Q16288; P00519; P42684; P07332; Q08881; Q05655; Q9UM73; P16234; P42685; P52333; P43405; Q05397; P06239; P08581; P10721; P07333; Q14289; P09619; Q9Y2K2; P12931; Q13555; P11274; Q13464; Q02763; P36888; P24941; Q13043; P06748; Q9H0K1; P16591; O75116; Q06187; Q07912; O60674; P29376; Q9Y6E0; Q16620; P06241; A0A0B4J2F2	0.255560692974	101
DB00997	Doxorubicin	investigational; approved	31703	-	"Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms? tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin?s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer."	P06241; P11229; Q14978; P04626; P06239; P11387; P11388	0.252369370754	102
DB01169	Arsenic trioxide	investigational; approved	261004	-	"For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15,17) translocation or PML/RAR-alpha gene expression"	P28482; P31749; Q12809; Q13547; P10276; P29590; P24385; Q16881; P05412; O14920; P38936; P27361	0.251698052851	103
DB00173	Adenine	approved; nutraceutical	190	-	"For nutritional supplementation, also for treating dietary shortage or imbalance"	P17802; O00763; Q9BY49; P78362; Q5SL87; P07741; P24666; P0AF12; Q05603; Q13126; P47989	0.245280729805	104
DB01248	Docetaxel	investigational; approved	148124	-	"For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer. "	P68366; P68363; Q6PEY2; P10636; Q71U36; P10415; O75469; Q13509; P04350; P00533; P11137; P0DPH7; P0DPH8; Q9BUF5; P68371; P08684; Q02643; Q3ZCM7; P27816; Q9BVA1; Q9H4B7; Q9BQE3; P07437; Q13885	0.244423700155	105
DB09061	Cannabidiol	investigational; approved	644019	-	"When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:   1) as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy [L886],    Due to the need for confirmatory studies to verify the clinical benefit coupled with the promising nature of the clinical evidence, Sativex was also given a Notice of Compliance with Conditions (NOC/c) by Health Canada for the following indications:   1) as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis,   2) as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain [L886]."	P24462; P28223; O75762; P35372; P04035; P46098; Q02083; P15559; P47775; Q7Z2W7; P05177; P23219; Q9P0X4; Q16678; P05093; O43497; P30542; P24752; P36544; P00390; P41143; P48167; O75311; P34972; P14902; O95180; Q8NET8; P21796; Q14330; P23415; P04040; Q8NER1; P07203; Q494W8; P35354; Q9Y5S1; Q9Y2T6; Q9HBA0; P37231; P08908; P21554; P00441	0.237927437716	106
DB00172	Proline	nutraceutical	145742	-	"L-Proline is extremely important for the proper functioning of joints and tendons and also helps maintain and strengthen heart muscles."	P07814; Q8IVL5; Q8IVL6; P45877; Q13427; P32322; O15460; P12821; Q99884; O43447; P30405; Q9UN76; Q96C36; Q7L3T8; Q53H96; P62937; Q96EM0; P23284; P13674; Q32P28	0.237232516879	107
DB00637	Astemizole	withdrawn; approved	2247	-	"Astemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias."	P0DP24; P08173; P0DP25; P18825; P10636; P28223; P35372; P04626; P08913; P35462; P46098; P0DP23; P08908; P00533; P41595; P11229; Q99720; Q12809; Q01959; P21728; P08588; P06239; P23975; P08172; P41145; P32245; P14416; P41143; P28335; P18089; P35346; P08684; O95259; P35367; P13945; P23415; P25021; P25103; P25100; P30559; P20309; P08912; P31645; P06241	0.23439297911	108
DB09079	Nintedanib	approved	9809715	-	"In the US, nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF)[L8453] and to slow declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease.[L8462] In the EU, nintedanib is indicated in combination with docetaxel for the treatment of adult patients with metastatic, locally advanced, or locally recurrent non-small cell lung cancer of adenocarcinoma histology who have already tried first-line therapy.[L8459]"	P21802; Q02750; P08069; P52333; P36507; P08631; P35968; P07947; P29597; P11802; P04629; Q07912; P07948; P07949; P29317; P22607; Q16288; P00519; Q08881; P29376; Q13131; Q9UM73; P16234; P17948; P35916; Q05397; P06239; P08581; P11362; Q14289; P06213; P09619; P12931; P07333; P22455; Q02763; P36888; P23458; P10721; P16591; Q06187; O60674; P07332; P49841; P49840; Q16620; P08922; P06241	0.233891345953	109-110
DB01268	Sunitinib	investigational; approved	5329102	-	"For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate."	P21802; Q02750; P08069; P52333; P36507; P08631; P35968; P07947; P29597; P11802; P22607; Q07912; P07948; P07949; P00533; P04629; Q16288; P00519; P48736; P29376; Q08881; Q12809; Q9UM73; P16234; P17948; Q13131; P35916; Q05397; P06239; P08581; P10721; P16591; P11362; Q14289; P06213; P42336; P09619; P12931; P22455; Q13464; Q96GD4; P36888; O00329; P23458; O75116; P07333; O60674; P07332; Q06187; Q16620; P06241	0.233891345953	109-110
DB00398	Sorafenib	investigational; approved	216239	-	"Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.  "	P21802; Q02224; P52333; P28223; P08631; P35968; Q16832; P22607; P07948; P07949; P29317; Q9BWU1; Q16288; P00519; P07333; P34969; P16234; P17948; P35916; P06213; P04629; P11362; P06239; P28335; P09619; P41595; P12931; P49336; Q02763; P36888; P10721; P04049; Q16620; P08908; P15056; P06241	0.233329242059	111
DB00530	Erlotinib	investigational; approved	176870	-	"Erlotinib is indicated for:    - The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [FDA label].     - In combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer [FDA label].    The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy. [FDA label]"	P21802; P52333; P08631; P35968; P07947; P29597; P04626; P07948; P07949; P00533; P00519; P29376; Q9UM73; P16234; P17948; P35916; P06239; P08581; Q15303; P09619; P12931; P36888; P10721; O60674; O75469	0.225545996386	112-114
DB09053	Ibrutinib	approved	24821094	-	"Ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapy.[FDA label] Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that develops in the outer edge of a lymph node. MCL is usually diagnosed at late stages and it is easily spread into bone marrow, spleen, liver and gastrointestinal tract.[L1929]    Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who have at least one prior therapy.[FDA label] CLL is a type of cancer caused by an overproduction of lymphocytes by the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness.[L1931]    Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion.[FDA label] CLL with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the TP53 gene. The remaining allele is mainly inactivated and thus, this type of leukemia is unresponsive to p53-dependent treatments.[A32305]    Ibrutinib is indicated for the treatment of patients with Waldenstrom's Macroglobulinemia (WM).[FDA label] WM, also called lymphoplasmacytic lymphoma, is a type of non-Hodgkin lymphoma in which the cancer cells make large amounts of macroglobulin. The macroglobulin is a monoclonal protein that corresponds to the type of IgM antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous system.[L1934]"	P21802; P42680; P42681; Q06187; P00533; P52333; P51451; P08631; P12931; P07947; P04626; P06239; P51813; P06241; Q08881; P07949; P07948; Q15303	0.225545996386	112-114
DB11828	Neratinib	investigational; approved	9915743	-	"For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label]."	Q02750; P52333; P36507; P08631; P35968; P07947; P04626; Q07912; P07948; Q15303; P00533; P00519; P07333; P07332; P43405; Q05397; P06213; P08581; Q14289; P06239; P12931; Q02763; P36888; P16591; Q06187; P06241	0.225545996386	112-114
DB04868	Nilotinib	investigational; approved	644241	-	"For the potential treatment of various leukemias, including chronic myeloid leukemia (CML)."	P21802; P43166; P23280; P08631; P07947; Q16790; Q16832; P35218; P07948; P07949; P29317; Q16288; P00519; P07333; P16234; Q9Y2D0; P06213; P11362; P06239; P22309; P09619; Q08345; P12931; O43570; Q02763; P36888; P07451; P35228; P10721; P00918; P22748; P11274; P42684; O60674; Q9ULX7; P00915; P04049; Q16620; P15056; P06241	0.215103359236	115
DB00623	Fluphenazine	approved	3372	-	"For management of manifestations of psychotic disorders."	P34969; Q99250; P08173; P18825; P28221; P28222; P28223; Q01959; P10275; P35372; P04626; P35462; P00533; P11229; Q99720; Q12809; P08912; Q9NY46; P18089; P21728; P08913; P14416; P23975; P08172; P41145; P41143; P28335; P41595; P21918; P35498; P35368; P35367; P35348; P13945; P25021; P25100; P50406; P20309; P08908; P31645; P06241; P01011	0.208857096819	116
DB06626	Axitinib	investigational; approved	6450551	-	"Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer."	P09603; P21802; Q02750; P52333; P36507; P35968; P07947; P29597; O00444; P04629; Q07912; P07949; P00533; P22607; P00519; P07333; Q08881; P16234; P17948; P35916; P06239; P08581; P11362; P09619; Q02763; P36888; P10721; O60674; P08922	0.208787744255	117
DB09092	Xanthinol	approved; withdrawn	9913	-	"Xanthinol is primarily used in diet supplements to increase the brain metabolism of glucose and obtain ATP. Xanthinol is also used as an agent to reduced cholesterol as it is a vasodilator.[L1080] Its action allows having an elevated rate of blood flow in the brain which helps improve memory function, concentration and awareness.[L1079] Thus, due to his actions, xanthinol is indicated to improve cerebrovascular and peripheral vascular disorders as well as hyperlipidaemias.[L1081]"	P50213; P39023; P04406; Q13423; P40926; Q02218	0.207738882579	118
DB08901	Ponatinib	investigational; approved	24826799	-	"Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy."	P21802; P11274; P00519; P22607; P35968; P16234; P12931; P49336; P10721; Q9BWU1; P22455; P11362; P06239; Q02763; P36888; P07948; P07949	0.206814337775	119-120
DB09063	Ceritinib	approved	57379345	-	"Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials."	P21802; P08069; P52333; P35968; P11802; P04629; P07948; P07949; P00533; P22607; P00519; Q12809; Q9UM73; P16234; P43405; Q9BXA7; P06239; P08581; P06213; P12931; P22455; P36888; P10721; P23458; O75116; Q06187; O60674; Q16620; P08922	0.206814337775	119-120
DB00331	Metformin	approved	4091	-	"**Metformin tablet**     Metformin is indicated as an adjunct to diet and exercise to increase glycemic control in _adults and pediatric patients_ 10 years of age and older diagnosed with type 2 diabetes mellitus.[FDA label]    **Metformin extended-release tablet (XR)**    The extended-release form is indicated as an adjunct to diet and exercise to improve glycemic control in only _adults_ with type 2 diabetes mellitus. Safety in children has not been determined to this date.[FDA label]    An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.[L11479]"	P03915; Q16134; O00483; O75380; Q9Y478; Q9NRX3; O75306; O75251; P56181; Q16795; O96000; O75489; O00217; P03886; O95182; O00763; O95168; O95169; O95167; O14561; Q9P032; Q16718; Q9Y6M9; O43674; O43677; O43676; O43678; Q9Y375; O75438; O43920; P03905; P03901; P19404; Q86Y39; P51970; P28331; Q8N183; P27487; O95299; O95139; P17568; Q96FL8; P49821; O95178; P03923; Q9BU61; Q9UI09; O43181; P21695; Q9NX14; O95298; P03891; Q9P0J0; O15239; P43304; P56556; P42345; P03897	0.205169693169	121
DB00642	Pemetrexed	investigational; approved	446556	-	"Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy"	P00374; P04818; P22102; P31939	0.201993474446	122
DB03147	Flavin adenine dinucleotide	approved	643975	-	"Used to treat eye diseases caused by vitamin B2 deficiency, such as keratitis and blepharitis."	P09063; Q9WYT0; P00387; P10902; P08373; P37747; P42593; P77967; P40859; P18925; P29475; Q56839; P05327; Q15067; Q16795; P61432; P06715; P16640; P16219; Q9Z4P0; P38038; P55792; P00438; P16435; P58558; P24232; P20586; P0C278; Q06319; P15559; Q9UKU7; P0A9P4; Q94655; P28593; P12676; P83223; P21890; Q9UHQ9; P14920; P00390; Q12882; P09622; P9WIQ3; P37062; P37063; Q47PU3; Q92947; P22570; P19480; P35340; P22637; O95831; P06149; P00914; P09546; P21397; P47989; Q9RC23; P14218; Q9AGP8; P55789; Q44532; P16083; P28861; P11310; P0AEZ1; Q96RQ9; P07771; P9WIQ1; Q16881; P39662; P09788; P61497; Q86YB8; P26440; P9WHH7	0.199996726541	123
DB01204	Mitoxantrone	investigational; approved	4212	-	"For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis"	P08172; P00533; Q9UNQ0; P11388; P11229; P08173; P28335; Q02880; P04626; P06241; P23975; Q12809; Q06187	0.19798149236	124
DB00317	Gefitinib	investigational; approved	123631	-	"For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies."	P00533; P36888; P12931; P00519; P29376; P08631; P35968; P07949; P04626; P06239; P08581; P10721; P07948; Q15303	0.197327152423	125-127
DB08916	Afatinib	approved	10184653	-	"Afatinib is a kinase inhibitor indicated as monotherapy [L2937] for the first-line [FDA Label] treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test [FDA Label], and (b) adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy [FDA Label, L2937].    Recently, as of January 2018, the US FDA approved a supplemental New Drug Application for Boehringer Ingelheim's Gilotrif (afatinib) for the first line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [L2939]. The new label includes data on three additional EGFR mutations: L861Q, G719X and S768I [L2939]."	P00533; P00519; P08631; P12931; P04626; P06239; P08581; P36888; Q15303	0.197327152423	125-127
DB11703	Acalabrutinib	investigational; approved	71226662	-	"Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy.[L10241] It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.[L10241]"	P00533; P42680; P42681; P12931; Q06187; P52333; P51451; P51813; P04626; P06239; P06241; Q08881; P07948; Q15303	0.197327152423	125-127
DB00363	Clozapine	approved	2818	-	"For use in patients with treatment-resistant schizophrenia."	P34969; P18825; P10635; P28222; P35368; P35462; P46098; P47898; P09211; Q03519; P28566; P11229; Q9H3N8; Q99720; Q12809; P08912; P30939; P21728; P08913; P14416; P28221; P23975; P08172; P08173; P28223; P28335; P41595; P08588; P18089; P31645; P35367; Q9NYX4; P35348; P21917; P21918; P25021; P25100; P50406; Q16602; P20309; P08908; P07550; P01011	0.196269054754	128
DB01373	Calcium	nutraceutical	5460341	-	"Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades."	P02585; P19801; P63316; P12644; Q01082; P04271; P98194; P20810; P29034; Q8TAB3; P05109; P08493; Q13936; P05187; O75340; P06702; Q99584; P00450; P49747	0.191836589343	129
DB14490	Ferrous ascorbate	approved	54710214	-	"Used in preventing and treating iron-deficiency anemia."	P02787; P02786; Q969S2; Q16595; Q9NZD4; Q9GZT9; Q96FI4; Q9BY41; P39748; P06746; P69905; P02794; P00450	0.190958495361	130-132
DB14501	Ferrous glycine sulfate	approved	167159	-	"Used in preventing and treating iron-deficiency anemia."	P02787; P02786; Q969S2; Q16595; P02794; Q9GZT9; Q96FI4; Q9BY41; P39748; P06746; P69905; Q9NZD4; P00450	0.190958495361	130-132
DB14488	Ferrous gluconate	approved	9291	-	"Used in preventing and treating iron-deficiency anemia."	P02787; P02786; Q969S2; Q16595; P02794; Q9GZT9; Q96FI4; Q9BY41; P39748; P06746; P69905; Q9NZD4; P00450	0.190958495361	130-132
DB14489	Ferrous succinate	approved	159252	-	"Used in preventing and treating iron-deficiency anemia."	P02787; P02786; Q969S2; P06746; P02794; Q9GZT9; Q96FI4; Q9BY41; P00450; Q16595; P69905; Q9NZD4; P39748	0.190958495361	133-135
DB01592	Iron	approved	23925	-	"Used in preventing and treating iron-deficiency anemia."	P02787; P02786; Q969S2; Q16595; P02794; Q9GZT9; Q96FI4; Q9BY41; P00450; P06746; P69905; Q9NZD4; P39748	0.190958495361	133-135
DB14491	Ferrous fumarate	approved	6433164	-	"Used in preventing and treating iron-deficiency anemia."	P02787; P02786; Q969S2; P06746; Q9NZD4; Q9GZT9; Q96FI4; Q9BY41; P00450; Q16595; P69905; P02794; P39748	0.190958495361	133-135
DB01064	Isoprenaline	investigational; approved	3779	-	"For the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis"	P27986; Q9Y463; P28482; Q92569; P08588; P07550; O00459; P13945; P00441	0.189478719776	136
DB00902	Methdilazine	approved	14677	-	"Used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders"	P35367; Q9P296	0.188411665755	137
DB00752	Tranylcypromine	investigational; approved	5530	-	"For the treatment of major depressive episode without melancholia."	P21397; P27338; P35626; Q01959; P08908; O60341; P23975	0.188261999529	138
DB01645	Genistein	investigational	5280961	-	"Currently Genistein is being studied in clinical trials as a treatment for prostate cancer.  "	O95718; Q14289; P31749; Q9UL62; Q15788; P04278; Q99527; Q15596; P03372; P02753; O75469; Q16678; P37231; Q92731; P13569; P11388; P11474	0.186440057846	139
DB05075	TG-100801	investigational	11973736	-	"Investigated for use/treatment in macular degeneration."	P21802; P12931; P41240; P51451; P42685; P08631; P09619; Q9H3Y6; P17948; P35968; P07947; P35916; P06239; P09769; P54760; P06241; P07948; P11362	0.186008306976	140
DB00619	Imatinib	approved	5291	-	"For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST)."	P21802; P43166; P25021; P28223; P35968; P29597; Q16832; P35218; P42684; P04629; P07948; P07949; P00533; Q9Y2D0; P07333; P16234; P43405; P06239; P10721; P11362; Q6UN15; P23280; P06213; P09619; Q08345; P12931; O43570; P31645; P36888; P00519; P00918; P22748; P11274; P07451; Q16790; O60674; Q9ULX7; P00915; P04049; P15056; P06241	0.185301008503	141
DB11348	Calcium Phosphate	approved	24456	-	"For use as an over the counter calcium and phosphate supplement, antacid, or a source of calcium and phosphate in toothpaste [FDA Label] [L851]."	P04271; Q99828; O14958; O75838; P0DP25; P28676; P27797; Q15493; P13693; Q99584; P09486; O75340; P80303; P27824; Q96FQ6; Q9ULB1; P62166; P0DP24; Q99653; Q9UBV8; Q86UW7; P0DP23; P41180; P35556; P06703; P31415; P30626; Q9ULU8; Q02818; P22676; Q96L12; Q75N90; Q13938; P58400	0.184885057339	142-143
DB11093	Calcium citrate	investigational; approved	13136	-	"For use as an over the counter calcium supplement."	Q02818; Q99828; O14958; P80303; P0DP25; P28676; P27797; Q15493; P13693; Q99584; P09486; O75340; O75838; Q96FQ6; P27824; P41180; Q9ULB1; P62166; P0DP24; Q99653; Q9UBV8; Q86UW7; P0DP23; Q9ULU8; P35556; P06703; P31415; P30626; P04271; P22676; Q96L12; Q75N90; Q13938; P58400	0.184885057339	142-143
DB00570	Vinblastine	approved	13342	-	"For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma."	Q9BQE3; Q9BVA1; P68366; P05412; P0DPH7; P68363; P07437; P23258; Q9UJT0; P0DPH8; Q6PEY2; Q3ZCM7; Q9H4B7; Q9UJT1; Q13509; P68371; Q13885; Q71U36; Q9BUF5; P04350	0.182329936573	144-149
DB06772	Cabazitaxel	approved	9854073	-	"For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen."	Q9BQE3; Q9BVA1; P68366; P0DPH7; P68363; Q6PEY2; P0DPH8; P68371; Q71U36; Q9H4B7; P07437; Q13885; Q13509; Q3ZCM7; Q9BUF5; P04350	0.182329936573	144-149
DB08871	Eribulin	investigational; approved	73425383	-	"For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer. "	Q9BVA1; P68366; P0DPH7; P68363; P10415; P0DPH8; Q9BQE3; Q6PEY2; Q3ZCM7; Q9H4B7; P07437; Q13885; Q13509; P68371; Q71U36; Q9BUF5; P04350	0.182329936573	144-149
DB00541	Vincristine	investigational; approved	5978	-	"Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). "	Q9BVA1; P68366; P68371; Q9H4B7; Q3ZCM7; P07437; Q13885; Q13509; Q9BUF5; P04350	0.182329936573	144-149
DB00361	Vinorelbine	investigational; approved	44424639	-	"   Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs [L1998].    Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents [L2011].     For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate [L2011].    For the treatment of recurrent or metastatic squamous cell head and neck cancer [L2011].    For the treatment of recurrent ovarian cancer [L2011].    For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy [L2011].    For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus [L2011].  "	Q9BQE3; Q9BVA1; P68366; P0DPH7; P68363; P68371; Q9H4B7; P0DPH8; Q6PEY2; Q71U36; P07437; P08684; Q13509; Q13885; Q3ZCM7; Q9BUF5; P04350	0.182329936573	144-149
DB04845	Ixabepilone	investigational; approved	6445540	-	"Investigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified)."	Q9BVA1; Q9BQE3; P0DPH7; P68363; P07437; P0DPH8; P68371; Q6PEY2; Q3ZCM7; Q9H4B7; P68366; Q13885; Q13509; Q71U36; Q9BUF5; P04350	0.182329936573	144-149
DB09221	Polaprezinc	experimental	6918055	-	"Peptic ulcer disease, dyspepsia [L1308]."	P01138; P08238; P05231; P09619; P17948; P08700; P01375; P07900	0.178286368163	150-153
DB06070	SNX-5422	investigational	44195571	-	"Investigated for use/treatment in cancer/tumors (unspecified)."	P08238; P07900	0.178286368163	150-153
DB05134	Tanespimycin	investigational	6505803	-	"Investigated for use/treatment in leukemia (myeloid) and solid tumors."	P08238; P07900; P08581	0.178286368163	150-153
DB12442	Alvespimycin	investigational	5288674	-	"Investigated for use as an antineoplastic agent for solid tumors, advanced solid tumours or acute myeloid leukaemia. "	P08238; P07900	0.178286368163	150-153
DB09118	Stiripentol	approved	5311454	-	"Indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet?s syndrome) whose seizures are not adequately controlled with clobazam and valproate."	P08684; Q9UN88; P30531; P07195; P00338	0.174936087446	154
DB00852	Pseudoephedrine	approved	7028	-	"Pseudoephedrine is a sympathomimetic amine used for its decongestant activity.[L11031,L11037,L11040,L11046,L11052,L11058,L11061]"	P05412; Q99873; O95644; P19838; Q01959; P60568; P08588; P08913; P01375; P31645; P07550; P23975; P35348	0.174239268773	155
DB09570	Ixazomib	investigational; approved	25183872	-	"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. "	P49721; P28074; P20618	0.170498218602	156
DB00615	Rifabutin	investigational; approved	6323490	-	"For the prevention of disseminated <i>Mycobacterium avium</i> complex (MAC) disease in patients with advanced HIV infection."	B5QTY1; B4T9Z3; B1X982; B2TTX9; C4ZXP1; B7NEV3; Q0SYH7; A7MQB3; P07900; B7NQ13; P0A7Z4; Q329K7; A8A6B1; A8ARN6; B1IYV1; Q0TBG0; Q31UQ7; A9MKM3; A1AHI0; B4SXF1; P0A800; P0A8V2; A9MVP7; B1LK86; B7UM71; Q5PC39; B6I3M8; A6TFP8; P14625; Q1R4U2; Q57I91; B7M4D4; Q3YW12; B5BI24; P0A8T7; B5FM73; P0A801; B7N2X2; B4U000; B7L773; B7LVL1; P0A804; B5EY10; B7MFL0; P0A803; P0A802; B5RG73; C0Q1Y1; A7ZTK1; B5YWE9	0.170496650954	157
DB01118	Amiodarone	investigational; approved	2157	-	"The FDA approved indications for amiodarone are recurrent ventricular fibrillation (VF)  and recurrent hemodynamically unstable ventricular tachycardia (VT). The FDA emphasizes that this drug should only be given in these conditions when they are clinically documented and have not responded to normal therapeutic doses of other antiarrhythmic agents, or when other drugs are not tolerated by the patient.[L3561]    Off-label indications include atrial fibrillation and supraventricular tachycardia.[A189666,A189720,A189723,L11286]"	P10827; P41145; P28223; P10828; P35372; P04626; P08913; P35462; Q9Y3Q4; Q9NS40; Q14524; O95180; P11229; Q9P0X4; Q99720; Q12809; Q01959; P18089; P21728; P08588; Q96RP8; P14416; P23975; P08172; P08173; P32245; P20309; P51679; P41143; P28335; P41595; P08684; O00305; P35348; P13945; P25021; P25101; P30411; Q07869; P37231; P08912; P31645; P06241; Q86YN6	0.167546319867	158-163
DB01110	Miconazole	investigational; vet_approved; approved	4189	-	"For topical application in the treatment of tinea pedis (athlete&rsquo,s foot), tinea cruris, and tinea corporis caused by <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, and <i>Epidermophyton floccosum</i>, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor."	P10613; P08173; Q9Y691; P10635; O94759; P25103; P35372; O75469; Q9NQA5; P35462; Q9H252; P00533; P29274; P11229; Q12809; Q01959; P21728; P08913; P35228; P14416; Q86W47; P23975; P30542; P08172; P41145; P22303; P28223; P32245; P20309; Q9NS40; P28335; P41595; P08588; P08684; P18089; O15554; P31645; P13945; Q12791; P41143; P05093; P04626; P25021; P35354; P25100; Q16558; Q92952; Q9UGI6; Q9H2S1; P29474; P08908; Q9NPA1; P06241; P21554; P11511	0.167546319867	158-163
DB00477	Chlorpromazine	investigational; approved; vet_approved	2726	-	"For the treatment of schizophrenia, to control nausea and vomiting, for relief of restlessness and apprehension before surgery, for acute intermittent porphyria, as an adjunct in the treatment of tetanus, to control the manifestations of the manic type of manic-depressive illness, for relief of intractable hiccups, for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance."	P0DP24; P19652; Q99250; Q05586; P18825; P10635; P28222; P28223; Q01959; Q12809; P35372; P04626; P25100; P35462; P46098; P0DP23; P00533; O15399; P11229; Q9H3N8; Q99720; P34969; P21728; Q9NY46; P18089; P08912; P08913; P14416; P28221; P23975; P08172; P08173; P21817; P32245; P41143; P28335; O60391; P41595; P21918; P35498; P35368; P35367; Q14957; P35348; P21917; P41145; Q9UL62; P0DP25; P17405; P25021; Q13224; Q12879; Q8TCU5; P50406; P20309; P08908; P31645; P06241; P01011	0.167546319867	158-163
DB01127	Econazole	approved	3198	-	"For topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, <i>Trichophyton tonsurans</i>, <i>Microsporum canis</i>, <i>Microsporum audouini</i>, <i>Microsporum gypseum</i>, and <i>Epidermophyton floccosum</i>, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor."	P10613; P08173; P10635; P28223; P35372; O75469; Q9NQA5; P35462; P00533; P11229; Q99720; Q01959; P21728; P08913; P14416; P29274; P30542; P08172; P41145; P22303; P41143; P28335; P41595; P08588; P08684; P18089; O94759; P23975; P13945; P05093; P04626; P25021; P25103; P25100; P20309; P08908; P31645; P06241; P21554	0.167546319867	158-163
DB00882	Clomifene	investigational; approved	2800	-	"Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome) to induce ovulation. "	P18825; P10635; P28223; P04626; P35462; P00533; P11229; Q99720; Q12809; Q01959; P03372; P08912; P08913; P04278; P23975; P08172; P08173; P28335; P18089; P41595; P35367; P23219; P13945; P20309; P31645; P06241	0.167546319867	158-163
DB11125	Benzethonium	approved	2335	-	"Indicated as an antiseptic agent. No therapeutic indications for clinical use. "	P08172; P08173; P22303; Q12809; P11229; P18825; P28335; Q01959; P18089; P08912; P08913; P04626; P28223; P20309; P31645; P06241; P23975	0.167546319867	158-163
DB00322	Floxuridine	approved	5790	-	"For palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion)."	P04818; Q8TDS4	0.167491759231	164-178
DB00441	Gemcitabine	approved	60750	-	"Gemcitabine is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy, metastatic ovarian cancer, inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer, and locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. "	Q7LG56; Q07864; P49005; P09884; P30085; P04818; P56282; Q14181; Q15054; P23921; P49643; P49642; P31350; P28340; Q9HCU8; Q9NRF9	0.167491759231	164-178
DB00432	Trifluridine	investigational; approved	6256	-	"Trifluridine is used for the treatment of primay keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2 in ophthalmic solutions.    Trifluridine, in combination with tipiracil as oral tablets, is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy [FDA Label]."	P04818	0.167491759231	164-178
DB09256	Tegafur	investigational; approved	5386	-	"Indicated for the treatment of cancer usually in combination with other biochemically modulating drugs.    Indicated in adults for the treatment of advanced gastric cancer when given in combination with [DB00515] [L933].     Indicated for the first-line treatment of metastatic colorectal cancer with [DB03419] and calcium folinate [L934]. "	P04818	0.167491759231	164-178
DB01101	Capecitabine	investigational; approved	60953	-	"For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated."	Q12882; P04818	0.167491759231	164-178
DB00293	Raltitrexed	investigational; approved	104758	-	"For the treatment of malignant neoplasm of colon and rectum"	Q05932; P04818; P00374	0.167491759231	164-178
DB04824	Phenolphthalein	approved; withdrawn	4764	-	"Used for over a century as a laxative."	P04818; Q14994; P03372; O75469; O60656; P04278; Q05940	0.167491759231	164-178
DB00544	Fluorouracil	approved	3385	-	"For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid."	Q12882; P04818; P11229	0.167491759231	164-178
DB05116	Thymectacin	investigational	6440764	-	"Investigated for use/treatment in colorectal cancer."	P04818	0.167491759231	164-178
DB00563	Methotrexate	approved	126941	-	"Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.[L7144] Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.[L7147,L7150,L10457]    Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma.[L7180] It is also used in the maintenance of acute lymphocytic leukemia.[L7180] Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.[L7180]"	P00374; P04818; P41440	0.167491759231	164-178
DB00650	Leucovorin	approved	6006	-	"For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer."	P00374; P04818; P46734; Q02750; P45985	0.167491759231	164-178
DB11256	Levomefolic acid	investigational; approved	444412	-	"For the treatment and prevention of folate deficiency and for use as an antidote against folic acid antagonists. Contained in oral contraceptives to reduce the risk of neural tube defects arising from folic acid deficiency for pregnant women who conceived during use or shortly after the discontinuation of the product. Being studied for use as a treatment for cardiovascular diseases [A19273] and adjunct therapy for patients undergoing antidepressant pharmacotherapy [A19271, A19272]."	P04818	0.167491759231	164-178
DB09327	Tegafur-uracil	investigational; approved	104747	-	"Tegafur-uracil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinate.[L934] Colorectal cancer is the third most diagnosed cancer and 30% of the cases can present the metastatic state.[A32077]"	P04818	0.167491759231	164-178
DB00158	Folic acid	vet_approved; approved; nutraceutical	6037	-	"Folic acid is indicated for the treatment of folic acid deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood."	P41440; O14757; P04818; P14207; P41439; P15328	0.167491759231	164-178
DB06813	Pralatrexate	investigational; approved	148121	-	"Treatment of relapsed or refractory peripheral T-cell lymphoma. "	P00374; P04818	0.167491759231	164-178
DB00499	Flutamide	investigational; approved	3397	-	"For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate"	Q9BYF1; P10275; O75469; P35869	0.166908470038	179
DB00756	Hexachlorophene	withdrawn; approved	3598	-	"For use as a surgical scrub and a bacteriostatic skin cleanser. It may also be used to control an outbreak of gram-positive infection where other infection control procedures have been unsuccessful."	P00533; P22303; P18825; Q92731; P28335; P00367; P41595; P03372; O14521; P35354; P08913; P04626; P06239; P0AEK4; P06149; P31645; P06241; P29274	0.166808769321	180-181
DB09115	Diiodohydroxyquinoline	approved	3728	-	"Used in the treatment of amoebiasis."	P00533; P06241; P04626; P06239	0.166808769321	180-181
DB00608	Chloroquine	investigational; vet_approved; approved	2719	-	"Chloroquine is indicated to treat infections of _P. vivax_, _P. malariae_, _P. ovale_, and susceptible strains of _P. falciparum_.[L12051] It is also used to treat extraintestinal amebiasis.[L12051]    Chloroquine is also used off label for the treatment of rheumatic diseases,[A191655] as well as treatment and prophylaxis of Zika virus.[A191649,A191652] Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.[A191631]"	Q8MU52; Q12809; Q9NR96; Q96LB2; P11413; P09488; P09429; Q9BYF1; P01375; P09210	0.16662947132	182
DB05260	Gallium nitrate	investigational; approved	61635	-	"For the treatment of hypercalcemia. Also intended for the treatment of non-hodgkin's lymphoma."	P21281; P01584; P02818; Q7LG56; P23921; P31350	0.165064687825	183
DB00128	Aspartic acid	approved; nutraceutical	5960	-	"There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids."	Q03154; Q7L266; Q12879; P00966; P22234; P08243; P27708; P07998; Q12797; P61626; Q9UJS0; O75746; Q96HD9; P30520; Q14957; P14868; P17174; Q6PI48; P45381; Q13224; P00505; Q8N142; P43005	0.164832754402	184
DB01242	Clomipramine	investigational; vet_approved; approved	2801	-	"May be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette?s disorder).  Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome. "	P18825; P10635; P28223; P35462; P09211; P11229; Q99720; Q01959; P21728; P08913; P14416; P23975; P08172; P08173; P28335; P18089; P41595; P35367; P35348; P25021; P25100; P20309; P08912; P31645	0.160998395975	185
DB00143	Glutathione	investigational; approved; nutraceutical	124886	-	"For nutritional supplementation, also for treating dietary shortage or imbalance"	Q7RTV2; Q9H4Y5; O95881; Q16873; Q04760; P15121; P09211; P30711; Q9Y2Q3; O75715; P22352; P35754; O60760; Q8TED1; P28161; Q16772; Q16775; O15217; P00390; P46439; P78417; P10768; P10620; P36969; P08684; Q96SL4; P48637; P19440; P14780; P59796; P18283; O14880; P09488; P21266; P07203; Q99735; Q03013; Q9NS18; O43708	0.160544429434	186
DB00811	Ribavirin	approved	37542	-	"Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates [A19644].    The addition of ribavirin in Technivie therapy indicated for treating HCV genotype 1a and 4 infections is recommended in patients with or without cirrhosis.     Resistance: viral genetic determinants resulting in variable response to ribavirin therapy has not been yet determined. "	P12268; P20839; P12823; P22413; P49902; P11387; P16502; P26676	0.160461059435	187
DB00762	Irinotecan	investigational; approved	60838	-	"For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. "	P08173; P22303; P18825; Q969P6; P03956; P22309; P11387	0.160229495365	188
DB00903	Etacrynic acid	investigational; approved	3278	-	"For the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure."	P05023; P09211; Q9UJU2; Q13621; P11229	0.160088818986	189
DB00988	Dopamine	approved	681	-	"For the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure"	P46098; P35462; P07550; Q96RJ0; P34969; Q01959; Q05940; P21918; P21728; P08588; P49286; O95264; P14416; P08908; P31645; P48039; P23975; P21917; P00441	0.15980744302	190
DB05289	Tarenflurbil	investigational	92337	-	"Investigated for use/treatment in alzheimer's disease and prostate cancer."	Q96BI3; Q92542; Q9NZ42; P49768; Q9Y6K9; Q8WW43; P49810	0.159328753555	191
DB01136	Carvedilol	investigational; approved	2585	-	"Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ?40%, or hypertension.[L7889,L7892]"	P17302; P18825; P10635; P28223; P08913; P35462; P19320; P16581; P63252; Q12809; Q01959; P21728; P08588; P14416; P23975; P16860; P28335; P41595; P18089; P35368; P31645; P35348; P13945; P48050; P25100; P08908; O95298; P07550; P15692; Q16665	0.158475615127	192
DB03496	Alvocidib	investigational; experimental	5287969	-	"Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified)."	P00533; P06493; P50613; P11217; P11216; Q00526; Q00534; Q00535; P49336; Q15131; P50750; P11802; P24941; P06737	0.158406923999	193-196
DB06195	Seliciclib	investigational	160355	-	"Investigated for use/treatment in breast cancer, lung cancer, lymphoma (unspecified), multiple myeloma, leukemia (lymphoid), and cancer/tumors (unspecified)."	P28482; P06493; P50613; Q00535; P27361; P49674; P50750; P24941	0.158406923999	193-196
DB06210	Eltrombopag	approved	9846180	-	"Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. "	P01008; P06493; P12259; P40238	0.158406923999	193-196
DB08142	AT-7519	investigational	11338033	-	"Investigated for use/treatment in leukemia (unspecified), lymphoma (unspecified), myelodysplastic syndrome, and solid tumors."	Q8IZL9; Q9BWU1; P06493; P50613; Q00526; Q00534; Q00537; Q00536; P21127; Q00535; Q14004; Q9NYV4; Q15131; P50750; O94921; P11802; Q96Q40; P24941; Q16667; Q07002; P49336	0.158406923999	193-196
DB04967	Lucanthone	investigational	10180	-	"Intended for use as a radiation sensitizer in the treatment of brain cancer."	P27695; P11388; P11387; Q02880	0.158109234778	197-199
DB05129	Elsamitrucin	investigational	5362259	-	"Investigated for use/treatment in lymphoma (non-hodgkin's)."	P11388; P11387	0.158109234778	197-199
DB00276	Amsacrine	investigational; approved	2179	-	"For treatment of acute myeloid leukaemia."	P02768; Q9BXC0; Q969P6; P02763; Q12809; P30559; P11387; P10635; P11388; P37288; Q02880	0.158109234778	197-199
DB09225	Zotepine	investigational; withdrawn; approved	5736	-	"Zotepine, like other atypical antipsychotics, is considered as the first-line treatment in newly diagnosed schizophrenia. It is usually thought to be an option of choice for managing acute schizophrenic episodes when discussion with the patient is not possible. Zotepine, as an atypical antipsychotic, is used in patients who are suffering unacceptable side effects from conventional antipsychotics or in relapse patients that were inadequately controlled.[T108]     It is important to consider that the indications stated above are related to atypical antipsychotics, that zotepine is not currently FDA, Canada or EMA approved and that studies have not shown any additional benefit when compared with other approved atypical antipsychotics.[A31857]    Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves. It is usually marked for a loose reality perspective delineated by hallucinations, delusions and thought and movement disorders.[L1320]"	P18825; P28221; P28222; P35368; Q01959; P08913; P35462; P46098; P28566; P11229; P34969; P08912; P21728; P08588; P14416; P23975; P08172; P08173; P28223; P28335; P18089; P21918; P31645; P35367; P35348; P21917; P25021; P50406; P20309; P08908; P07550; P01011	0.156207942905	200-208
DB01224	Quetiapine	approved	5002	-	"Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546]    Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.[A185438,A185447,T685]  "	P34969; P18825; P28221; P28222; P28223; P35462; P46098; P28566; P11229; Q99720; Q12809; P21728; P30939; P08912; P08913; P14416; P23975; P08172; P08173; P28335; P41595; P21918; P18089; P35368; P35367; P35348; P21917; P25100; P50406; P20309; P08908; P07550; P08588	0.156207942905	200-208
DB01151	Desipramine	investigational; approved	2995	-	"For relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management. "	Q7RTT9; P18825; P10635; P28222; P28223; Q01959; P08913; Q99250; P41595; P11229; Q12809; P21728; P35348; P08912; P08588; P14416; P23975; P08172; P08173; P28335; P18089; P35498; P07550; P35367; Q9NY46; P17405; P25100; P20309; P08908; P31645	0.156207942905	200-208
DB00246	Ziprasidone	approved	60854	-	"In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder.[L7342] The injectable formulation is approved only for treatment of acute agitation in schizophrenia.[L7342]"	Q12809; P18825; P28221; P28222; P35368; P08913; P35462; P46098; P47898; P28566; P11229; P34969; Q01959; A5X5Y0; P21728; P08588; P14416; P23975; P08172; P08173; P28223; P36544; P28335; P41595; P21918; P18089; P07550; P35367; P35348; P21917; P08912; Q494W8; P25021; P50406; P20309; P08908; P31645; P01011	0.156207942905	200-208
DB01238	Aripiprazole	investigational; approved	60795	-	"Aripiprazole is indicated for manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, treatment of schizophrenia, treatment of Tourette's disorder, and as an adjunctive treatment of major depressive disorder[Label]. An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania[Label]."	P34969; P25021; P08173; P18825; P28221; P28222; P28223; Q01959; P35372; P35462; P46098; P47898; P28566; P11229; P07550; Q9H3N8; Q12809; P08912; P21728; P08913; P14416; P10635; P23975; Q9Y5N1; P08172; P41145; P41143; P28335; P41595; P21918; P18089; P35368; P35367; P35348; P21917; O60391; P50406; P20309; P08908; P31645; P08588	0.156207942905	200-208
DB00734	Risperidone	investigational; approved	5073	-	"Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder.[L12885] It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.[L12885]    Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.[L12906]    Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.[A177226]"	Q12809; P18825; P10635; P28222; P28223; P08913; P35462; P28566; P11229; P07550; Q99720; Q14209; P30939; P21728; P08588; P34969; P14416; P28221; P08172; P08173; P28335; P41595; P18089; P35368; P35367; P35348; P23415; P25021; P25100; P50406; P20309; P08908; P31645; O00716; P01011	0.156207942905	200-208
DB00334	Olanzapine	investigational; approved	4585	-	"Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.[A177014]     Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.[FDA label]    As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.[A177014]    Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.[FDA label]    Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.[L5936]    Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.[L5939]"	Q12809; P18825; P28221; P28222; P28223; P35462; P46098; P28566; P11229; P34969; P08912; P30939; P21728; P08913; P13945; P14416; P35368; P08172; P08173; P28335; P18089; P21918; P41595; P07550; P35367; P35348; P21917; P08588; P25021; P25100; P50406; P20309; P08908; P31645; Q99928; P01011	0.156207942905	200-208
DB00496	Darifenacin	investigational; approved	444031	-	"For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency."	P08172; P08173; P20309; P10635; P08912; P08588; P14416; P07550; P11229	0.156207942905	200-208
DB00574	Fenfluramine	illicit; investigational; approved; withdrawn	3337	-	"For the management of exogenous obesity as a short-term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction."	P18825; P28221; P28222; P28223; P08913; P11229; Q99720; P34969; P08588; P08172; P08173; P28335; P41595; P18089; P35368; P31645; P35348; P17752; P02746; P20309; P08908; P07550	0.156207942905	200-208
DB00841	Dobutamine	approved	36811	-	"Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures."	P43166; P23280; Q16790; P21964; P35462; P35218; Q8N1Q1; P00533; Q9Y2D0; Q99720; Q01959; P03372; P08588; P06239; P23975; P18089; O43570; P07550; P00918; P22748; P07451; Q9ULX7; P00915; P25100; P31645; P06241	0.155416593864	209-210
DB00696	Ergotamine	approved	8223	-	"For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called \"histaminic cephalalgia\"."	P18825; P28221; P28222; P28223; P08913; P35462; P47898; P28566; P11229; P30939; P21728; P08588; P06239; P23975; P08172; P14416; P28335; P18089; P21918; P08684; P41595; P35368; P35348; P25100; P50406; P08908; P07550; P06241	0.155416593864	209-210
DB00119	Pyruvic acid	investigational; approved; nutraceutical	1060	-	"For nutritional supplementation, also for treating dietary shortage or imbalance"	P11498; Q9BYV1; Q99500; O15375; P30613; P36021; O15403; P21453; P80404; P14618; O95907; P11177; O15374	0.155314365886	211
DB01158	Bretylium	approved	2431	-	"For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine."	P05023; P07550; P08588; P23975	0.155270305868	212
DB00116	Tetrahydrofolic acid	nutraceutical	91443	-	"For nutritional supplementation, also for treating dietary shortage or imbalance."	P42898; P48728; O95954; P34896; P34897; P11586; O75891; Q99707; P13995; Q96DP5; P31939	0.154952875702	213
DB01611	Hydroxychloroquine	approved	3652	-	"Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by _P. falciparum_, _P. malariae_, _P. ovale_, or _P. vivax_), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.[L8072]"	P08172; P25116; Q9NYK1; Q12809; Q9NR96; P25100; Q9BYF1; P69905	0.154147894232	214
DB00139	Succinic acid	approved; nutraceutical	1110	-	"For nutritional supplementation, also for treating dietary shortage or imbalance"	Q96I99; Q99643; Q9GZT9; P51649; O14521; Q9BYC2; Q9BXA5; Q32P28; O14756; O15460; Q8WWT9; P13674; Q02809; Q9P2R7; P31040; Q9BZW2; Q8IVL6; Q12797; P21912; P53597; Q8IVL5; O60568; Q13183; Q9UBX3; Q9NVH6; P55809; O75936	0.154113178339	215
DB00387	Procyclidine	approved	4919	-	"For the treatment of all forms of Parkinson's Disease, as well as control of extrapyramidal reactions induced by antipsychotic agents."	P08172; P08173; O15399; P11229; Q05586; P22001; O60391; Q13224; Q12879; Q8TCU5; P08912; P20309; Q14957	0.151132611687	216-217
DB00420	Promazine	approved; vet_approved	4926	-	"Used as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly."	P35462; P18825; P10635; P28223; Q99250; P11229; Q99720; P08912; P35348; P21728; P08913; P14416; P23975; P08172; P08173; P28335; P41595; P18089; P35368; P35367; Q9NY46; P21917; P22001; P25021; P25100; P20309; P08908; P31645; P35498	0.151132611687	216-217
DB00887	Bumetanide	approved	2471	-	"For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome."	Q9H2X9; P05023; Q13621; Q9UP95; P13569; P55011; Q9HC97	0.150097262675	218-219
DB00695	Furosemide	vet_approved; approved	3440	-	"Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.[L7958]     Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.[L9659]    Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.[L7958]"	P00918; P22748; P28845; Q9Y2D0; P43166; P05023; Q9ULX7; P23280; Q13621; P00915; O43570; Q16790; P55011; P35218; Q9HC97	0.150097262675	218-219
DB03010	Patupilone	investigational; experimental	448013	-	"Investigated for use/treatment in ovarian cancer, lung cancer, brain cancer, breast cancer, and gastric cancer."	P68366; P0DPH7; P68363; Q9H4B7; P0DPH8; Q9BQE3; Q71U36; P07437; Q9NY65; Q13509; P68371; P04350	0.147447941275	220-222
DB01873	Epothilone D	investigational	447865	-	"Investigated for use/treatment in colorectal cancer, lung cancer, breast cancer, solid tumors, and prostate cancer."	P68366; P0DPH7; P68363; P68371; P0DPH8; Q9BQE3; Q71U36; Q9H4B7; P07437; Q9NY65; Q13509; P04350	0.147447941275	220-222
DB01394	Colchicine	approved	2833	-	"Colchicine is indicated for the prophylaxis and treatment of gout flares.  It is also indicated in Familial Mediterranean fever (FMF) in children and adults of 4 years of age and older. It is important to note that this medication is not a pain reliever to be used for other painful conditions. Consider analgesics for this purpose.[L8138] Some off-label uses of colchicine include the treatment of the manifestations of Behcet's syndrome, pericarditis, and postpericardiotomy syndrome.[A183932,A183935]"	P07437; P23415; P08684; P68371	0.147447941275	220-222
DB11823	Esketamine	investigational; approved	182137	-	"This drug is indicated in conjunction with an oral antidepressant for the treatment of treatment-resistant depression (TRD) in adults [FDA label].    Note: Esketamine is not approved as an anesthetic agent. The safety and effectiveness of esketamine as an anesthetic agent have not been established to this date [FDA label]. "	Q05586; O15399; O60391; Q13224; P23560; Q8TCU5; Q12879; Q16620; Q14957; P13639	0.145302073009	223
DB00993	Azathioprine	approved	2265	-	"Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]"	P51580; Q06203; P63000	0.143670997134	224
DB06094	Apatorsen	investigational	131704298	-	"Investigated for use/treatment in cancer/tumors (unspecified)."	P04792	0.143662417542	225
DB00277	Theophylline	approved	2153	-	"For the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis."	Q99829; Q9Y4R7; P27815; O00329; O76074; Q7Z5B4; Q14432; P0DMS8; Q13370; Q08493; Q07343; Q92769; Q15155; P09874; Q08499; P29274; P29275; P30542; Q8TCT9	0.142332580695	226-230
DB11793	Niraparib	investigational; approved	24958200	-	"Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy"	P09874; Q9Y6F1; Q9UGN5	0.142332580695	226-230
DB11760	Talazoparib	investigational; approved	44819241	-	"Talazoparib is indicated for the treatment of deleterious or suspected deleterious germline BRCA mutated, HER2 negative locally advanced or metastatic breast cancer in adults [FDA Label]."	P09874; Q9UGN5	0.142332580695	226-230
DB12332	Rucaparib	investigational; approved	9931954	-	"Indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for rucaparib."	P09874; P10635; Q9Y6F1; P05177; Q9UGN5	0.142332580695	226-230
DB04335	Inosine	investigational; experimental	6021	-	"The primary popular claim made for inosine, that it enhances exercise and athletic performance, is refuted by the available research data. There is some preliminary evidence that inosine may have some neurorestorative, anti-inflammatory, immunomodulatory and cardioprotective effects."	P09874; P00491; P0ABP8	0.142332580695	226-230
DB09078	Lenvatinib	investigational; approved	9823820	-	"Lenvatinib is indicated for the treatment of following conditions.    - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.    - Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy.    - First-line treatment of unresectable hepatocellular carcinoma (HCC)."	P21802; P00533; P09619; P16234; P17948; P35968; P35916; P22455; P11362; P22607; P07949; P10721	0.141795879516	231-233
DB05928	Dovitinib	investigational	9977819	-	"Investigated for use/treatment in multiple myeloma and solid tumors."	P00533; P36888; P07333; P21802; P09619; P16234; P17948; P35968; P35916; O75469; P11362; P06213; P22607; P10721	0.141795879516	231-233
DB12147	Erdafitinib	investigational; approved	67462786	-	"Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor [FDA Label][A177109, A177112, A177115] that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has:  i) susceptible FGFR3 or FGFR2 genetic alterations and has [FDA Label],  ii) progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy [FDA Label].    The selection of patients for the treatment of locally advanced or metastatic urothelial carcinoma with erdafitinib should be based on the presence of susceptible FGFR genetic alterations in tumor specimens as detected by an FDA-approved companion diagnostic like the FDA approved therascreen FGFR RGQ RT-PCR Kit as developed by QIAGEN [FDA Label].    This above indication is approved under accelerated approval by the US FDA based on tumor response rate [FDA Label]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials [FDA Label]."	P21802; P07333; P35968; P16234; P09619; P10721; P22455; P22607; P11362	0.141795879516	231-233
DB00091	Cyclosporine	investigational; approved; vet_approved	5284373	-	"Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy[L3002] and to prevent or treat graft-versus-host disease (GVHD).[L11097]    Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone.[L3734] It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated.[L3734] The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca.[L11097] In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.[L11097]    Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.[A139,A174085,A189393,A189396,A189399]"	Q9UNQ0; Q14973; Q99500; Q96LZ3; P62942; Q02127; Q9NPD5; Q9UBY5; P30405; P49069; P62937; P08684; P21462; Q9Y6L6	0.133694837564	234
DB00142	Glutamic acid	approved; nutraceutical	33032	-	"Considered to be nature's \"Brain food\" by improving mental capacities, helps speed the healing of ulcers, gives a \"lift\" from fatigue, helps control alcoholism, schizophrenia and the craving for sugar."	O43424; O94925; Q9H1K4; Q5TDP6; P24298; Q05932; O15382; Q05329; Q5JPH6; P80404; Q13224; P48507; P48506; Q13002; Q12879; P54886; P08243; P54687; Q99259; Q8N5Z0; Q8TCU5; O15399; Q13255; Q04609; Q9Y646; P15104; P48664; P48058; Q05586; P39086; P49915; Q6YP21; Q8N159; P07814; O00222; Q13003; O14841; Q9UDR5; O00341; P00390; P49448; Q07075; O95954; O60391; Q8TD30; Q6IA69; Q9UI32; Q14957; Q14831; Q14833; O15067; P38435; P17174; Q9ULA0; P17735; Q9ULK0; P00367; Q9UPY5; P00505; Q16478; P43003; P43005; Q16099; Q9H936; P43004; Q9Y617; O75879; P42261; P42262; P42263	0.128275394931	235
DB00947	Fulvestrant	investigational; approved	17756771	-	"For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents."	P06401; Q99527; Q92731; P41597; P03372; Q6NYC1; Q96RI1; P04626	0.127561382172	236-246
DB01590	Everolimus	approved	6442177	-	"Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.  Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.  Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.  Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.  Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected."	P62942; P04626; P42345; P03372	0.127561382172	236-246
DB11963	Dacomitinib	investigational; approved	11511120	-	"Dacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an FDA-approved test.[L4812]    Lung cancer is the leading cause of cancer death and NSCLC accounts for 85% of lung cancer cases. From the cases of NSCLC, approximately 75% of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5%. The presence of a mutation in EGFR accounts for more than the 60% of the NSCLC cases and the overexpression of EGFR is associated with frequent lymph node metastasis and poor chemosensitivity.[A40018, A19201]"	P00533; P04626; P21860; Q15303	0.127561382172	236-246
DB00796	Candesartan cilexetil	approved	2540	-	"May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors."	P00533; P50052; P18089; P08684; P04626; P23975; P30556; P13945	0.127561382172	236-246
DB12267	Brigatinib	investigational; approved	68165256	-	"The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target.[A31311] The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules.[A31313] The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival.[A31316] Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.[A31314]"	P00533; P08069; Q9UM73; P04626; P06213; P08922; Q15303; P08581; P36888; P00519	0.127561382172	236-246
DB11652	Tucatinib	investigational; approved	51039094	-	"Tucatinib is indicated with trastuzumab and capecitabine for treatment of adults diagnosed with advanced unresectable or metastatic HER2-positive breast cancer. This includes patients with brain metastases and those   who have received one or more prior anti-HER2-based regimens in the metastatic setting.[L12945] "	P04626; P21860; Q15303	0.127561382172	236-246
DB00803	Colistin	approved	131704173	-	"For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly <i>Pseudomonas aeruginosa</i>."	P04626; P06241; P32245; P00533	0.127561382172	236-246
DB05944	Varlitinib	investigational	42642648	-	"Investigated for use/treatment in cancer/tumors (unspecified)."	P00533; P04626	0.127561382172	236-246
DB09073	Palbociclib	investigational; approved	5330286	-	"Palbociclib is indicated in combination with [letrozole] as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with [fulvestrant] in patients with disease progression with prior endocrine therapy.[A176783]    In the official labeling, the use of palbociclib should be accompanied with either an aromatase inhibition, no restricted to letrozole, as initial endocrine-based therapy in postmenopausal women or in man.[FDA label]    The breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue. This growth can spread into other parts of the body which is called metastasis. According to the location of the cancer cells, it can be categorized in ductal carcinoma and lobular carcinoma. However, other types of breast cancer include inflammatory breast cancer, Paget disease of the breast, triple negative breast cancer non-Hodgkin lymphoma and soft tissue sarcoma.[L5870] In males, breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinoma.[L5873]"	P24385; P52333; Q00534; P03372; P04626; P14416; P11802; P36888; P21917	0.127561382172	236-246
DB05424	Canertinib	investigational	156414	-	"Investigated for use/treatment in breast cancer and lung cancer."	P00533; P04626; Q15303	0.127561382172	236-246
DB01259	Lapatinib	investigational; approved	208908	-	"Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma."	P00533; P00519; P06401; P09619; P03372; P04626; P01909; P06213; P01911; Q15303	0.127561382172	236-246
DB00795	Sulfasalazine	approved	5359476	-	"For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent."	P00918; P04054; O15111; P09917; P24752; O95696; Q9UPY5; P03956; P11413; P35354; Q00653; P37231; P00915; P21675; P23219; O14920; P24557	0.125880735319	247
DB12941	Darolutamide	investigational; approved	67171867	-	"This drug is indicated for the treatment of patients diagnosed with non-metastatic and castrate-resistant prostate cancer.[L10872]"	P10275; P06401	0.124697704833	248-284
DB08804	Nandrolone decanoate	illicit; approved	9677	-	"For the treatment of refractory deficient red cell production anemias, breast carcinoma, hereditary angioedema, antithrombin III deficiency, fibrinogen excess, growth failure and Turner's syndrome. It is also indicated in the prophylaxis of hereditary angioedema."	P10275	0.124697704833	248-284
DB06713	Norelgestromin	investigational; approved	62930	-	"Norelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy. "	P02768; P06401; P03372; P10275	0.124697704833	248-284
DB08899	Enzalutamide	approved	15951529	-	"Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel."	P10275	0.124697704833	248-284
DB01608	Periciazine	investigational; approved	4747	-	"For use as adjunctive medication in some psychotic patients. Propericiazine (Pericyazine)is used for the control of residual prevailing hostility, impulsiveness and aggressiveness. "	P25100; P10275; P21728; P08913; P35368; P35348	0.124697704833	248-284
DB00957	Norgestimate	investigational; approved	6540478	-	"Norgestimate is formulated with [ethinylestradiol] as a combined oral contraceptive.[L11845,L11848] It can also be given with low dose ethinylestradiol for contraception as well as the treatment of moderate acne vulgaris in women ?15 years old.[L11848]"	P10275; P06401; P03372	0.124697704833	248-284
DB01564	Calusterone	illicit; experimental	28204	-	"An anabolic steroid which can theoretically aid in restauration and buildup of certain tissues, especially muscle. It is similar to synthetic testosterone and is still in early investigation. It was also investigated for use as a treatment for metastatic breast cancer."	P10275	0.124697704833	248-284
DB01420	Testosterone propionate	vet_approved; investigational; approved; withdrawn	5995	-	"Testosterone propionate is often used for muscle mass building. The original medical indication is for the treatment of androgen deficiency in male adults either in hypogonadism or andropause.[L1161] Nowadays testosterone propionate is indicated for its use in heifers in order to stimulate maximal growth.[L1160]"	P05093; P10275	0.124697704833	248-284
DB09216	Tolfenamic acid	investigational; approved	610479	-	"In the information for tolfenamic acid, it is stated that this drug, being an NSAID, is effective in treating the pain associated with the acute attack of migraines in adults.[L1293]"	P10275; P35354; P23219; P42330; P02766	0.124697704833	248-284
DB00655	Estrone	approved	5870	-	"For management of perimenopausal and postmenopausal symptoms."	Q92731; P41595; P03372; P10275; P04278; P31645; P11511	0.124697704833	248-284
DB09086	Eugenol	approved	3314	-	"Eugenol is not currently available in any FDA-approved drug products. There are a number of unapproved OTC products that advertise it for the use of toothache.  Eugenol is is also commonly used in combination with zinc oxide in dental procedures for the cementation of temporary prostheses and the temporary restoration of teeth and cavities."	Q92731; Q8NET8; P03372; P23219; P10275	0.124697704833	248-284
DB09123	Dienogest	approved	68861	-	"Indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol. "	P10275; P06401; P03372	0.124697704833	248-284
DB05812	Abiraterone	approved	132971	-	"Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. "	P31213; P05093; Q9H8P0; P18405; P10275; P08684; P15538	0.124697704833	248-284
DB09389	Norgestrel	approved	4542	-	"Norgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception."	P10275; P06401; P18405; P03372	0.124697704833	248-284
DB00990	Exemestane	investigational; approved	60198	-	"For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy."	Q6NYC1; P10275; P03372; P11511	0.124697704833	248-284
DB00984	Nandrolone phenpropionate	illicit; investigational; approved	229455	-	"For the treatment of refractory deficient red cell production anemias, breast carcinoma, hereditary angioedema, antithrombin III deficiency, fibrinogen excess, growth failure and Turner's syndrome. It is also indicated in the prophylaxis of hereditary angioedema."	P10275; P03372	0.124697704833	248-284
DB06412	Oxymetholone	illicit; approved	5281034	-	"Indicated in the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Oxymetholone should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy and the appropriate use of corticosteroids. "	P10275; P03372; P16860	0.124697704833	248-284
DB11219	Enzacamene	approved	7019255	-	"Indicated for use as an active sunscreen agent. "	P10275; Q92731; P06401; P03372	0.124697704833	248-284
DB05234	LGD2941	investigational	16750192	-	"For the treatment and prevention of osteoporosis."	P10275	0.124697704833	248-284
DB00665	Nilutamide	investigational; approved	4493	-	"For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2)."	P10275	0.124697704833	248-284
DB00301	Flucloxacillin	investigational; approved	21319	-	"Used to treat bacterial infection by susceptible microorganisms."	P10275; Q8XJ01	0.124697704833	248-284
DB00328	Indomethacin	investigational; approved	3715	-	"Oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.[A177871,L6778]     Intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.[L10553]"	Q8N8N7; P37231; P51787; P42330; Q07869; P10275; P35354; Q96RP8; P15382; P15121; Q9Y5Y4; Q04760; P43116; P14555; P23219	0.124697704833	248-284
DB01708	Prasterone	investigational; approved; nutraceutical	5881	-	"DHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men), improving the appearance of older people?s skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial ?age spots? in elderly men and women), improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids).  DHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy."	Q9UN88; Q92731; Q99720; O60391; Q14994; P03372; P10275; O75469; Q07869	0.124697704833	248-284
DB00939	Meclofenamic acid	vet_approved; approved	4037	-	"For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis."	P09917; P02766; P23786; P10275; P35354; O43525; P23219; O43526	0.124697704833	248-284
DB02132	Zenarestat	experimental	5724	-	"Investigated for use/treatment in neuropathy (diabetic)."	P10275; P15121; Q8TDV5	0.124697704833	248-284
DB11901	Apalutamide	investigational; approved	24872560	-	"Indicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC) [FDA Label]."	Q9UN88; P10275	0.124697704833	248-284
DB01128	Bicalutamide	approved	2375	-	"For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer."	P10275	0.124697704833	248-284
DB01063	Acetophenazine	approved	17676	-	"For the treatment of disorganized and psychotic thinking. Also used to help treat false perceptions (e.g. hallucinations or delusions.)"	P10275; P21728; P14416	0.124697704833	248-284
DB00621	Oxandrolone	investigational; approved	5878	-	"Use to promote weight gain after weight loss following extensive surgery."	P10275; P14778	0.124697704833	248-284
DB08604	Triclosan	investigational; approved	5564	-	"Triclosan is used in a variety of common household products, including soaps, mouthwashes, dish detergents, toothpastes, deodorants, and hand sanitizers.  It is also used in health care settings in surgical scrubs and personnel hand washes."	P07202; P9WGR1; O24990; Q14994; P10275; O75469; P37231; P0AEK4; Q6GI75	0.124697704833	248-284
DB13155	Esculin	approved	5281417	-	"As medication, esculin is sometimes used as a vasoprotective agent.  Esculin is also used in a microbiology laboratory to aid in the identification of bacterial species (especially Enterococci and Listeria), as all strains of Group D Streptococci hydrolyze ?sculin in 40% bile."	P10275	0.124697704833	248-284
DB00179	Masoprocol	investigational; approved	71398	-	"Used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated)."	P09917; P08069; P04278; P02766; P10275; P03372; P11511	0.124697704833	248-284
DB09070	Tibolone	investigational; approved	444008	-	"For the relief of post-menopausal symptoms and for the prevention of osteoporosis [L1724]."	P10275; P31645; P06401; P03372	0.124697704833	248-284
DB01428	Oxybenzone	investigational; approved	4632	-	"Used as an ingredient in sunscreen and other cosmetics."	P06401; P03372; Q92731; P10275	0.124697704833	248-284
DB00648	Mitotane	approved	4211	-	"For treatment of inoperable adrenocortical tumours, Cushing's syndrome"	P06401; P10109; P23975; Q01959; P41595; P03372; P05108; P10275; P08913; P31645; P15538	0.124697704833	248-284
DB01026	Ketoconazole	investigational; approved	3823	-	"Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.[FDA Label] In Europe, it is also used in the treatment of endogenous Cushing's syndrome.[L7736]"	P08172; P10613; Q16322; P41143; P10275; P23975; Q12809; P25021; Q01959; P25100; P50859; P08913; O75469; P18089; P08686; P05093; P08684; P31645; P15538; Q14994; P11511	0.124697704833	248-284
DB06718	Stanozolol	vet_approved; approved	25249	-	"Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating C1-inhibitor deficient hereditary angioedema. C1-inhibitor is a protease that inhibits the complement system (part of the innate immune system), a biochemical chain of reactions which assists the body in removing pathogens from the body. Stanozolol may help control attacks of hereditary angioedema.  Stanozolol can be administered orally or intramuscularly. "	P10635; P10275; P03372	0.124697704833	248-284
DB05869	Ethyl pyruvate	investigational	12041	-	"Investigated for use/treatment in burns and burn infections, cardiac surgery, inflammatory disorders (unspecified), ischemic reperfusion injury, and sepsis and septicemia."	P09429; P01375	0.124324015913	285
DB00448	Lansoprazole	investigational; approved	3883	-	"Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label]  It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label]  Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label]  Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]"	P20648; P10635; P10636; P33261; Q96RI0; P51164	0.123753949652	286
DB00716	Nedocromil	investigational; approved	50294	-	"For the treatment of mild to moderate asthma"	Q13258; Q9NS75; P07900; P21462; Q9Y271	0.122298278781	287
DB00755	Tretinoin	investigational; approved; nutraceutical	5538	-	"For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.), For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage."	P10826; O43174; P49116; P48443; P10276; P29590; Q9NY56; P00352; O94788; P19793; Q16654; O60760; P28702; P13631; P02753; Q6V0L0; Q9NR63; P41595; P51843; Q03181; P31025; Q8NFJ5; P49788	0.121547087788	288
DB05448	PX-12	investigational	219104	-	"Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, and pancreatic cancer."	P10599; Q16881	0.120007527568	289
DB06774	Capsaicin	approved	1548943	-	"The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain. "	Q8NER1; Q99623; P23219; P13569	0.119844515309	290
DB00149	Leucine	investigational; nutraceutical	6106	-	"Indicated to assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress."	O60294; O43603; O15382; Q15031; Q9P2J5; P54687; Q9UIC8; P47211	0.119050426353	291
DB04972	Canfosfamide	investigational	5312109	-	"Intended for the treatment of various forms of cancer."	P09211	0.118830216811	292-297
DB05460	Ezatiostat	investigational	5310939	-	"Investigated for use/treatment in myelodysplastic syndrome."	P09211	0.118830216811	292-297
DB04339	Carbocisteine	investigational; approved	193653	-	"Used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis."	P09211	0.118830216811	292-297
DB09462	Glycerin	investigational; approved	753	-	"It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent."	Q93PP9; O43252; P52477; P09211; P17802; P23367; O60760; O14717; P84077; P13632; P0A6E4; P06988; P32246; Q14643; P37173; Q9NPH2; Q52369; Q03181; P00325; P51681; P17050; Q9NZK7; P09466; Q8GR70; P0AER0; P69924	0.118830216811	292-297
DB00197	Troglitazone	investigational; approved; withdrawn	5591	-	"For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise."	P00918; P11474; Q99808; P37231; P27338; O60488; P41595; Q07869; P62508; P08684; P15121; Q03181; P09211; Q9HCF6; P21397; P05121	0.118830216811	292-297
DB03619	Deoxycholic acid	approved	222528	-	"For improvement in appearance of moderate to severe fullness associated with submental fat in adults. "	P25553; P31224; P07445; P33517; Q96RI1; P54965; Q03736; P09211; P21462; Q8TDU6	0.118830216811	292-297
DB04882	Edotecarin	investigational	9808998	-	"Clinical studies with edotecarin have shown activity in subjects with colorectal cancer, esophageal cancer and other solid tumors."	P11387	0.117786366383	298-306
DB05630	Sodium stibogluconate	investigational; approved	56927674	-	"For the treatment of various types of a protozoal infection called leishmaniasis, which may result from sandfly bites in tropical and temperate parts of the world. Also investigated for use/treatment in cancer/tumors (unspecified) and solid tumors."	P29350; P11387	0.117786366383	298-306
DB05482	7-ethyl-10-hydroxycamptothecin	investigational	104842	-	"Investigated for use/treatment in colorectal cancer."	Q969P6; P11387	0.117786366383	298-306
DB04690	Camptothecin	experimental	24360	-	"Investigated for the treatment of cancer."	P11387	0.117786366383	298-306
DB06159	Rubitecan	investigational	11954380	-	"Investigated for use/treatment in pancreatic cancer, leukemia (unspecified), melanoma, ovarian cancer, and cancer/tumors (unspecified)."	P11387	0.117786366383	298-306
DB11254	Hexylresorcinol	approved	3610	-	"Hexylresorcinol is predominantly employed as the active ingredient in lotions, sprays, or lozenges indicated as a (a) topical antiseptic to help prevent skin infection in minor cuts, scrapes, or burns, or (b) as an antiseptic and local anesthetic for the relief of a sore throat and its associated pain [L2734, L2735].    In addition, hexylresorcinol is used as an active ingredient in various commercial cosmetic skincare products as an anti-aging cream [L2736] while other studies have looked into whether or not the compound could be used effectively as an anti-inflammatory agent or even as an anti-cancer therapy [L2736]."	P09917; P21980; P11387; P14679	0.117786366383	298-306
DB01392	Yohimbine	investigational; vet_approved; approved	8969	-	"Indicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins."	Q99250; P18825; P10635; P28222; P28223; P35462; P47898; P28566; P41595; P48736; P34969; Q9NY46; P30939; P08913; P11387; P14416; P28221; P42338; P42336; P28335; P18089; P35498; P35368; P35348; O00329; P53634; P25100; Q15842; P08908; P42345; P01011	0.117786366383	298-306
DB05806	Cositecan	investigational	148202	-	"Investigated for use/treatment in brain cancer, lung cancer, and melanoma."	P11387	0.117786366383	298-306
DB01030	Topotecan	investigational; approved	60700	-	"For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy."	Q969P6; P08684; P11387	0.117786366383	298-306
DB01083	Orlistat	investigational; approved	3034010	-	"For obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Also used to reduce the risk for weight regain after prior weight loss. Use of orlistat is pending revision due to reports of liver-related adverse events."	P16233; P49327; P07098; P21554; P06858	0.117081886505	307-308
DB01034	Cerulenin	experimental	28517	-	"For use as a biochemical tool, Cerulenin is shown to cause dramatic weight loss in animals"	P0A6R0; P49327; P0A953; P0AAI5	0.117081886505	307-308
DB01133	Tiludronic acid	investigational; vet_approved; approved	60937	-	"For treatment of Paget's disease of bone (osteitis deformans)."	P08253; P22894; P38606; P18031	0.116880742724	309
DB00160	Alanine	nutraceutical	5950	-	"Used for protein synthesis."	P24298; Q9BYV1; Q9UHI5; Q9Y697; P49588; P80404; Q5T6X5; Q8TD30; P21549; P43007; Q16719; Q7Z2H8; Q8IUZ5; Q5JTZ9	0.116121925426	310
DB03904	Urea	investigational; approved	1176	-	"<ul>  <li>10% hydrate skin</li>  <li>15% accelerate fibrin degradation</li>  <li>20-30% are antipruritic, break down keratin, decrease the thickness of the stratum corneum and are used in scaling conditions such as ichthysosis</li>  <li>40% are proteolytic and may be used to dissolve and peel dystrophic nails</li>  </ul>  <br>[Patient Self Care, 2010]</br>"	P05089; P00918; P0ABQ4; P35222; P09592	0.114985606056	311
DB05786	Irofulven	investigational	148189	-	"Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma."	Q96AE4	0.113814968316	312
DB05025	Arimoclomol	investigational	208924	-	"Investigated for use/treatment in amyotrophic lateral sclerosis (ALS), diabetes mellitus type 2, neurologic disorders, and neuropathy (diabetic)."	P00441	0.113742518423	313
DB00720	Clodronic acid	investigational; vet_approved; approved	25419	-	"For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors."	P12236; P12235; P05141; Q9BYT1	0.113546141082	314
DB00491	Miglitol	approved	441314	-	"For use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone."	P04062; P10253; P04746; Q8IWI9; O43451; Q14697; Q8TET4	0.113490850375	315
DB09270	Ubidecarenone	investigational; approved; nutraceutical	5281915	-	"The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies.[L1064] It is important to highlight that these products are not FDA approved and it is recommended to use under discretion."	P31040; P56181	0.113006580039	316
DB09352	Hydroxyamphetamine	approved	3651	-	"Mydriatic agent (eye pupil dilatation) for diagnosis of ophthalmic nerve lesions."	P18825; P18089; P08588; P08913; P25100; P35368; P07550; P35348; P13945	0.112254435758	317-390
DB00668	Epinephrine	vet_approved; approved	5816	-	"Epinephrine injection is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Injectable epinephrine is intended for immediate/urgent administration in patients, who are found to be at increased risk for anaphylaxis, including individuals with a history of anaphylaxis. Selection of the appropriate dosage strength is determined according to body weight [FDA label].     Epinephrine's cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock [F1247].    Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis, to relieve bronchial asthmatic paroxysms, in syncope due to complete heart block or carotid sinus hypersensitivity, for symptomatic relief of serum sickness, urticaria, angioneurotic edema, for resuscitation in cardiac arrest following anesthetic accidents, in simple (open angle) glaucoma, for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics [F1247].    In addition to the above, epinephrine is used as an over the counter (OTC) agent for the intermittent symptoms of asthma, such as wheezing, tightness of chest and shortness of breath [F2131].  It is also used for the maintenance of mydriasis during intraocular surgery [L4825]."	P18825; P25100; P18089; P21728; P08588; P08913; P01375; P35368; P07550; P23975; P35348; P13945	0.112254435758	317-390
DB04842	Fluspirilene	investigational; approved	3396	-	"Used for the treatment of schizophrenia."	P28566; P23415; Q12809; P14416; P18825; P28221; P28222; P28223; Q06432; P41595; P18089; P08588; P08913; P35462; P08908; P35367; P07550	0.112254435758	317-390
DB00521	Carteolol	approved	2583	-	"For the treatment of intraocular hypertension and chronic open-angle glaucoma"	P08588; P15144; P09960; P07550; P08473; P13945	0.112254435758	317-390
DB06190	Solabegron	investigational	9887812	-	"Investigated for use/treatment in diabetes mellitus type 2, irritable bowel syndrome (IBS), and urinary incontinence."	P07550; P13945	0.112254435758	317-390
DB01001	Salbutamol	vet_approved; approved	2083	-	"Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.[Label,F3265,F3268]"	P07550; P35346; P08588; P13945	0.112254435758	317-390
DB09273	Doxofylline	experimental	50942	-	"Indicated for the treatment of chronic obstructive pulmonary disease (COPD), bronchial asthma and pulmonary disease with spastic bronchial component."	P07550; P29274	0.112254435758	317-390
DB01214	Metipranolol	approved	31477	-	"Indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma."	P07550; P08588	0.112254435758	317-390
DB01407	Clenbuterol	investigational; approved; vet_approved	2783	-	"Used as a bronchodilator in the treatment of asthma patients. "	P01138; P08588; P01375; P08908; P07550; P13945	0.112254435758	317-390
DB00925	Phenoxybenzamine	approved	4768	-	"For the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension."	P18825; P56817; P18089; P35348; P08913; P25100; Q99250; P35368; P07550; Q9NY46; P35498	0.112254435758	317-390
DB00397	Phenylpropanolamine	withdrawn; approved; vet_approved	26934	-	"For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity."	P34969; P11229; P18825; Q12809; Q01959; P18089; P08588; P21728; P08913; P07550; P23975; P35348	0.112254435758	317-390
DB06216	Asenapine	approved	11954293	-	"Used for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination."	P18825; P28221; P28222; P28223; P08913; P35462; P46098; P47898; P11229; P34969; Q01959; P21728; P08588; P14416; P08172; P28335; P41595; P18089; P35368; P35367; P35348; P21917; P08912; P25021; P50406; P20309; P08908; P07550	0.112254435758	317-390
DB00866	Alprenolol	withdrawn; experimental	2119	-	"For the treatment of hypertension, angina, and arrhythmia"	P08908; P08588; P28223; P13945; P07550	0.112254435758	317-390
DB04861	Nebivolol	investigational; approved	71301	-	"Nebivolol is indicated to treat hypertension.[A2762,A182579,L7985,L7988]"	P10635; P08588; P07550; P13945; P08908	0.112254435758	317-390
DB00335	Atenolol	approved	2249	-	"**Indicated** for:[label]    1) Management of hypertension alone and in combination with other antihypertensives.    2) Management of angina pectoris associated with coronary atherosclerosis.    3) Management of acute myocardial infarction in hemodynamically stable patients with a heart rate greater than 50 beats per minutes and a systolic blood pressure above 100 mmHg.    **Off-label** uses include:    1) Secondary prevention of myocardial infarction.[A178156]    2) Management of heart failure.[A178153]    3) Management of atrial fibrillation.[A178141]    4) Management of supraventricular tachycardia.[A178162]    5) Management of ventricular arrythmias such as congenital long-QT and arrhythmogenic right ventricular cardiomyopathy.[A178168]    6) Management of symptomatic thyrotoxicosis in combination with [methimazole].[A178147]    7) Prophylaxis of migraine headaches.[A178171]    8) Management of alcohol withdrawal.[A178174,A178177]"	P07550; P30559; P08588; P20393	0.112254435758	317-390
DB01102	Arbutamine	approved	60789	-	"Used to elicit acute cardiovascular responses (cardiac stumulant), similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease (CAD) in patients who cannot exercise adequately."	P07550; P08588; P13945	0.112254435758	317-390
DB00836	Loperamide	approved	3955	-	"For the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis. Also used for reducing the volume of discharge from ileostomies."	Q99250; P0DP25; P25021; P35372; P25100; P35462; Q02763; O15399; P01189; Q99720; P41143; P10635; P0DP24; P41145; P0DP23; P41595; P35346; P35498; P31645; P35367; Q14957; Q9NY46; O00555; Q13224; Q12879; P07550; Q14994	0.112254435758	317-390
DB01295	Bevantolol	experimental	2372	-	"For the treatment of angina pectoris and hypertension."	P07550; P08588; P35348	0.112254435758	317-390
DB05039	Indacaterol	approved	6918554	-	"For the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.  "	P14416; P22309; P08588; P35462; P07550; P11229	0.112254435758	317-390
DB09351	Levobetaxolol	investigational; approved	60657	-	"Used in the treatment of open-angle glaucoma and ocular hypertension [FDA Label]."	P07550; P08588	0.112254435758	317-390
DB00571	Propranolol	investigational; approved	4946	-	"Propranolol is indicated to treat hypertension.[L6907,L6904] Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.[L6904,L6907]"	Q9Y3Q4; P07550; P10635; P28222; P28223; P28221; P41595; P47898; P08588; P08908; P35367; P31645; P28335; Q14973; Q99720; P13945; Q13936	0.112254435758	317-390
DB00502	Haloperidol	approved	3559	-	"Haloperidol is indicated for a number of conditions including for the treatment of schizophrenia, for the manifestations of psychotic disorders, for the control of tics and vocal utterances of Tourette?s Disorder in children and adults, for treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also indicated in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics.[F4645]"	Q12809; P35462; P18825; P28221; P28222; P28223; P18089; Q99705; P35372; Q99250; P11229; Q99720; P34969; P21728; P35348; P30939; P08912; P08913; P14416; P23975; P0DP24; P0DP25; P0DP23; P28335; P41595; Q05940; P21918; P35498; P35368; P35367; P31645; Q9NY46; P21917; P25021; Q13224; P25100; P50406; P20309; P08908; P07550; O95259; P01011	0.112254435758	317-390
DB04846	Celiprolol	investigational; approved	2663	-	"Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. "	P18825; P18089; P08588; P08913; P07550; P13945	0.112254435758	317-390
DB00368	Norepinephrine	approved	439260	-	"Mainly used to treat patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine. Also used as a vasopressor medication for patients with critical hypotension."	P00439; P18825; P54219; Q01959; P25100; Q05940; P18089; P08588; P08913; P35368; P07550; P35348; P13945	0.112254435758	317-390
DB01366	Procaterol	investigational; approved	688561	-	"For the treatment of asthma and chronic obstructive pulmonary disease (COPD)."	P07550	0.112254435758	317-390
DB00373	Timolol	approved	33624	-	" Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure.[L6724,L6727] In certain cases, timolol is used in the prevention of migraine headaches.[A179530,L6742] "	P00720; P08588; P07550; P13945; P08908	0.112254435758	317-390
DB00221	Isoetharine	approved	3762	-	"For the treatment of asthma, wheezing, and chronic asthmatic bronchitis."	P07550; P08588	0.112254435758	317-390
DB00612	Bisoprolol	approved	2405	-	"Bisoprolol is indicated for the treatment of mild to moderate hypertension.[L7219] It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.[A180460,A180463]"	P07550; P08588; P13945	0.112254435758	317-390
DB01408	Bambuterol	investigational	54766	-	"For the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema."	P07550; P22303; P06276; P10635	0.112254435758	317-390
DB09013	Befunolol	experimental	2309	-	"Used in the management of open angle glaucoma. PMID: 12480285. "	P07550; P08588	0.112254435758	317-390
DB00960	Pindolol	investigational; approved	4828	-	"For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation."	P28335; P28221; P28222; P28223; P41595; P08588; P08908; P07550; P13945	0.112254435758	317-390
DB08808	Bupranolol	experimental	2475	-	"Used to manage hypertension and tachycardia. Also used to treat glaucoma."	P07550; P08588; P13945	0.112254435758	317-390
DB01580	Oxprenolol	approved	4631	-	"Used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety."	P07550; P08588; P13945	0.112254435758	317-390
DB09080	Olodaterol	approved	11504295	-	"Olodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma."	P07550; P08588; P13945	0.112254435758	317-390
DB06144	Sertindole	investigational; withdrawn; approved	60149	-	"Used in the treatment of schizophrenia."	Q12809; P18825; P28221; P28222; P28223; P08913; P35462; P28566; P34969; P30939; P21728; P08588; O43613; P14416; P28335; P18089; P35368; P35367; P35348; P21917; P25100; P50406; P20309; P08908; P07550	0.112254435758	317-390
DB00816	Orciprenaline	approved	4086	-	"For the treatment of bronchospasm, chronic bronchitis, asthma, and emphysema."	P07550	0.112254435758	317-390
DB00590	Doxazosin	approved	3157	-	"Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension.[L7282] Off-label uses of doxazosin include the treatment of pediatric hypertension[A180634] and the treatment of ureteric calculi.[A180637]"	Q9NS40; Q12809; P18825; P28335; Q01959; P25100; P03956; P08913; P41595; P35368; P07550; P31645; P35348	0.112254435758	317-390
DB09082	Vilanterol	approved	10184665	-	"Vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename Breo Ellipta and in combination with umeclidinium bromide as Anoro Ellipta. Approved by the FDA in 2013, use of Breo Ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease."	P07550; P08588; P13945	0.112254435758	317-390
DB00195	Betaxolol	investigational; approved	2369	-	"For the management of hypertension."	O60479; P16066; P08588; P07550; P17342	0.112254435758	317-390
DB01364	Ephedrine	approved	9294	-	"Ephedrine commonly used as a stimulant, appetite suppressant, concentration aid, decongestant, and to treat hypotension associated with anaesthesia."	P22303; P18825; P18089; Q05940; P08588; P13945; P25100; P35368; P07550; P23975; P35348; P08913	0.112254435758	317-390
DB01210	Levobunolol	approved	39468	-	"For lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension."	P07550; Q99720; P08588; P08908; P31645; P13945	0.112254435758	317-390
DB08893	Mirabegron	approved	9865528	-	"Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency."	P07550; P13945	0.112254435758	317-390
DB00871	Terbutaline	approved	5403	-	"For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial."	P07550; P08588; P13945	0.112254435758	317-390
DB08807	Bopindolol	experimental	44112	-	"For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation."	P10635; P28222; P28223; P41595; P08588; P08908; P07550; P13945	0.112254435758	317-390
DB00867	Ritodrine	investigational; approved	33572	-	"For the treatment and prophylaxis of premature labour"	P07550; P13945	0.112254435758	317-390
DB00983	Formoterol	investigational; approved	3410	-	"Formoterol is indicated in various formulations for the treatment of asthma and COPD. For the treatment of COPD, formoterol is available as a single-entity inhalation solution,[L10986] in combination with the long-acting muscarinic antagonists (LAMAs) [aclidinium][L10992] and [glycopyrronium],[L10989] and in combination with the corticosteroid [budesonide].[L10619] For the treatment of asthma, formoterol is available in combination with [mometasone furoate] for patients 5 years and older[L10995] and with budesonide for patients 6 years and older.[L10619] Formoterol may also be used on an as-needed basis for prophylaxis against exercise-induced bronchospasm.[L10998]"	P07550; P08588; P13945; P35462	0.112254435758	317-390
DB01193	Acebutolol	investigational; approved	1978	-	"For the management of hypertension and ventricular premature beats in adults."	Q99572; P08588; P07550	0.112254435758	317-390
DB00264	Metoprolol	investigational; approved	4171	-	"Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.[A175141]    Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.[A175141]    All the indications of metoprolol are part of cardiovascular diseases. These conditions correspond to a number of diseases that involve the function of the heart and blood vessels. The underlying causes of these conditions are variable and can be due to genetic disposition, lifestyle decisions such as smoking, obesity, diet, and lack of exercise, and comorbidity with other conditions such as diabetes. The cardiovascular diseases are the leading cause of death on a global scale.[L5533]"	P10635; P08588; P07550	0.112254435758	317-390
DB09204	Arotinolol	investigational	2239	-	"Artinolol was introduced to be used as an antihypertensive agent since 1986.[T88] It has been studied for other functions like tremor control for patients with Parkinson disease and it is currently in clinical trials for its use in the control of blood pressure and heart rate.[L1168]"	P07550; P08588; P25100	0.112254435758	317-390
DB00127	Spermine	experimental; nutraceutical	1103	-	"For nutritional supplementation, also for treating dietary shortage or imbalance"	P48050; P41180; P11926; P08588; Q9NZQ8; P52788; P07550; Q8TD43; Q9NWM0	0.112254435758	317-390
DB01167	Itraconazole	investigational; approved	55283	-	"For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis."	P22888; P51679; P50859; Q16850; P08684; P07550; P06241; P30518	0.112254435758	317-390
DB00449	Dipivefrin	approved	3105	-	"Dipivefrin is a prodrug which is used as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma."	P22303; P06276; P18825; P25100; P08588; P13945; P18089; P35368; P07550; P30043; P35348; P08913	0.112254435758	317-390
DB01288	Fenoterol	investigational; approved	3343	-	"Fenoterol is used for the treatment of asthma."	P07550; P08588; P13945	0.112254435758	317-390
DB09286	Pipamperone	investigational	4830	-	"Treatment of chronic psychoses and states of aggressiveness of various origins [L1515]."	P28335; P14416; P18825; P28221; P28222; P28223; P18089; P41595; P30939; P08588; P21728; P08913; P25100; P35462; P08908; P35367; P07550; P21917	0.112254435758	317-390
DB01182	Propafenone	approved	4932	-	"Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia."	P10635; Q9UQD0; P28223; Q14654; O60706; Q99250; Q9Y3Q4; P22460; Q14524; Q99720; Q12809; Q01959; P08588; P23975; P28335; P41595; Q01118; Q9Y5Y9; P35498; P07550; P36888; Q9NY46; P13945; Q15858; P25100; P08908; P35499; Q9UI33	0.112254435758	317-390
DB00901	Bitolterol	withdrawn	35330	-	"Used to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation. It is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)."	P07550	0.112254435758	317-390
DB01200	Bromocriptine	investigational; approved	31101	-	"For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome."	P18825; P28221; P28222; P28223; P08913; P35462; P34969; P21728; P08588; P14416; P28335; P41595; P21918; P08684; P18089; P35368; P35348; P21917; P25100; P50406; P08908; P07550	0.112254435758	317-390
DB00489	Sotalol	approved	5253	-	"Sotalol is indicated to treat life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutter.[Label] There are also oral solutions and intravenous injections indicated for patients requiring sotalol, but for whom a tablet would not be appropriate.[Label,L6373,L6376]"	P07550; Q12809; P08588	0.112254435758	317-390
DB06262	Droxidopa	investigational; approved	92974	-	"For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells."	P00439; P18825; P25100; P18089; P08588; P08913; P35368; P07550; P35348; P13945	0.112254435758	317-390
DB09128	Brexpiprazole	investigational; approved	11978813	-	"As an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia. "	P18825; P10635; P28222; P28223; P08913; P35462; P34969; Q01959; P21728; P08588; P14416; P23975; P35368; P28335; P41595; P18089; P31645; P35367; P35348; P25100; P08908; P07550	0.112254435758	317-390
DB00248	Cabergoline	approved	54746	-	"For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease. "	P34969; P41595; P14416; P18825; P28221; P28222; P28223; P25100; P08913; P21918; P21728; P08588; P18089; P35462; P35368; P07550; P28335; P35348; P21917; P08908	0.112254435758	317-390
DB01291	Pirbuterol	approved	4845	-	"For the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma."	O60479; P08588; P07550; P17342	0.112254435758	317-390
DB00598	Labetalol	approved	3869	-	"Labetalol injections are indicated to control blood pressure in severe hypertension.[L7727] Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.[L7730]"	P10635; P18825; P08913; Q99720; P08908; Q01959; P41595; P18089; P08588; P25100; P35368; P07550; P23975; P35348; P13945; P30518	0.112254435758	317-390
DB00589	Lisuride	investigational; approved	28864	-	"For the management of Parkinson's Disease"	P18825; P10635; P28222; P28223; P35462; P34969; P21728; P08913; P14416; P28221; P28335; P41595; P21918; P18089; P35368; P35367; P35348; P21917; P25021; P25100; P50406; P08908; P07550; P08588	0.112254435758	317-390
DB01359	Penbutolol	investigational; approved	37464	-	"Penbutolol is indicated in the treatment of mild to moderate arterial hypertension. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity."	P07550; P28222; P08588; P08908	0.112254435758	317-390
DB00938	Salmeterol	approved	5152	-	"Salmeterol is indicated in the treatment of asthma with an inhaled corticosteroid, prevention of exercise induced bronchospasm, and the maintenance of airflow obstruction and prevention of exacerbations of chronic obstructive pulmonary disease.[L11545,L11548,L11551,L11554,L11557]"	P07550; P08588; P15260; P35462; P13945	0.112254435758	317-390
DB00187	Esmolol	approved	59768	-	"For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention."	P07550; P41145; P08588; P35372; P41143	0.112254435758	317-390
DB00471	Montelukast	approved	5281040	-	"Montelukast is indicated for:    (a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304],    (b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307], and    (c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].    Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]    Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]    Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an 'as required' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]"	P00533; O95977; P09917; P11229; Q99500; P41143; P18825; P20309; P21453; Q01959; P41595; Q9Y271; P08913; P35462; P07550; P06241; P23975; P13945	0.112254435758	317-390
DB09068	Vortioxetine	investigational; approved	71768094	-	"Vortioxetine is indicated for the treatment of major depressive disorder (MDD)."	P46098; P08908; P35367; P34969; P25021; P28223; P10635; P28222; P28335; P28221; P50406; P08588; P31645; P47898; P07550; P23975; P01011	0.112254435758	317-390
DB01203	Nadolol	approved	39147	-	"Nadolol is indicated to treat angina pectoris and hypertension.[L7922] Another product formulated with [bendroflumethiazide] is indicated to treat hypertension.[L7925]"	P07550; P08588; P13945	0.112254435758	317-390
DB13139	Levosalbutamol	investigational; approved	123600	-	"Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma."	P07550	0.112254435758	317-390
DB01274	Arformoterol	investigational; approved	3083544	-	"A bronchodilator used for the long term, symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. "	P22309; P07550; P08588; P13945; P10635	0.112254435758	317-390
DB01365	Mephentermine	approved	3677	-	"Used to maintain blood pressure in hypotensive states."	P18825; P25100; P25025; P08913; P18089; P35368; P07550; P08588; P35348; P13945	0.112254435758	317-390
DB01267	Paliperidone	approved	115237	-	"For the treatment of schizophrenia."	P34969; P18825; P28221; P28222; P35368; P35462; P28566; Q12809; P21728; P08913; P14416; P28223; P28335; P43115; P18089; P08588; P41595; P31645; P35367; P35348; P21917; P25021; P08908; P07550	0.112254435758	317-390
DB00135	Tyrosine	investigational; approved; nutraceutical	6057	-	"Tyrosine is claimed to act as an effective antidepressant, however results are mixed. Tyrosine has also been claimed to reduce stress and combat narcolepsy and chronic fatigue, however these claims have been refuted by some studies."	P54577; P07101; P17735; Q9Y2Z4	0.112247762742	391
DB05223	Pracinostat	investigational	49855250	-	"For the treatment of various forms of cancer."	Q9UBN7; Q96DB2; Q9BY41; P56524; Q9UKV0; Q13547; Q92769; Q969S8; Q8WUI4; Q9UQL6; O15379	0.111826409418	392-402
DB06603	Panobinostat	investigational; approved	6918837	-	"Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015. "	Q9UBN7; Q96DB2; Q9BY41; P56524; Q969S8; Q13547; Q92769; Q9UKV0; Q8WUI4; Q9UQL6; O15379	0.111826409418	392-402
DB06769	Bendamustine	investigational; approved	65628	-	"Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen."	Q9UBN7; O15379; Q9BY41; Q13547; Q92769; Q969S8	0.111826409418	392-402
DB05015	Belinostat	investigational; approved	6918638	-	"Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia [A19161]. "	Q9UQL6; Q96DB2; P22309; P56524; Q9UKV0; Q13547; Q92769; Q969S8; Q8WUI4; Q9UBN7; Q9BY41; O15379	0.111826409418	392-402
DB06819	Phenylbutyric acid	investigational; approved	4775	-	"Adjunctive therapy for the management of chronic urea cycle disorders due to deficiencies in carbamylphosphate (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase. it is indicated in all neonatal- onset efficiency presenting within the first 28 days of life. Also indicated in patients with late-onset, presenting after the first month of life with a history of hyperammonemic encephalopathy.  "	P95468; P00800; Q13547	0.111826409418	392-402
DB00227	Lovastatin	investigational; approved	53232	-	"Lovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C. It is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease. The administration of this agent should be accompanied by the implementation of a fat and cholesterol-restricted diet.[F4661]    Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.[F4661,F4664]    Lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels.[F4661]    Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls with Heterozygous Familial Hypercholesterolemia (HeFH) who are at least one year post-menarche, 10 to 17 years of age, with HeFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than 189 mg/dL or LDL-C remains greater than 160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient.    Before administering lovastatin, it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performed.    Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]"	Q9UBN7; Q01959; Q13547; Q92769; Q8TDS4; P04035; P20701; P23975; P30542	0.111826409418	392-402
DB05103	AN-9	investigational	60748	-	"Investigated for use/treatment in liver cancer, lung cancer, melanoma, and leukemia (lymphoid)."	Q13547	0.111826409418	392-402
DB01076	Atorvastatin	approved	60823	-	"Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.[A177397]    Dyslipidemia describes an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025]     Atorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.[A177397]    Atorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.[A177397]    Atorvastatin may be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.[A177397]    Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]"	Q9UBN7; P04035; P35869; Q14994; Q13547; Q92769; P08684; P27487	0.111826409418	392-402
DB06176	Romidepsin	investigational; approved	57515973	-	"For the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated. "	Q969S8; O75376; Q9UQL6; Q9Y618; P56524; Q96DB2; Q9BY41; Q13547; Q92769; Q9UKV0; Q8WUI4; P33527; Q9UBN7; O15379	0.111826409418	392-402
DB08868	Fingolimod	investigational; approved	107970	-	"Fingolimod is indicated for the treatment of patients aged 10 and above with relapsing forms of multiple sclerosis, which may include clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.[L12651]    This drug is being studied for administration in patients infected with COVID-19 with a high risk for acute respiratory distress syndrome, or ARDS.[L12654] As of April 3 2020, this is currently not an approved indication and clinical trials are underway.[L12657]"	O95977; Q99500; P21453; Q13547; O95136; Q9H228	0.111826409418	392-402
DB02546	Vorinostat	investigational; approved	5311	-	"For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies."	Q969S8; O75376; Q9UBN7; Q96DB2; O15379; Q8WUI4; Q9BY41; Q13547; Q92769; Q9UKV0; Q9Y618; Q9UQL6; P56524	0.111826409418	392-402
DB00316	Acetaminophen	approved	1983	-	"In general, acetaminophen is used for the treatment of mild to moderate pain and reduction of fever.[F4124] It is available over the counter in various forms, the most common being oral forms.    Acetaminophen _injection_ is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.[Label]    Because of its low risk of causing allergic reactions, this drug can be administered in patients who are intolerant to salicylates and those with allergic tendencies, including bronchial asthmatics.[F4124] Specific dosing guidelines should be followed when administering acetaminophen to children.[L5780]"	P00918; P22748; P07451; P43166; Q9ULX7; Q16790; O00519; P00915; P21554; P23786; P35354; Q15185; O43570; Q8NER1; P21731; P23219	0.111784464744	403
DB13191	Phosphocreatine	nutraceutical	9548602	-	"Phosphocreatine is a naturally occuring substance that is found predominantly in the skeletal muscles of vertebrates. Its primary utility within the body is to serve in the maintanence and recycling of adenosine triphosphate (ATP) for muscular activity like contractions.    Given this utility of phosphocreatine to recycle ATP, the most plausible therapeutic potentials for its use involve conditions caused by energy shortage or by increased energy requirements - such as in ischemic stroke and other cerebrovascular diseases. It is important to note however that relatively little clinical research has been done to significantly further the evidence for any such indications, although it is administered intravenously for cardiovascular conditions in some countries.    Additionally, because phosphocreatine is not regulated as a controlled substance it is taken as a supplement by some professional athletes as a means to perhaps increase short bursts of muscle strength or energy for professional athletics. "	Q14353; P12277; P06732; P12532; P17540; P48029	0.110960823858	404-405
DB00148	Creatine	investigational; approved; nutraceutical	586	-	"For nutritional supplementation, also for treating dietary shortage or imbalance."	Q14353; P12277; P06732; P12532; P17540; P48029	0.110960823858	404-405
DB00722	Lisinopril	investigational; approved	5362119	-	"Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ?6 years, and as an adjunct therapy for heart failure.[L8384,L8387] A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.[L8390]"	Q9BYF1; P00797; P12821	0.110945571249	406
DB06654	Safinamide	investigational; approved	131682	-	"Safinamide is indicated as an add-on treatment to levodopa with or without other medicines for Parkinson?s disease"	P21397; Q01118; Q14524; Q99250; P27338; Q9NY47; Q9UQD0; P54289; Q00975; Q9UI33; O00305; P53350; P35499; P54284; Q15858; Q9NY46; P35498	0.109761587476	407
DB11157	Anthralin	approved	2202	-	"Stable plaque psoriasis of the skin and scalp [L1933].    It is also used topically in the management of psoriasis, dermatoses, and alopecia areata. Anthralin is also used in biomedical research due to its effect on EGFR autophosphorylation [L1936]."	Q99456; P35908; Q9UQF2	0.109610967962	408
DB00352	Tioguanine	approved	2723601	-	"For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias."	P20839; P51580; P47989; P23219; P12268	0.108968451808	409-412
DB00688	Mycophenolate mofetil	investigational; approved	5281078	-	"Mycophenolate mofetil is indicated for the prophylaxis of organ rejection in patients undergoing allogeneic renal, hepatic, or cardiac transplants. It should be used with cyclosporine and corticosteroids.[L7363] Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy.[A180814] Other off-label uses of this drug include lupus-associated nephritis and dermatitis in children.[A180817]"	P20839; P12268; Q03393	0.108968451808	409-412
DB01024	Mycophenolic acid	approved	446541	-	"For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids."	P20839; P12268; P00492	0.108968451808	409-412
DB01033	Mercaptopurine	approved	667490	-	"For remission induction and maintenance therapy of acute lymphatic leukemia."	P12268; Q06203; P00491; P51580; P00492; P47901; P23219; P37288; P30518	0.108968451808	409-412
DB00340	Metixene	approved	4167	-	"Used for the symptomatic treatment of parkinsonism."	P08172; P08173; P11229; P28335; P08912; P20309	0.108627174682	413-494
DB01231	Diphenidol	investigational; withdrawn; approved	3055	-	"For use in the prevention and symptomatic treatment of peripheral (labyrinthine) vertigo and associated nausea and vomiting that occur in such conditions as Meniere's disease and surgery of the middle and inner ear. Also for the control of nausea and vomiting associated with postoperative states, malignant neoplasms, labyrinthine disturbances, antineoplastic agent therapy, radiation sickness, and infectious diseases."	P08172; P08173; P35462; P10635; Q99720; P28223; Q99250; P20309; P08912; P35498; P14416; P10721; Q9NY46; P11229	0.108627174682	413-494
DB00777	Propiomazine	approved	4940	-	"Propiomazine is largely used for its antihistamininc sleep inducing effects in treating insomnia."	P08172; P08173; P28335; P11229; P20309; P28223; P21728; P25100; P08912; P14416; P35368; P35367; P35348; P21917	0.108627174682	413-494
DB00670	Pirenzepine	approved	4848	-	"For the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer."	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB00767	Benzquinamide	withdrawn	2342	-	"Used to prevent and treat nausea and vomiting associated with anesthesia and surgery, administered intramuscularly or intravenously."	P08172; P08173; P11229; P18825; P20309; P35354; P18089; P23786; P08912; P14416; P08913; P35462; P35367; P21439	0.108627174682	413-494
DB01069	Promethazine	investigational; approved	4927	-	"Promethazine tablets and suppositories are indicated to treat rhinitis, allergic conjunctivitis, allergic reactions to blood or plasma, dermographism, anaphylactic reactions, sedation, nausea, vomiting, pain, motion sickness, and allergic skin reactions.[A189907,L4000] Promethazine cough syrup with phenylephrine and codeine is indicated to relieve cough and upper respiratory symptoms, and nasal congestion associated with allergy or the common cold.[L11326]"	P35462; P18825; P10635; P28223; Q99250; P41595; P06276; Q99720; Q15858; P21728; P35348; P08912; P08913; P14416; P23975; P08172; P08173; P28335; P18089; P35498; P35367; Q9NY46; P11229; Q13303; P25021; P25100; P20309; P08908; P31645; O00398	0.108627174682	413-494
DB01403	Methotrimeprazine	investigational; approved	72287	-	"For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder."	P08172; P08173; P28223; P35462; P25100; P18825; P14416; P28335; P08912; P41595; P21918; P21728; P08913; P18089; P20309; P35368; P35367; P35348; P21917; P11229	0.108627174682	413-494
DB06148	Mianserin	investigational; approved	4184	-	"For the treatment of depression."	Q99250; P08173; P18825; P28221; P28222; P28223; P18089; P35462; P46098; P11229; Q9H3N8; P34969; Q01959; P35408; Q9NY46; P30939; P21728; P08913; P14416; P23975; P08172; P41145; P28335; P41595; P21918; P35498; P35368; P35367; P35348; P08912; P25021; P25100; P50406; P20309; P08908; P31645; P01011	0.108627174682	413-494
DB00568	Cinnarizine	investigational; approved	2761	-	"For the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins."	P35462; P18825; P28223; P18089; P35372; Q99250; O60840; O95180; P11229; Q99720; Q01959; Q9P0X4; P08912; P08913; P14416; Q01668; P23975; P08173; O43497; P41595; P21918; P35498; P35367; Q9NY46; P25100; Q13936; P20309; P08908; Q13698; P31645	0.108627174682	413-494
DB00967	Desloratadine	investigational; approved	124087	-	"For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria."	P08172; P08173; P28223; P11229; P28335; P25021; Q01959; P41595; P08912; P18089; P20309; P35367; P31645; P23975; P35462	0.108627174682	413-494
DB00411	Carbamoylcholine	approved	5831	-	"Primarily used in the treatment of glaucoma, but is also used during ophthalmic surgery."	P08172; P08173; P22303; P11229; Q15822; P08912; P20309; P17787; P43681	0.108627174682	413-494
DB09167	Dosulepin	approved	5284550	-	"Indicated in the treatment of symptoms of depressive illness, especially where an anti-anxiety effect is required."	P08172; P08173; P11229; P18825; P28223; Q01959; P25100; P08912; P18089; P20309; P08908; P35367; P31645; P23975; P35348	0.108627174682	413-494
DB01036	Tolterodine	investigational; approved	443879	-	"For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence)."	P08172; P08173; P11229; P10635; Q12809; P08912; P20309; Q14833	0.108627174682	413-494
DB00245	Benzatropine	approved	1201549	-	"Benztropine is indicated to be used as an adjunct in the therapy of all forms of parkinsonism. It can also be used for the control of extrapyramidal disorders due to neuroleptic drugs.[T203]    The extrapyramidal symptoms are defined as drug-induced disorders that include symptoms of dystonia, akathisia, parkinsonism, bradykinesia, tremors, and dyskinesia.[A175120]     Parkinsonism is a general term that refers to the group of neurological disorders that produce symptoms similar to Parkinson's disease such as tremors, slow movement, and stiffness. The parkinsonism includes a large number of disorders and some of them have not been clearly defined.[L5509]"	P08172; P08173; Q695T7; P28335; P35462; P18825; Q99720; P28223; P25021; Q01959; P41595; P18089; P08912; P08913; P25100; P20309; P35367; P31645; P23975; P11229	0.108627174682	413-494
DB06702	Fesoterodine	approved	6918558	-	"For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence)."	P08172; P08173; P11229; P10635; P08912; P20309	0.108627174682	413-494
DB00433	Prochlorperazine	vet_approved; approved	4917	-	"Indicated for the symptomatic treatment of severe nausea and vomiting.[label]    Indicated for the management of manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety. The use of prochlorperazine for the management of generalized non-psychotic anxiety is typically not a first-line therapy and should be limited to doses of less than 20 mg per day or for shorter than 12 weeks.[label,L6634]    Off-label uses include use in emergency settings for adult and pediatric migraines. The American Headache Society recommends the use of prochlorperazine as the first-line medication in this setting. In pediatric migraines, a non-steroidal anti-inflammatory agent is often used in combination with dopamine antagonist.[L6637]"	P18825; P10635; P28223; P35462; P11229; Q99720; Q12809; Q01959; P08912; P08913; P14416; P21728; P08172; P08173; P28335; P18089; P41595; P35367; P35348; P21917; P23975; P25100; P20309; P08908; P31645; P06241	0.108627174682	413-494
DB00251	Terconazole	approved	441383	-	"For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina."	P08172; P08173; P22303; P28223; P11229; P10613; P18825; P20309; Q99720; P28335; P08912; P18089; Q01959; P21728; P08913; P25100; P35462; P31645; P06241; P23975	0.108627174682	413-494
DB01062	Oxybutynin	investigational; approved	4634	-	"Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency.  Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptoms.[L8648] On occasion, oxybutynin may be used off-label to relieve bladder spasms associated with ureteral stents or urinary catheters.[T689]"	P08172; P08173; P11229; Q99720; Q01959; P41595; P08912; P20309; P23975; P35462	0.108627174682	413-494
DB00572	Atropine	vet_approved; approved	174174	-	"For the treatment of poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) as well as organophosphorous or carbamate insecticides."	P08172; P08173; P28335; P11229; P28223; P25100; Q8TCU4; P08912; P23415; P20309; P35367; P17787; P43681	0.108627174682	413-494
DB00376	Trihexyphenidyl	approved	5572	-	"Indicated for the treatment of parkinson's disease and extrapyramidal reactions caused by drugs."	P08172; Q13163; P11229; Q13164; P08173; P10635; Q99720; P08912; P36897; P20309	0.108627174682	413-494
DB00782	Propantheline	approved	4934	-	"For the treatment of enuresis. It has also been used for hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder."	P08172; P08173; P11229; P20309	0.108627174682	413-494
DB01074	Perhexiline	investigational; approved	4746	-	"For the management of severe angina pectoris."	P00533; O95180; O43497; P08173; P10635; Q99720; Q12809; P50416; Q9P0X4; P08912; Q92523; P20309; P06241; P23975; P23786; P42345; P11229	0.108627174682	413-494
DB04946	Iloperidone	approved	71360	-	"Treatment of acute schizophrenia. "	P18825; P10635; P28222; P28223; P32239; P35462; P11229; Q99720; P34969; Q01959; P20292; P21728; P08913; P14416; P28221; P23975; P08172; P08173; P28335; P18089; P35367; P35348; P21917; P50406; P08908; P01011	0.108627174682	413-494
DB00450	Droperidol	vet_approved; approved	3168	-	"Droperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures."	P35462; P18825; P28223; Q99250; P14324; Q12809; P08912; P35348; P21728; P08913; P14416; P08173; P28335; P41595; P18089; P35367; Q9NY46; P21917; P25100; P08908; P21554; P35498	0.108627174682	413-494
DB00835	Brompheniramine	approved	6834	-	"For the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing."	P08172; P08173; P20309; Q12809; P08912; P35498; Q99250; P35367; Q9NY46; P11229	0.108627174682	413-494
DB06820	Sulconazole	approved	5318	-	"Sulconazole solution 1.0% is indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis, and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete?s foot)."	P10613; P28335; P11229; P08173; P18825; P10635; P28223; Q01959; P18089; Q96RI1; P08912; P08913; P08684; P41595; P20309; P31645; P06241; P23975; P35462	0.108627174682	413-494
DB00434	Cyproheptadine	approved	2913	-	"For treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine."	P08172; Q12809; Q99250; P08173; P18825; P28221; P28223; P35462; Q92633; Q9UBY5; P11229; P34969; P08912; P35348; P21728; P08913; P14416; P23975; P0DP24; P0DP25; P0DP23; P28335; P41595; P18089; P35368; P35367; Q9NY46; P25021; P25100; P50406; P20309; P08908; P31645; P01011; P35498	0.108627174682	413-494
DB00679	Thioridazine	withdrawn; approved	5452	-	"For the treatment of schizophrenia and generalized anxiety disorder."	P34969; P35462; P41145; P18825; P10635; P28222; P28223; Q99250; P00533; P11229; Q99720; Q12809; Q01959; Q9NY46; P18089; P08912; P08913; P14416; P28221; P21728; P08172; P08173; P28335; P41595; P21918; P35498; P35368; P35367; P35348; P21917; P23975; P25021; P25100; P50406; P20309; P08908; P31645; P06241; P01011	0.108627174682	413-494
DB00747	Scopolamine	investigational; approved	3000322	-	"For the treatment of excessive salivation, colicky abdominal pain, bradycardia, sialorrhoea, diverticulitis, irritable bowel syndrome and motion sickness."	P08172; P08173; P11229; P14410; P08912; P20309; P17787; P43681	0.108627174682	413-494
DB00458	Imipramine	approved	3696	-	"For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older [FDA Label].     May also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for ADHD in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [L1349,L1348,A31900,L1351,L1352,L1353,A31904]. "	Q12809; P35462; P10635; P28223; P19652; Q99250; P11229; Q99720; P34969; Q01959; P35348; P08912; P14416; P23975; P08172; P08173; Q9NZV8; P28335; P18089; P21918; O95259; P35368; P35367; Q9UK17; Q9NY46; P25100; P50406; P20309; P08908; P31645; P35498	0.108627174682	413-494
DB01625	Isopropamide	approved; vet_approved	3775	-	"For the treatment of a wide range of gastrointestinal disorders, including such conditions as peptic ulcer, gastritis, hyperchlorhydria, functional diarrhea, irritable or spastic colon, pyloroduodenal irritability, pylorospasm, acute nonspecific gastroenteritis, biliary dyskinesia and chronic cholelithiasis, duodenitis, gastrointestinal spasm, it may also be used to treat genitourinary spasm."	P08173; P22888; P11229; P20309	0.108627174682	413-494
DB00622	Nicardipine	investigational; approved	4474	-	"Used for the management of patients with chronic stable angina and for the treatment of hypertension."	P08172; P08173; P54750; O95180; P11229; Q01064; P54289; P25100; P0DMS8; P08912; Q13936; P08684; Q08289; P20309; P35368; Q13698; O60840; Q01668; P35348	0.108627174682	413-494
DB01239	Chlorprothixene	investigational; approved; experimental; withdrawn	667466	-	"For treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders."	P08172; P08173; P28335; P35462; P28223; P08912; P41595; P21728; P14416; P20309; P35367; P11229	0.108627174682	413-494
DB01409	Tiotropium	approved	5487427	-	"Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD.[L7084] A combination tiotropium and [olodaterol] metered inhalation spray is indicated for maintenance of COPD.[L7087] A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old.[L7090] A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.[L7093]"	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB00472	Fluoxetine	approved; vet_approved	3386	-	"Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa, however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present.[L7664] Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression.[L7664]"	Q7RTT9; Q15822; Q5XXA6; P28223; P08913; P35462; P61024; P32297; P11229; Q99720; Q12809; Q01959; P08912; P08588; P10635; P23975; Q9Y5N1; P08172; P08173; P22303; P28335; P18089; P41595; P35367; P35348; P43088; P20309; P31645; P30926	0.108627174682	413-494
DB00424	Hyoscyamine	approved	154417	-	"For treatment of bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis. Also used to treat certain heart conditions, to control the symptoms of Parkinson's disease and rhinitis."	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB09224	Melperone	investigational	15387	-	"For the treatment of schizophrenia, sleep, disorders, agitation and mentally confused states [L1317, L1319, L1322].  "	P08172; P08173; P28223; P35462; P28221; P28335; Q12809; P08913; P14416; P10635; P35367; P35348; P08908	0.108627174682	413-494
DB00940	Methantheline	investigational; approved	4097	-	"For the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children."	P08172; P08173; P11229; P25021; P08912; P20309	0.108627174682	413-494
DB00934	Maprotiline	investigational; approved	4011	-	"For treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis."	P18825; P28223; P30532; P35462; P11229; P34969; Q01959; P21728; P08913; P14416; P23975; P08172; P08173; P28336; P28335; P41595; P08684; P18089; O15554; P35367; P35348; P25021; P25100; P03971; P20309; P08912; P31645	0.108627174682	413-494
DB00408	Loxapine	approved	3964	-	"For the management of the manifestations of psychotic disorders such as schizophrenia"	P02708; P18825; P28221; P28222; Q9GZZ6; P08913; P35462; P46098; P47898; P28566; P11229; Q9H3N8; P34969; Q01959; P21728; P08588; P14416; P23975; Q9UGM1; P08172; P08173; P28223; P20309; P28335; P18089; P21918; P35368; P35367; P35348; P21917; Q5JUK3; P08912; Q494W8; P25021; P50406; Q92952; P36544; P08908; P31645	0.108627174682	413-494
DB09089	Trimebutine	approved	5573	-	"Indicated for symptomatic treatment of irritable bowel syndrome (IBS) and treatment of postoperative paralytic ileus following abdominal surgery. "	P08172; Q9UGI6; P11229; P08173; O00555; Q9P0X4; P35372; P20309	0.108627174682	413-494
DB01191	Dexfenfluramine	illicit; investigational; withdrawn; approved	66265	-	"For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet"	P18825; P28221; P28222; P28223; O95264; P46098; P47898; P28566; P11229; Q99720; P34969; A5X5Y0; P30939; P08913; P08172; P08173; Q70Z44; P28335; P41595; P08588; P18089; P35368; P35348; Q13639; P50406; Q8WXA8; P20309; P08908; P31645	0.108627174682	413-494
DB01071	Mequitazine	experimental	4066	-	"For the treatment of Hay fever, urticaria (hives) and allergic rhinitis"	P08172; P08173; P11229; P08912; P20309; P35367	0.108627174682	413-494
DB01623	Thiothixene	approved	941651	-	"For the management of schizophrenia."	P18825; P28221; P28222; P28223; P35462; P46098; P11229; P34969; P21728; P08912; P08913; P14416; P08172; P08173; P28335; P18089; P35368; P35367; P35348; P25021; P20309; P08908; P31645	0.108627174682	413-494
DB08801	Dimetindene	investigational; approved	21855	-	"Indicated as symptomatic treatment of allergic reactions: urticaria, allergies of the upper respiratory tract such as hey fever and perennial rhinitis, food and drug allergies, pruritus of various origins, except pruritus due to cholestasis, insect bites. Dimethindene is also indicated for pruritus in eruptive skin diseases such as chicken-pox. Dimethindene can also be used as an adjuvant in eczema and other pruriginous dermatoses of allergic origin. "	P08172; P08173; P11229; P08912; P20309; P35367	0.108627174682	413-494
DB11855	Revefenacin	investigational; approved	11753673	-	"Revefenacin is indicated as an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).[L4820]    COPD is a growing disease being the third leading cause of death in the US. This disease is characterized by not fully reversible airflow limitation.[L4821]"	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB03128	Acetylcholine	investigational; approved	187	-	"Used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required."	P08172; P08173; P22303; P20309; Q494W8; P08912; P36544; P17787; P43681; P11229	0.108627174682	413-494
DB00540	Nortriptyline	approved	4543	-	"Nortriptyline is indicated for the relief of the symptoms of major depressive disorder (MDD).[L11878] Some off-label uses for this drug include treatment of chronic pain, myofascial pain, neuralgia, and irritable bowel syndrome.[A191083,L11878]"	P18825; P10635; P28223; P78508; P35462; P07949; P11229; Q99720; Q01959; P08912; P08913; P14416; P23975; P08172; P08173; P08909; P28335; P41595; P18089; P35368; P35367; P35348; P13945; P25021; P25100; P20309; P08908; P31645; P21728	0.108627174682	413-494
DB00920	Ketotifen	approved	3827	-	"Indicated as an add-on or prophylactic oral medication in the chronic treatment of mild atopic asthmatic children. Also used as self-medication for the temporary relief of itching of the eye due to allergic conjunctivitis (ophthalmic)."	P08172; P08173; P52209; P28335; P41595; P11229; P28223; P25021; P21728; P18089; Q99705; P08912; P08913; P25100; P20309; P08908; P35367; P35462	0.108627174682	413-494
DB00332	Ipratropium	approved; experimental	657308	-	"Inhaled ipratropium is indicated in combination with inhaled beta-agonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatment.[A176939]    Asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flow.[L5900]    As a single agent, ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older. It does not alleviate nasal congestion nor sneezing.[FDA label]    Rhinorrhea refers to recurrent or chronic watery nasal discharge. This condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burden.[L5903]    Additionally, ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.[FDA label]    The chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness. As this includes several conditions, the etiology, symptoms, and treatments are diverse.[L5906]    Ipratropium has also been studied to be used for the treatment of sialorrhea.[A176942]    Sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivation.[A176963]"	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB01142	Doxepin	investigational; approved	667468	-	"Oral doxepin is approved for the following indications:    - Treatment of depression and/or anxiety.[A177163]  - Treatment of depression and/or anxiety associated with different conditions, including alcoholism, organic disease and manic-depressive disorders.[T249]  - Treatment of psychotic depressive disorders with associated anxiety.[T249]  - Treatment of involutional depression.[T249]   - Treatment of manic-depressive disorder.[T249]  - Treatment of insomnia characterized by difficulties with sleep maintenance.[A177163]    Topical doxepin is also approved for short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis, pruritus or lichen simplex chronicus.[T249]    Off-label, doxepin is used topically for the management of neuropathic pain.[A177172]    Depression is a common medical illness that causes feelings of sadness and or loss of interest in prior enjoyable activities. This condition can lead to emotional and physical disturbances that can decrease the ability of a person to function in a regular environment.[L5980]    Anxiety is a normal reaction of the body towards a normal danger. When the anxious state is exacerbated or appears on situations without danger, it is defined as an anxiety disorder. This disorders can appear in different forms such as phobias, panic, obsessive-compulsive disorder and post-traumatic stress disorder.[L5983]    Insomnia is a sleep disorder that directly affects the quality of life of the individual. It is characterized by the complication either to fall asleep or to stay asleep. This condition can be occasional or chronic.[L5986]    Pruritus is defined as an unpleasant skin reaction that provokes the urge to scratch. It can be localized or generalized and it can appear in an acute or chronic manner.[L5989]    Neuropathic pain occurs due to the damage or dysfunction of the peripheral or central nervous system rather than stimulation of the pain receptors.[L5992]"	Q12809; P18825; P10635; P28223; P33261; P35462; P11229; Q9H3N8; Q99720; P34969; P21728; P08912; P08913; P14416; P23975; P08172; P08173; P28335; P41595; P18089; P35368; P35367; P35348; P25021; P25100; P50406; P20309; P08908; P31645	0.108627174682	413-494
DB00738	Pentamidine	investigational; approved	4735	-	"For the treatment of pneumonia due to <i>Pneumocystis carinii</i>."	P08172; Q05586; Q12809; P08173; P28223; O14717; P25100; Q01959; P08912; P08913; Q12879; P35462; P28335; P23975; P07477; P21397	0.108627174682	413-494
DB00342	Terfenadine	approved; withdrawn	5405	-	"For the treatment of allergic rhinitis, hay fever, and allergic skin disorders."	P51589; P18825; P28223; P35462; P00533; P11229; Q12809; Q01959; P08912; P14416; P23975; P08172; P08173; P28335; P41595; P21728; O95259; P35368; P35367; P35348; P51681; P25100; P20309; P06241	0.108627174682	413-494
DB00804	Dicyclomine	approved	3042	-	"Dicyclomine is indicated for the treatment of functional bowel disorder and irritable bowel syndrome.[L7967]"	P08172; P08173; Q12809; P41595; P11229; Q99720; P28223; P25021; Q99250; P08912; P35498; P20309; P28335; Q9NY46; P35462	0.108627174682	413-494
DB00935	Oxymetazoline	investigational; approved	4636	-	"For treatment of nasal congestion and redness associated with minor irritations of the eye"	P10635; P08173; Q9Y2I1; P41595; P18825; P28221; P28222; P28335; P18089; P08912; P08913; P25100; P08908; P35348; P35368; P28223	0.108627174682	413-494
DB01085	Pilocarpine	investigational; approved	5910	-	"For the treatment of radiation-induced dry mouth (xerostomia) and symptoms of dry mouth in patients with Sj&ouml,grens syndrome."	P08172; P08173; P00519; P08912; Q15077; P20309; P11229	0.108627174682	413-494
DB00809	Tropicamide	investigational; approved	5593	-	"Indicated to induce mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) in diagnostic procedures, such as measurement of refractive errors and examination of the fundus of the eye."	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB00725	Homatropine methylbromide	approved	6646	-	"Used in conjunction with antacids or histamine H2-receptor antagonists in the treatment of peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying."	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB01176	Cyclizine	approved	6726	-	"For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness, and vertigo (dizziness caused by other medical problems)."	P08172; P08173; P28335; P11229; P27338; P10635; P28223; Q01959; P25100; P20309; P08912; P08913; P41595; P35462; P35367; P49888	0.108627174682	413-494
DB08897	Aclidinium	approved	11434515	-	"Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema."	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB01019	Bethanechol	approved	2370	-	"For the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention."	P08172; P08173; P11229; P20309	0.108627174682	413-494
DB00283	Clemastine	investigational; approved	26987	-	"For the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and acrimation. Also for the management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Used as self-medication for temporary relief of symptoms associated with the common cold."	P18825; P10635; P28223; P35462; P11229; Q99720; Q12809; Q01959; P08912; P08913; P14416; P23975; P08172; P08173; P28335; P41595; P18089; P35367; P25021; P25100; P20309; P21728	0.108627174682	413-494
DB01104	Sertraline	approved	68617	-	"Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]  "	P08172; P08173; Q12809; Q7RTT9; P28223; Q99720; P28335; Q01959; P41595; P18825; P08912; P08913; P18089; P20309; P31645; P23975; P35348; P11229	0.108627174682	413-494
DB12278	Propiverine	investigational; approved	4942	-	"Indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB) [L2315].  Propiverine may also be used in patients with neurogenic bladder as a result of spinal cord injury [A32581]."	P08172; P08173; P11229; P08912; Q13936; P20309; P35348	0.108627174682	413-494
DB00185	Cevimeline	approved	25137844	-	"For the treatment of symptoms of dry mouth in patients with Sj&ouml,gren's Syndrome."	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB00344	Protriptyline	approved	4976	-	"For the treatment of depression. "	P08172; P08173; Q12809; P11229; P28223; P10635; P28335; Q01959; P41595; P08912; P23975; P20309; P35367; P31645; P14735; P21554	0.108627174682	413-494
DB04841	Flunarizine	approved	941361	-	"Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy."	P08173; P18825; P28223; P18089; P35372; P35462; O95180; P11229; Q99720; Q12809; Q01959; Q9P0X4; P08912; P08913; O43497; P23975; P0DP24; P41145; P14416; P0DP23; P28335; P41595; P35498; P35367; Q9UK17; P41143; P0DP25; P25100; Q00975; P20309; P08908; P31645; P21728; P21554	0.108627174682	413-494
DB11235	Thonzylamine	approved	5457	-	"Thozylamine is indicated for use in the symptomatic control of allergic rhinitis or other upper respiratory allergic symptoms [FDA Label]. It is typically a part of combination over the counter products."	P08172; P08173; P11229; P08912; P20309; P35367	0.108627174682	413-494
DB00985	Dimenhydrinate	approved	441281	-	"Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness."	P08172; P08173; P28223; P11229; P10635; Q99720; P28335; Q01959; P41595; P18089; P08912; P08913; P25100; P20309; P35367; P23975	0.108627174682	413-494
DB00986	Glycopyrronium	investigational; vet_approved; approved	9933193	-	"For use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. Also used to treat chronic obstructive pulmonary disease (COPD)."	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB00715	Paroxetine	investigational; approved	43815	-	"Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.[L3358] One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause.[L7703] Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).[A1093,A181754,A181904]"	P34969; P18825; P10635; P28223; P29597; P35462; P11229; Q99720; Q12809; Q01959; P52333; P08912; P08588; P14416; P23975; P08172; P08173; P41595; P21918; P35367; P13945; P23458; O60674; P25103; P25100; P20309; P08908; P31645	0.108627174682	413-494
DB01075	Diphenhydramine	investigational; approved	3100	-	"Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea [L5263, L5266, L5269, F3379, A174541].    Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for:  i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated [F3352],  ii) the active treatment of motion sickness [F3352], and  iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents, mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents [F3352]."	P08172; P08173; P28335; P11229; P10635; P28223; Q01959; P41595; Q12809; P08912; P35498; P20309; P35367; P31645; Q99250; P23975; Q9NY46	0.108627174682	413-494
DB01173	Orphenadrine	approved	4601	-	"Indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo skeletal conditions."	P08173; P25021; P10635; Q9UQD0; P28223; Q99250; Q9Y5Y9; Q14524; O15399; P11229; Q12809; P18089; P08912; P08913; Q15858; P08172; Q05586; P28335; P41595; Q01118; P35499; P35498; P31645; P35367; Q14957; Q9NY46; P23975; O60391; Q13224; Q12879; Q8TCU5; P20309; Q9UI33	0.108627174682	413-494
DB06709	Methacholine	investigational; approved	1993	-	"It is most commonly used for diagnosing bronchial hyperreactivity, using the bronchial challenge test."	P08172; P08173; P11229; P20309	0.108627174682	413-494
DB00933	Mesoridazine	investigational; approved	4078	-	"Used in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses."	P08172; P08173; Q12809; P11229; P20309; P28223; P08912; Q12879; Q13224; P21728; P14416; P08908; P35367; Q14957; P28335; P35462	0.108627174682	413-494
DB09076	Umeclidinium	approved	11519070	-	"Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)."	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB00810	Biperiden	investigational; approved	2381	-	"For use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy."	P08172; P08173; P11229; Q15822; P08912; P20309	0.108627174682	413-494
DB00321	Amitriptyline	approved	2160	-	"This drug in indicated for the following conditions [FDA label]:    Major depressive disorder in adults    Management of neuropathic pain in adults    Prophylactic treatment of chronic tension-type headache (CTTH) in adults    Prophylactic treatment of migraine in adults    Treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products. This product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis [FDA label]    Off-label uses: irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation, fibromyalgia, and insomnia "	P34969; P35462; P41145; P18825; P10635; P28222; P28223; Q16620; P35372; Q99250; P04629; O43525; O43526; Q9NS40; Q14524; P11229; Q09470; Q9H3N8; Q99720; Q12809; Q01959; P08912; P08913; P14416; P28221; P07949; Q15858; P08172; P08173; P20309; P41143; P41180; P28335; P18089; P41595; P35368; P35367; P35348; P23975; P25021; P25100; P50406; P08909; P08908; P31645; P21728	0.108627174682	413-494
DB00372	Thiethylperazine	withdrawn; approved	5440	-	"For the treatment or relief of nausea and vomiting."	P08172; P08173; P28335; P11229; P20309; Q99720; P28223; P21728; P41595; P08912; P14416; P08908; P35367; P35348; P21917; P35462	0.108627174682	413-494
DB01591	Solifenacin	approved	154059	-	"Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511]"	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB01103	Quinacrine	investigational	237	-	"For the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions."	P08172; P08173; P22303; P11229; P18825; Q15111; P20309; P28223; P25021; P18089; P47712; P08912; P08913; P25100; Q99250; O60733; P23975; Q9NY46; P35462; P35498	0.108627174682	413-494
DB06787	Hexocyclium	approved	24199	-	"The World Health Organization classifies hexocyclium as a drug for functional gastrointestinal disorders [L876]. Like other anti-muscarinic agents, hexocyclium was likely used to treat peptic ulcers or diarrhea."	P08172; P08173; P08912; P11229; P20309	0.108627174682	413-494
DB00167	Isoleucine	investigational; nutraceutical	6306	-	"The branched-chain amino acids may have antihepatic encephalopathy activity in some. They may also have anticatabolic and antitardive dyskinesia activity."	P41252; P45954; O15382; P54687; Q9NSE4	0.108187708885	495
DB08896	Regorafenib	approved	11167602	-	"Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate."	P29317; P21802; Q15759; P23415; P00519; P42685; P35968; P16234; P17948; P07949; P35916; P04049; Q16832; P15056; Q02763; P09619; P11362; P04629; P10721	0.108029463067	496-500
DB05913	OSI-930	investigational	9868037	-	"Investigated for use/treatment in solid tumors."	P07333; P35968; P17948; P35916; P04049; P10721	0.108029463067	496-500
DB08881	Vemurafenib	approved	42611257	-	"Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271]   Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]"	P15056; P35968; P04049	0.108029463067	496-500
DB08912	Dabrafenib	investigational; approved	44462760	-	"Tafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test [FDA label].    Tafinlar in combination with [DB08911] is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for Tafinlar in combination with trametinib [FDA label].    In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene [L2712]."	P53667; Q8NG66; P04049; P57059; P15056; A0A0B4J2F2	0.108029463067	496-500
DB11718	Encorafenib	investigational; approved	50922675	-	"Used in combination with [Binimetinib] in metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [L3335]."	P15056; P24385; P04049	0.108029463067	496-500
DB02659	Cholic Acid	approved	221493	-	"Oral cholic acid is indicated for: treatment of bile acid synthesis disorders due to single enzyme defects, and as adjunctive treatment of peroxisomal disorders including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption. "	Q02221; P23141; P20674; P14854; P09669; P04054; P00414; P22830; P24310; P24311; P00395; P10606; Q96RI1; P10176; P15954; P00403; P00326; P13073; P51161; P62508; P54965; Q8TDU6	0.107625268928	501
DB00220	Nelfinavir	approved	64143	-	"Used in combination with other antiviral drugs in the treatment of HIV in both adults and children."	P41145; P06239; P41143; Q01959; P21728; P08684; P35372; P08912; P06241; P23975; P00533; P13945	0.107486088871	502-509
DB00626	Bacitracin	vet_approved; approved	10909430	-	"Bacitracin is indicated in topical formulations for acute and chronic localized skin infections.[A181997] Occasionally, it is also used intramuscularly for infantile streptococcal pneumonia and empyema.[A181997] Bacitracin is also formulated as an ointment with neomycin and polymyxin B for over the counter use.[A181997,L7769] A bacitracin ointment formulated with neomycin and polymyxin B along with hydrocortisone is indicated for the treatment of corticosteroid responsive dermatoses with secondary infection.[L7772]"	P00533; P01023; P14735; P06239	0.107486088871	502-509
DB03166	Acetic acid	approved	176	-	"Used to treat infections in the ear canal."	P28223; Q9NS39; P28335; P41595; O15552; P06239; P06241	0.107486088871	502-509
DB00027	Gramicidin D	approved	45267103	-	"For treatment of skin lesions, surface wounds and eye infections."	P06241; P32245; P06239; P25101	0.107486088871	502-509
DB01235	Levodopa	approved	6047	-	"Levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in Parkinson's patients who are already being treated with carbidopa and levodopa[FDA Label]. Levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism following carbon monoxide intoxication or manganese intoxication[F4579]."	P00533; P35462; P06239; P43405; P21918; P21728; P51810; P43403; P14416; P06241; P21917	0.107486088871	502-509
DB00515	Cisplatin	approved	2767	-	"For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer."	P02787; P00533; P29372; P01023; P06239; O00244; P08912; P35462; P06241	0.107486088871	502-509
DB08895	Tofacitinib	investigational; approved	9926791	-	"For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient.      Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis.     It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.   "	P23458; O75116; P00519; P52333; O60674; Q16512; P29597; P06239; Q13464; P06241; Q05655; P07949	0.107486088871	502-509
DB00190	Carbidopa	approved	34359	-	"Carbidopa is indicated with [levodopa] for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication.[FDA label]    The combination therapy is administered for the reduction of [levodopa]-driven nausea and vomiting.[FDA label]    The product of carbidopa should be used in patients where the combination therapy of carbidopa/[levodopa] provide less than the adequate daily dosage.[FDA label]    As well carbidopa can be used in patients where the dosages of carbidopa and [levodopa] require individual titration.[FDA label]"	P06241; P20711; P06239	0.107486088871	502-509
DB00133	Serine	investigational; nutraceutical	5951	-	"Used as a natural moisturizing agent in some cosmetics and skin care products."	P49591; P35520; Q9GZT4; P20132; P0DN79; Q5T6X5; O15269; P21549; O15270	0.107331656205	510
DB01129	Rabeprazole	investigational; approved	5029	-	"For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use."	P20648; P05023; P28221; P18089; P33261; P21860; P35462; P51164; Q15303	0.107274458922	511-525
DB01345	Potassium cation	investigational; approved	5462222	-	"Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions. "	P05023	0.107274458922	511-525
DB00511	Acetyldigitoxin	approved	5284512	-	"Used for fast digitalization in congestive heart failure."	P05023; P50993; P05026; P13637; Q13733; P14415; P54709; P54710	0.107274458922	511-525
DB01396	Digitoxin	investigational; approved	441207	-	"For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure."	P05023; P50993; Q12809; P05026; P13637; Q13733; P14415; P54709; P54710	0.107274458922	511-525
DB00213	Pantoprazole	approved	4679	-	"  **Pantoprazole Injection**:    **Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis**    Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. _Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time_.[FDA label]    **Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome**    Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions.[FDA label]    **Pantoprazole delayed-release oral suspension**:    **Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)**    Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined.[F3202]    **Maintenance of healing of erosive esophagitis**    Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.[F3202]    **Pathological hypersecretory conditions including Zollinger-Ellison syndrome**    Indicated for the long-term treatment of the above conditions.[F3202]"	P05023; P33261; P51164; P20648; O94760	0.107274458922	511-525
DB01188	Ciclopirox	investigational; approved	2749	-	"Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to <i>Trichophyton rubrum</i>."	P05023	0.107274458922	511-525
DB01430	Almitrine	approved	33887	-	"For the treatment of chronic obstructive pulmonary disease."	P05023	0.107274458922	511-525
DB01021	Trichlormethiazide	vet_approved; approved	5560	-	"Used in the treatment of oedema (including that associated with heart failure) and hypertension."	P00918; P22748; Q9Y2D0; P43166; P05023; Q13621; P23280; Q9ULX7; P00915; P55017; Q16790; Q9Y2T6; O43570; P35218; Q12791	0.107274458922	511-525
DB00774	Hydroflumethiazide	investigational; approved	3647	-	"Used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension."	P00918; P22748; P43166; P05023; Q13621; P00915; P55017; Q16790; O43570; Q12791	0.107274458922	511-525
DB01092	Ouabain	approved	439501	-	"For the treatment of atrial fibrillation and flutter and heart failure"	P05023; P13637; Q12809; P50993	0.107274458922	511-525
DB01078	Deslanoside	approved	28620	-	"For the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure."	P05023; P50993; P05026; P13637; Q13733; P14415; P54709; P54710	0.107274458922	511-525
DB01119	Diazoxide	approved	3019	-	"Used parentally to treat hypertensive emergencies. Also used to treat hypoglycemia secondary to insulinoma."	P00918; P51841; Q09428; P05023; Q14654; P00915; P55017; Q15842; Q12791	0.107274458922	511-525
DB06708	Lumefantrine	approved	6437380	-	"Lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by <i>Plasmodium falciparum</i>, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the <i>Plasmodium</i> species has not been identified. Indicated for use in adults and children greater than 5 kg. "	P05023; Q12809	0.107274458922	511-525
DB00390	Digoxin	approved	2724385	-	"Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients.[L9143] 2) To increase myocardial contraction in children diagnosed with heart failure.[L9143] 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.[L9143]    In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.[L9143]    "	P05023; P50993; Q12809; P05026; P13637; Q13733; P14415; P54709; Q6ZQN7; P54710	0.107274458922	511-525
DB01244	Bepridil	approved; withdrawn	2351	-	"For the treatment of hypertension, and chronic stable angina (classic effort-associated angina)."	P32241; Q9UBN1; Q01064; P62955; P41586; P41587; Q06432; Q9Y698; O00257; Q99250; O60840; Q9Y3Q4; P0DP23; O60359; Q14524; Q9BXT2; P51787; Q12809; Q08289; Q9P0X4; Q7Z3S7; P63316; O43497; O00555; Q01668; Q9UF02; P0DP24; P0DP25; Q15878; P54750; Q8WXS5; P54284; Q15746; P05023; Q9H1R3; O00305; O95180; Q9NY47; Q9NY46; Q14123; Q8IZS8; P54289; Q00975; Q13936; Q13698; Q02641; P56696; P35498	0.107274458922	511-525
DB06154	Pentaerythritol tetranitrate	approved	6518	-	"Used for the treatment of angina pectoris [L2393]."	P68871; P69905	0.107017071145	526-533
DB09147	Ferric pyrophosphate	experimental	24877	-	"Ferric pyrophosphate is intended to be indicated for the treatment of iron loss or iron deficiency as a formulation with a milder gastrointestinal effect.[L1423, L1433]     Iron deficiency appears when the dietary intake does not meet the body's requirement or when there is chronic external blood loss. During acute blood loss, body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis. But when the altered homeostasis remains for weeks to months then some supplement is needed. Some causes of iron deficiency include ectoparasitism, endoparasitism, hematuria, epistaxis, hemorrhagic skin, coagulopathy, thrombocytopenia, thrombocytopathia and gastrointestinal hemorrhage.[A31984]"	P68871; P02792; P69905	0.107017071145	526-533
DB00468	Quinine	approved	3034034	-	"For the treatment of malaria and leg cramps"	Q7RTT9; Q12809; Q92953; P35498; Q99250; O15554; P69905; Q9NY46; P14770	0.107017071145	526-533
DB01087	Primaquine	approved	4908	-	"For the treatment of malaria."	P21397; P27338; P16083; Q12809; P11413; P08729; P31645; P69905; O95436	0.107017071145	526-533
DB00358	Mefloquine	investigational; approved	4046	-	"For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of <i>Plasmodium falciparum</i> (both chloroquine-susceptible and resistant strains) or by <i>Plasmodium vivax</i>. Also for the prophylaxis of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria infections, including prophylaxis of chloroquine-resistant strains of <i>Plasmodium falciparum</i>."	P23415; Q12809; P46663; Q96G91; P69905; P29274; P30542	0.107017071145	526-533
DB09517	Sodium ferric gluconate complex	approved	76968835	-	"Used to replete the total body content of iron during iron deficiency anemia in patients age 6 years and older with chronic kidney disease receiving hemodialysis and receiving supplemental epoetin therapy."	P68871; P02792; P69905	0.107017071145	526-533
DB13257	Ferrous sulfate anhydrous	approved	62662	-	"Ferrous sulfate is used for the prevention and treatment of iron deficiency anemia in adults and children.[A190804,L2240,L11800]  "	P69905; Q9UP52	0.107017071145	526-533
DB09112	Nitrous acid	investigational; approved	23668193	-	"For sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be life-threatening [FDA Label]."	P00918; P02144; P69905; P00915; P68871	0.107017071145	526-533
DB00953	Rizatriptan	approved	5078	-	"For treatment of acute migraine attacks with or without aura."	P28566; P28335; P28221; P28222; P28223; P30939; P10635; P25445; P08908	0.106872171359	534
DB00518	Albendazole	approved; vet_approved	2082	-	"For the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <i>Taenia solium</i> and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <i>Echinococcus granulosus</i>."	P68371; Q71U36; Q9H4B7; Q8TDU9; P83223; Q9NSD7	0.105502296414	535-537
DB00643	Mebendazole	approved; vet_approved	4030	-	"For the treatment of <i>Enterobius vermicularis</i> (pinworm), <i>Trichuris trichiura</i> (whipworm), <i>Ascaris lumbricoides</i> (common roundworm), <i>Ancylostoma duodenale</i> (common hookworm), <i>Necator americanus</i> (American hookworm) in single or mixed infections."	P35968; Q9H4B7; P68371; P00519; Q71U36	0.105502296414	535-537
DB04910	Oxibendazole	investigational; vet_approved	4622	-	"Investigated for use/treatment in infectious and parasitic disease (unspecified) and pediatric indications."	P68371	0.105502296414	535-537
DB04576	Fleroxacin	experimental	3357	-	"Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone."	P11388; P43700; P43702; Q02880	0.10547465106	538-558
DB01177	Idarubicin	approved	42890	-	"For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7."	P11388	0.10547465106	538-558
DB05022	Amonafide	investigational	50515	-	"Investigated for use/treatment in breast cancer, ovarian cancer, and prostate cancer."	P11388; Q02880	0.10547465106	538-558
DB01165	Ofloxacin	approved	4583	-	"For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea."	P11229; P30531; P0AES4; P0AES6; P47869; P31645; P11388; P43700; Q9Y5N1; P43702; P48065	0.10547465106	538-558
DB09047	Finafloxacin	investigational; approved	11567473	-	"Finafloxacin is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> in patients age 1 year and older. "	P0C1S7; P20831; P0A0K8; Q9I7C2; P0C1U9; Q9HUJ8; P48372; P11388; P43700; Q9HUK1; P43702	0.10547465106	538-558
DB00773	Etoposide	approved	36462	-	"For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme."	P11388; Q02880	0.10547465106	538-558
DB00467	Enoxacin	investigational; approved	3229	-	"For the treatment of adults (&ge,18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: (1) uncomplicated urethral or cervical gonorrhea due to <i>Neisseria gonorrhoeae</i>, (2) uncomplicated urinary tract infections (cystitis) due to <i>Escherichia coli</i>, <i>Staphylococcus epidermidis</i>, or <i>Staphylococcus saprophyticus</i>, and (3) complicated urinary tract infections due to <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Proteus mirabilis</i>, <i>Pseudomonas aeruginosa</i>, <i>Staphylococcus epidermidis</i>, or <i>Enterobacter cloacae</i>."	P22118; P43700; P16615; P48371; P11388; P48374; P43702; Q02880	0.10547465106	538-558
DB00444	Teniposide	approved	452548	-	"Teniposide is used for the treatment of refractory acute lymphoblastic leukaemia"	P11388; Q02880	0.10547465106	538-558
DB00537	Ciprofloxacin	investigational; approved	2764	-	"Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493]    Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478]    A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493]    A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475]    A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]"	P20831; P0C1U9; Q12809; Q02880; Q59192; P0AES4; P0AES6; P11388; P43700; P43702; P05653	0.10547465106	538-558
DB00694	Daunorubicin	approved	30323	-	"For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults."	P11388; Q02880	0.10547465106	538-558
DB01208	Sparfloxacin	investigational; withdrawn; approved	60464	-	"For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by <i>Chlamydia pneumoniae</i>, <i>Haemophilus influenzae</i>, <i>Haemophilus parainfluenzae</i>, <i>Moraxella catarrhalis</i>, <i>Mycoplasma pneumoniae</i>, or <i>Streptococcus pneumoniae</i>) and acute bacterial exacerbations of chronic bronchitis (caused by <i>Chlamydia pneumoniae</i>, <i>Enterobacter cloacae</i>, <i>Haemophilus influenzae</i>, <i>Haemophilus parainfluenzae</i>, <i>Klebsiella pneumoniae</i>, <i>Moraxella catarrhalis</i>, <i>Staphylococcus aureus</i>, or <i>Streptococcus pneumoniae</i>)."	P0AFI2; Q12809; P0AES4; P20083; P0AES6; P43702; P11388; P43700; P42345; Q02880	0.10547465106	538-558
DB00685	Trovafloxacin	investigational; withdrawn; approved	62959	-	"For treatment of infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by <i>Neisseria gonorrhoeae</i> as well as non gonoccocal urethritis and cervicitis due to <i>Chlamydia trachomatis</i>."	P11388; P0AFI2; Q01959; P0AES4; P0AES6; Q02880; P43700; P43702; P20083	0.10547465106	538-558
DB00445	Epirubicin	approved	41867	-	"For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer."	P06241; O14646; P11388; Q02880	0.10547465106	538-558
DB06263	Amrubicin	investigational	3035016	-	"Investigated for use/treatment in lung cancer [A4138]."	P11388	0.10547465106	538-558
DB00385	Valrubicin	approved	454216	-	"For the treatment of cancer of the bladder."	P11388; Q02880	0.10547465106	538-558
DB00978	Lomefloxacin	investigational; approved	3948	-	"For the treatment of bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: <i>S.pneumoniae</i>, <i>H.influenzae</i>, <i>S.aureus</i>, <i>P.aeruginosa</i>, <i>E. cloacae</i>, <i>P. mirabilis</i>, <i>C. civersus</i>, <i>S. asprphyticus</i>, <i>E.coli</i>, and <i>K.pneumoniae</i>."	P0AES4; P0AES6; P11388; P43700; P43702; Q02880	0.10547465106	538-558
DB00218	Moxifloxacin	investigational; approved	152946	-	"For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye)."	P11388; P0AFI2; P0AES4; P0AES6; Q02880; P43700; P43702; P20083	0.10547465106	538-558
DB00380	Dexrazoxane	withdrawn; approved	71384	-	"For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines."	P11388; Q02880	0.10547465106	538-558
DB04975	Banoxantrone	investigational	9955116	-	"For the treatment of various forms of cancer."	P11388	0.10547465106	538-558
DB01059	Norfloxacin	approved	4539	-	"For the treatment of urinary tract infection"	Q16445; P0AFI2; P0AES4; P20083; P48169; P31644; P14867; P0AES6; P47869; P11388; P34903; P43700; P43702; Q02880	0.10547465106	538-558
DB00487	Pefloxacin	approved	51081	-	"For the treatment of uncomplicated gonococcal urethritis in males and for gram-negative-bacterial infections in the gastrointestinal system and the genitourinary tract."	P43700; P11388; Q06AK7; P43702; Q02880	0.10547465106	538-558
DB06803	Niclosamide	investigational; approved; vet_approved	4477	-	"For the treatment of tapeworm and intestinal fluke infections: Taenia saginata (Beef Tapeworm), Taenia solium (Pork Tapeworm), Diphyllobothrium latum (Fish Tapeworm), Fasciolopsis buski (large intestinal fluke). Niclosamide is also used as a molluscicide in the control of schistosomiasis."	P00533; Q5JUK3; P0DQD5; P35968; P50391; P12931; P49841; Q02763; P10721; O60674; P07948; P11362	0.105417453776	559-561
DB05109	Trabectedin	investigational; approved	108150	-	"Indicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in Europe, Russia and South Korea. Approved for orphan drug status by the U.S. FDA for treatment of soft tissue sarcomas and ovarian cancer. Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, ovarian cancer, pediatric indications, sarcoma, and solid tumors."	P12931	0.105417453776	559-561
DB00131	Adenosine phosphate	investigational; approved; nutraceutical	6083	-	"For nutritional supplementation, also for treating dietary shortage or imbalance"	P12931; Q9Y478; Q08828; O60755; P16220; O43603; O43741; Q9NR19; P11309; Q9NUB1; Q07343; P55263; P06737; P49773; P33121; Q08499; Q13131; P09467; P47211	0.105417453776	559-561
DB11967	Binimetinib	investigational; approved	10288191	-	"  On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [L3335]."	Q02750; P36507; P05231; P01584; P01375; Q13233	0.105315451954	562-563
DB06061	AZD-8330	investigational	16666708	-	"Investigated for use/treatment in cancer/tumors (unspecified)."	P36507; Q02750; Q13233; O14733	0.105315451954	562-563
DB06637	Dalfampridine	approved	1727	-	"Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS). "	Q96KK3; Q03721; Q9H3M0; Q6PIU1; P22459; Q9UIX4; Q9UQ05; Q9BQ31; Q9UJ96; Q9H252; P22460; P17658; Q9NS40; Q96PR1; P11308; Q16322; Q09470; O43525; Q12809; Q8TAE7; Q9NR82; Q92953; Q96RP8; Q9ULD8; Q96L42; P48544; Q8NCM2; Q14721; Q9NZV8; Q9NSA2; O60928; P16389; Q9ULS6; P47900; O95259; O43526; Q9UK17; Q8TDN2; Q8TDN1; P22001; P51787; P48547; Q14003; P56696	0.105077129938	564-568
DB00661	Verapamil	approved	2520	-	"Verapamil is indicated in the treatment of vasopastic (i.e. Prinzmetal's) angina, unstable angina, and chronic stable angina. It is also indicated to treat hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutter.[L8791] Given intravenously, it is indicated for the treatment of various supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate in patients with atrial fibrillation or atrial flutter.[L10481]    Verapamil is commonly used off-label for prophylaxis of cluster headaches.[A13983]"	Q7RTT9; O00555; P28223; Q06432; Q14654; Q99250; O60840; Q9Y3Q4; Q14524; O95180; Q16322; Q12809; Q08289; P35348; Q9P0X4; P08913; Q02641; Q9ULQ1; O43497; Q96RP8; Q8NHX9; Q96PR1; P28335; P41595; P08684; O00305; Q8IZF0; P35368; Q01668; Q9NY46; P54284; P22001; P25021; P00915; P25100; Q00975; Q13936; P08908; Q13698; P31645; P35462; P35498	0.105077129938	564-568
DB01081	Diphenoxylate	illicit; approved	13505	-	"For as adjunctive therapy in the management of diarrhea"	P35372; P22001; P41143	0.105077129938	564-568
DB06200	Tedisamil	investigational	65825	-	"Investigated for use/treatment in arrhythmia, atrial fibrillation, and angina."	Q9BQ31; Q9H3M0; Q6PIU1; Q9UIX4; Q9UQ05; Q96KK3; Q9UJ96; Q9H252; P48547; P17658; Q9NS40; P11308; Q16322; Q09470; Q03721; Q8TAE7; Q9NR82; Q14003; Q96RP8; Q96PR1; O43526; Q8NCM2; P16389; Q14721; Q9NZV8; Q9NSA2; Q9ULD8; Q9ULS6; Q9UK17; O95259; P22459; Q96L42; P22460; Q8TDN2; P22001; P51787; Q92953; P56696; O43525	0.105077129938	564-568
DB00536	Guanidine	approved	3520	-	"For the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis."	Q96KK3; Q03721; Q9H3M0; Q9NSA2; Q9UIX4; Q9UQ05; Q9BQ31; Q9UJ96; Q9H252; P48547; P17658; Q9NS40; P00720; Q16322; Q09470; P22460; Q12809; Q8TAE7; Q9NR82; P22001; Q14003; Q96RP8; Q9ULD8; P07998; O43526; P0A6E4; Q8NCM2; Q14721; Q9NZV8; Q96PR1; P16389; Q9ULS6; P78352; Q9UK17; O95259; P22459; Q96L42; P05091; Q8TDN2; Q6PIU1; P53608; P51787; Q92953; P56696; Q14353; Q8TDN1; O43525	0.105077129938	564-568
DB11156	Pyrantel	vet_approved; approved	708857	-	"For the treatment of enterobiasis including roundworm (ascariasis), pinworm (enterobius) and hookworm (strongyloides) and hookworm (ancylostoma) in the pyrantel pamoate form [L1893].    Pyrantel is available in various formulations for humans, dogs, and cats as the pamoate (US Pharmacopeia nomenclature) or embonate (European Pharmacopoeia nomenclature) salt, which contains 34.7% pyrantel base combined with pamoic acid [L1893]. [L1900], [A32283].    Pyrantel pamoate (embonate) ingested orally is effective for removal and control of ascarid and hookworm infections in puppies and dogs (adult Toxocara canis, Toxascaris leonina, Ancylostoma tubaeforme, An. braziliense, Uncinaria stenocephala), cats (adult Toxocara cati, Toxa. leonina, An. caninum, An. braziliense, U. stenocephala), horses and ponies (adult and immature Parascaris equorum, adult Strongylus vulgaris, S. edentatus, S. equinus, Cyathostomes (Triodontophorus spp., Cyathostomum spp., Cylicodontophorus spp., Cylicocyclus spp., Cylicostephanus spp., Poteriostomum spp.), Oxyuris equi, Anoplocephala perfoliata), swine (adult Ascaris suum, Oesophagostomum dentatum), and humans (adult A. lumbricoides, Enterobius vermicularis, An. duodenale, Necator americanus) [L1900]."	P11229; Q9HC97	0.10498275442	569-570
DB00279	Liothyronine	approved; vet_approved	5920	-	"Liothyronine is officially approved for the following indications:    - Replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism.    - As an adjunct therapy to surgery and radioiodine in the management of thyroid cancer.    - As a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomy.[FDA label]    In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.[T457]    The lack of liothyronine can be presented as a pale and puffy face, coarse,  brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy.[T457]    Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.[FDA label]"	Q9UN88; P10827; P28472; P18507; P18505; Q99928; O14764; P48169; P14867; P10828; Q8N1C3; P47869; P47870; P31644; P12004; P34903; Q16445; O00591; P30542; P78334	0.10498275442	569-570
DB08846	Ellagic acid	investigational	5281855	-	"Ellagic acid is being investigated for use in follicular lymphoma, brain injury in intrauterine growth restricted babies, obese adolescents, and solar lentigines."	P00918; P22748; P07451; P43166; P17252; P23280; Q9ULX7; P43405; P00915; Q16790; O43570; P35218; P17612; P05771; P68400; Q14534; Q9Y2D0	0.104913164392	571
DB05412	Talmapimod	investigational	9871074	-	"Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis."	P00403; Q15759; P53778; Q16539; P01584; P01375	0.1047368061	572-576
DB05470	VX-702	investigational	10341154	-	"Investigated for use/treatment in coronary artery disease, inflammatory disorders (unspecified), and rheumatoid arthritis."	Q15759; Q16539; P53778; P05231; P01584; P01375; O15264	0.1047368061	572-576
DB00647	Dextropropoxyphene	illicit; investigational; approved; withdrawn	10100	-	"For the relief of mild to moderate pain."	P41145; Q14524; P41143; Q16539; P23141; Q8TCU5; P35372; Q07343; Q08499	0.1047368061	572-576
DB12140	Dilmapimod	investigational	10297982	-	"Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others."	P05231; P01584; P01375; Q16539	0.1047368061	572-576
DB04951	Pirfenidone	investigational; approved	40632	-	"For the treatment of idiopathic pulmonary fibrosis (IPF)."	Q15759; P53778; Q16539; P01375; P09958; O15264	0.1047368061	572-576
DB00201	Caffeine	approved	2519	-	"Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth.[T716,L9851] In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs.[L9899] Caffeine has a broad range of over the counter uses, and is found in energy supplements, athletic enhancement products, pain relief products, as well as cosmetic products.[T716,L9854,L9872]"	P22303; P21817; P42338; P78527; P42336; P35913; Q13315; Q92736; Q14573; Q12809; P0DMS8; Q15413; Q07343; O76074; P29274; P29275; P30542; O00329	0.10467770224	577
DB00118	Ademetionine	investigational; approved; nutraceutical	34755	-	"S-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being."	P17707; P35520; Q00266; P0DN79; Q8N1G2; P31153; P21964; Q14749; Q9HBK9	0.103920791519	578
DB00480	Lenalidomide	approved	216326	-	"Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities."	Q13619; Q16531; Q96SW2; O14788; P62877; P33151; P35354; P01375	0.103425081727	579-581
DB08910	Pomalidomide	approved	134780	-	"Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy."	Q13619; Q16531; Q96SW2; P62877; P35354; P01375	0.103425081727	579-581
DB01041	Thalidomide	investigational; approved; withdrawn	5426	-	"For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence."	P21802; P19652; P01375; Q13619; P62877; P19838; P35354; Q16531; Q96SW2; P23219	0.103425081727	579-581
DB11731	Depatuxizumab mafodotin	investigational	71300933	-	"No approved indication."	P00533; P07437	0.103005634979	582
DB08827	Lomitapide	investigational; approved	9853053	-	"Used in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C)."	P55157; P48039; P07237; P49286	0.102567122471	583
DB00156	Threonine	approved; nutraceutical	6288	-	"L-Threonine makes up collagen, elastin, and enamel protein. It aids proper fat metabolism in the liver, helps the digestive and intestinal tracts function more smoothly, and assists in metabolism and assimilation."	Q9BW92; P26639; Q8IYQ7	0.102304014965	584
DB00120	Phenylalanine	investigational; approved; nutraceutical	6140	-	"L-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs."	P00439; Q9UHI5; Q6DWJ6; O43603; P07101; Q9Y285; Q9NSD9; O95363; P17735	0.102030421292	585
DB12483	Copanlisib	investigational; approved	24989044	-	"Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies."	P27986; P48736; P42338; P42336; Q92569; O00459; Q8WYR1; O00329	0.101802585445	586
DB00123	L-Lysine	approved; nutraceutical	5962	-	"Supplemental L-lysine has putative anti-herpes simplex virus activity. There is preliminary research suggesting that it may have some anti-osteoporotic activity."	Q8WY07; O43246; Q15046; P00390; P52569	0.101611927832	587
DB00145	Glycine	nutraceutical; vet_approved; approved	750	-	"Supplemental glycine may have antispastic activity. Very early findings suggest it may also have antipsychotic activity as well as antioxidant and anti-inflammatory activities."	P34896; P34897; Q12879; O75600; Q6IB77; P21549; Q14032; Q14749; Q9P0Z9; Q8WU03; P48167; Q14957; O75311; P48637; Q9BYV1; P22557; P23416; Q14330; P23415; Q969I3; O60391; Q13224; Q969I6; Q5T6X5; Q8TCU4; P50440; P13196	0.101467981335	588-589
DB00114	Pyridoxal phosphate	investigational; approved; nutraceutical	1051	-	"For nutritional supplementation and for treating dietary shortage or imbalance."	P32929; Q9HD40; Q96GA7; Q9GZT4; Q6ZQY3; P34897; P80404; Q6P996; Q16773; Q96I15; O95470; Q9NUV7; Q9NVS9; P20711; Q99259; Q8N5Z0; Q96A70; Q9BYV1; P35520; Q99527; Q9Y697; P20132; P0DN79; P21549; P19113; Q16719; O15270; Q6YP21; Q9Y600; P24298; P23378; P34896; P04181; O95954; P11926; Q8TD30; Q96EN8; O75600; P22557; Q96GD0; P17174; Q6WRI0; P17735; P11217; Q8IYQ7; P11216; O15382; Q8IUZ5; P00505; O15269; P54687; Q9Y617; P13196; P06737	0.101467981335	588-589
DB00266	Dicoumarol	approved	54676038	-	"For decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis."	P15559; Q08257; Q9BQB6	0.101115264752	590-591
DB00170	Menadione	approved; nutraceutical	4055	-	"The primary known function of vitamin K is to assist in the normal clotting of blood, but it may also play a role in normal bone calcification."	P00734; P38435; P00390; P27338; P22891; P04070; P16083; P00742; P02818; Q06278; P08709; P00740; P07225; Q9BQB6; Q8N0U8; P15559; P21397	0.101115264752	590-591
